

An  
OPEN LETTER  
to  
VETERINARIANS

from  
BETHANY QUAM,  
Group President at Blue Buffalo Co.







We're in this for pets.

You, because your love of animals and science was likely with you from a young age.

Us, because we were founded on a promise to a lovable Airedale named Blue who struggled with health issues.

We know our approach was different. Untraditional. But it came from the right place.

We also know this isn't the easiest of times for veterinarians. Your pressures are great. The stresses of life-and-death decisions are with you daily. Pet ownership is surging. Staff shortages make it harder. And the pandemic adds even more challenges.

We can't make everything right, but we can help. We have 19 million households who believe that when you love them like family, you feed them like family. We will remind them that their veterinarians take care of them like family, too.

In other words, we're in this together. It's time we truly worked together.

As an industry disrupter, we know how to make a difference. We'll be active in professional support and sponsorships. And we're establishing a grant program to honor innovative veterinarians and help them further their special causes.

We'll continue to add to our more than \$30 million in funds raised for animal cancer research and treatment.

We'll give you more information about our industry-leading team of full-time nutritionists, food scientists and veterinarians and about our testing and quality assurance protocols as well and offer you more transparency into what we do and how we do it.

And we will pay off these words with our actions. This is just the beginning.

Together we can do more. Together we make the profession stronger.  
Like you, we are committed and we care.

Together for pets. After all, it's why we're both here.

Sincerely,  
Bethany Quam

  
Group President at Blue Buffalo Co.





**Practice management:**  
Improving your communication skills

page 56

## Identifying passion and purpose energizes your life

By discovering what you love, what you need to do, and why you need to do it, you can achieve personal and professional satisfaction.

By Julia Burke, Assistant Editor

Being a “heart-centered veterinarian” means fostering a peaceful mindset in which what you do is aligned with your values, desires, purpose, and passions, according to Patricia D. White, DVM, MS, DACVD, CPC. Regardless of your role in the veterinary industry, it’s important to understand that relationships and communication are key to success in both your personal and professional life. By realizing that others have a need to be valued, seen, heard, and cared for, you can design the life you want to lead and contribute to a rewarding, profitable profession.

During her presentation at the 2021 Atlantic Coast Veterinary Conference®,

See page 25



## Managing superficial pyoderma with light therapy

Phobia is highly effective for treating superficial and deep skin infections.

By Amelia G. White, DVM, MS, DACVD

Superficial bacterial folliculitis, also called superficial pyoderma, is a commonly diagnosed dermatological condition in dogs.<sup>1,2</sup> These infections are secondary to primary conditions affecting normal skin barrier function (eg, allergic skin disease, trauma, burns), keratinization (eg, nutritional deficiency, liver disease), and immune regulation (eg, neoplasia, autoimmunity, endocrinopathy).<sup>2</sup> Cats less commonly develop superficial pyoderma perhaps because of decreased adhesion of staphylococci to feline corneocytes, but the primary issues causing infection are similar to those seen in dogs.<sup>3-8</sup>

The primary pathogen associated with superficial pyoderma in dogs and cats is a normal resident of the skin, *Staphylococcus pseudintermedius*, but other flora may be involved.<sup>2,8-12</sup> As the normal homeostasis of this organism is disrupted from a primary disease, these gram-positive cocci invade

See page 26



### Surgery

Gastric dilatation-volvulus: the twisted truth


page 34



### Integrative Medicine

Product comparison in an unregulated industry

page 42



### Dermatology

New treatment options for dermatologic issues

page 44



### Feline Behavior

Managing feline stress-related conditions

page 46



Now approved  
for cats and dogs\*



# THE PROVEN WAY TO TREAT CANINE DIABETES ONCE-A-DAY



The breakthrough you've been waiting for is here: now you can deliver glycemic control in most diabetic dogs WITH A SINGLE DAILY INJECTION.<sup>1,2</sup> To learn more, contact your Boehringer Ingelheim Sales Representative or Professional Services Veterinarian.

**ProZinc**<sup>®</sup>  
(protamine zinc recombinant  
human insulin)

\*PROZINC is approved for twice-daily use in cats.<sup>3</sup>

**IMPORTANT SAFETY INFORMATION:** PROZINC is for use in dogs and cats only. Keep out of the reach of children. Animals presenting with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdose can result in profound hypoglycemia and death. The most common adverse reactions were lethargy, anorexia, hypoglycemia, vomiting, seizures, shaking (dogs only), diarrhea, and ataxia. Many of the adverse reactions, such as lethargy, seizures, shaking (dogs only), and ataxia, are associated with hypoglycemia. Glucocorticoid and progestogen use should be avoided. The safety and effectiveness of PROZINC in puppies, kittens, or breeding, pregnant, and lactating animals has not been evaluated. PROZINC is contraindicated during episodes of hypoglycemia and in animals sensitive to protamine zinc recombinant human insulin or any other ingredients in PROZINC. **For more information, please see full prescribing information.**

**References:**

<sup>1</sup> Data on file at Boehringer Ingelheim.

<sup>2</sup> ProZinc<sup>®</sup> (protamine zinc recombinant human insulin) [Freedom of Information Summary]. Duluth, GA: Boehringer Ingelheim Animal Health USA, Inc.; 2019.

<sup>3</sup> ProZinc<sup>®</sup> (protamine zinc recombinant human insulin) [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2009.

PROZINC<sup>®</sup> is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2020 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0418-2020





**Brief Summary: Cats and Dogs - This information is not comprehensive. Before using PROZINC, please consult the product insert, a summary of which follows. The product insert may be obtained from your veterinarian or by visiting [www.prozinc.us](http://www.prozinc.us).**

## ProZinc® (protamine zinc recombinant human insulin)

40 IU/mL

**Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**Description:** PROZINC® is a sterile aqueous protamine zinc suspension of recombinant human insulin.

**Each mL contains:** recombinant human insulin 40 International Units (IU), protamine sulfate 0.466 mg, zinc oxide 0.088 mg, glycerin 16.00 mg, dibasic sodium phosphate, heptahydrate 3.78 mg, phenol (added as preservative) 2.50 mg, hydrochloric acid 1.63 mg, water for injection (maximum) 1005 mg, pH is adjusted with hydrochloric acid and/or sodium hydroxide.

**Indication:** PROZINC (protamine zinc recombinant human insulin) is indicated for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats and dogs with diabetes mellitus.

**Contraindications:** PROZINC is contraindicated in cats and dogs sensitive to protamine zinc recombinant human insulin or any other ingredients in PROZINC. PROZINC is contraindicated during episodes of hypoglycemia.

### Warnings:

**User Safety:** For use in cats and dogs only. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with running water for at least 15 minutes. Accidental injection may cause hypoglycemia. In case of accidental injection, seek medical attention immediately. Exposure to product may induce a local or systemic allergic reaction in sensitized individuals.

**Animal Safety:** Owners should be advised to observe for signs of hypoglycemia. Use of this product, even at established doses, has been associated with hypoglycemia. A dog or cat with signs of hypoglycemia should be treated immediately. Glucose should be given orally or intravenously as dictated by clinical signs. Insulin should be temporarily withheld and, if indicated, the dosage adjusted.

Any change in insulin should be made cautiously and only under a veterinarian's supervision. Changes in insulin strength, manufacturer, type, species (human, animal) or method of manufacture (rDNA versus animal-source insulin) may result in the need for a change in dosage.

Appropriate diagnostic tests should be performed to rule out other endocrinopathies in diabetic dogs and cats that are difficult to regulate.

**Precautions:** Cats and dogs presenting with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdose can result in profound hypoglycemia and death.

Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

The safety and effectiveness of PROZINC in breeding, pregnant, and lactating cats and dogs has not been evaluated.

The safety and effectiveness of PROZINC in kittens and puppies has not been evaluated.

**Adverse Reactions - Cats:** In a 45-day effectiveness field study, 176 cats received PROZINC. Hypoglycemia (low blood sugar) was the most common reported adverse event. Clinical signs of hypoglycemia were generally mild in nature (described as lethargic, sluggish, weak, trembling, uncoordinated, groggy, glassy-eyed or dazed).

In severe cases of hypoglycemia, seizures and coma can occur. Hypoglycemia can be fatal if an affected cat does not receive prompt treatment.

Local transient injection site reactions may occur.

**Dogs:** In a 182-day field study, 276 dogs received PROZINC. The most common adverse reactions were lethargy, anorexia, hypoglycemia (low blood sugar), vomiting, seizures, shaking, diarrhea, and ataxia.

Clinical signs of hypoglycemia varied and included seizure, collapse, ataxia, staggering, trembling, twitching, shaking, disorientation, lethargy, weakness, and vocalization.

**Information for Cat Owners:** PROZINC, like other insulin products, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the associated clinical signs.

The most common adverse reaction observed is hypoglycemia (low blood sugar). Signs may include: weakness, depression, behavioral changes, muscle twitching, and anxiety. In severe cases of hypoglycemia, seizures and coma can occur. Hypoglycemia can be fatal if an affected cat does not receive prompt treatment.

Local transient injection site reactions may occur.

Appropriate veterinary monitoring of blood glucose, adjustment of insulin dose and regimen as needed, and stabilization of diet and activity help minimize the risk of hypoglycemic episodes. The attending veterinarian should evaluate other adverse reactions on a case-by-case basis to determine if an adjustment in therapy is appropriate, or if alternative therapy should be considered.

**Information for Dog Owners:** PROZINC, like other insulin products, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the associated clinical signs.

The most common adverse reaction observed is hypoglycemia. Signs may include weakness, depression, behavioral changes, muscle twitching, and anxiety. In severe cases of hypoglycemia, seizures and coma can occur. Hypoglycemia can be fatal if an affected dog does not receive prompt treatment.

Appropriate veterinary monitoring of blood glucose, adjustment of insulin dose and regimen as needed, and stabilization of diet and activity help minimize the risk of hypoglycemic episodes. The attending veterinarian should evaluate other adverse reactions on a case-by-case basis to determine if an adjustment in therapy is appropriate, or if alternative therapy should be considered.

**Effectiveness - Cats:** A total of 187 client-owned cats were enrolled in a 45-day field study, with 176 receiving PROZINC. One hundred and fifty-one cats were included in the effectiveness analysis. The patients included various purebred and mixed breed cats ranging in age from 3 to 19 years and in weight from 4.6 to 20.8 pounds.

Effectiveness was based on successful control of diabetes which was defined as improvement in at least one blood glucose variable (glucose curve mean, nadir, or fructosamine) and at least one clinical sign (polyuria, polydipsia, or body weight). Based on this definition, 115 of 151 cases (76.2%) were considered successful.

**Dogs:** A total of 276 client-owned dogs were enrolled in an 84-day field study followed by a 98-day extended-use phase with 276 dogs receiving PROZINC. The dogs included various purebred and mixed breed dogs ranging in age from 2 to 16 years and in weight from 3.3 to 123 pounds.

Effectiveness was based on successful control of diabetes which was defined as improvement in at least one laboratory variable (blood glucose curve mean, blood glucose curve nadir, or fructosamine) and at least one clinical sign (polyuria, polydipsia, or weight loss). Based on this definition, 162 of 224 cases (72%) were considered successful.

Approved by FDA under NADA # 141-297

**Marketed by:**  
Boehringer Ingelheim Animal Health USA Inc.  
Duluth, GA 30096

PROZINC® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc.  
© 2019 Boehringer Ingelheim Animal Health USA Inc. All rights reserved.

Revised 08/2019

449986-01



# Celebrating veterinary professionals one initiative at a time

We are pleased to announce the booming success of the *dvm360*® Veterinary Heroes™ recognition program, designed to celebrate the achievements of veterinary professionals in today's industry. The program encourages veterinarians, veterinary technicians, practice managers, and client service representatives to nominate a professional who makes a significant impact in elevating patient and client care.

Our editorial Advisory Board has been given the difficult task of choosing winners in each category from among a large field of impressive nominees. The winners of the inaugural Veterinary Heroes™ awards will be announced in the December issue of *dvm360*®.

We also want to take a moment to celebrate the triumphant return of the Atlantic Coast Veterinary Conference® (ACVC), a *dvm360*® event. Faculty and attendees were able to learn, network, and engage with each other in Atlantic City, New Jersey, while following safety protocols that included mask-wearing throughout the convention center (except when eating or drinking), social distancing, and hand sanitizing.

Be sure to visit [dvm360.com](http://dvm360.com) to view our online coverage of ACVC with articles and video interviews. Articles also appear in this issue of *dvm360*®.

To add to the plate of successes, *dvm360*® is thrilled to welcome 11 new partners to its Strategic Alliance Partnership (SAP) program including the addition of international inductees. The new SAP members demonstrate the organization's commitment to advancing veterinary medicine worldwide.

As you flip through the pages of this month's issue of *dvm360*®, you will find a variety of topics to digest. Highlights include articles about managing feline stress-related conditions (page 46), ways to promote a healthier work-life balance (page 50), and a look at the role of veterinary technicians in their own words (page 57).

We look forward to seeing all the new and familiar faces at our next live Fetch conference in San Diego, where we will be showcasing the latest veterinary advances and insights. Until then, we hope you are enjoying the crisp air and holidays the fall season brings.

—Mike Hennessy Sr  
Chairman and Founder,  
MJH Life Sciences™


*dvm360*® (Print ISSN: 2326-0688, Digital ISSN: 2326-070X) is published monthly by MultiMedia Healthcare, LLC, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512. Subscription rates: \$48 for one year in the United States & Possessions, Canada and Mexico; all other countries \$108. International pricing includes air-expedited service. Periodicals postage paid at Trenton, NJ 08650 and additional mailing offices. POSTMASTER: Please send address changes to *dvm360*, PO Box 457, Cranbury NJ 08512-0457. Attn: Publications Mail Printed in the U.S.A.

© 2021 MultiMedia Animal Care, LLC All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical including by photocopy, recording, or information storage and retrieval without permission in writing from the publisher. Authorization to photocopy items for internal/educational or personal use, or the internal/educational or personal use of specific clients is granted by MultiMedia Animal Care, LLC for libraries and other users registered with the Copyright Clearance Center, 222 Rosewood Dr. Danvers, MA 01923, 978-750-8400 fax 978-646-8700 or visit [www.copyright.com](http://www.copyright.com) online. For uses beyond those listed above, please direct your written request to Permission Dept. email: [KScaffidi@mjhassoc.com](mailto:KScaffidi@mjhassoc.com).

MultiMedia Animal Care, LLC provides certain customer contact data (such as customers' names, addresses, phone numbers, and email addresses) to third parties who wish to promote relevant products, services, and other opportunities which may be of interest to you. If you do not want MultiMedia Animal Care, LLC to make your contact information available to third parties for marketing purposes, simply email [mmhinfa@mmhgroup.com](mailto:mmhinfa@mmhgroup.com) and a customer service representative will assist you in removing your name from MultiMedia Animal Care, LLC's lists. *dvm360* does not verify any claims or other information appearing in any of the advertisements contained in the publication, and cannot take responsibility for any losses or other damages incurred by readers in reliance on such content. *dvm* cannot be held responsible for the safekeeping or return of unsolicited articles, manuscripts, photographs, illustrations, or other materials. Address correspondence to *dvm360*, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512.



## EDITOR-IN-CHIEF LETTER



## Give thanks. Be thankful.

As we approach the holiday season, it always gives me great pause to be thankful for so many things. This year has been another challenging one, but I am happy to be in a profession that understands the meaning of gratitude, appreciation, and giving back.

Giving back to the profession is one huge way of giving thanks to a profession that is hungry for talented future veterinary professionals. This is something that I am personally passionate about and hope you will find inspiration in this story to do the same.

Over the summer, my very good friend and colleague, Dr Robert Mankowski from Mount Laurel Animal Hospital in Mount Laurel, New Jersey, and I participated in Vet Summer (<https://vetsummer.com/>). This fantastic program is a weeklong, high-level, immersive experience for students ages 12 to 17 years who are interested in entering the field of veterinary medicine. We all know the importance of creating a more diverse, inclusive, and equitable profession for vet med, and when I was approached about helping the director out with the program, I instantly jumped on the opportunity.

The vet summer camp is housed at the College of Mount Saint Vincent in Riverdale, New York. Students experience interactive, hands-on classes

to better understand the variety of fields and careers within veterinary medicine. These are students from all walks of life with the same common denominator—the love of the human-animal bond and the goal of entering our wonderful profession.

On the last day of camp, the 80 students had the privilege to take a bus south to Mount Laurel Animal Hospital, where they had the ability to hang out with Dr Mankowski and me. The happiness, the intrigue, and the passion we saw on these kids' faces were far too similar to the look he and I had as children, when we had that glorious opportunity to shadow a veterinarian. The students were hungry to learn and eager to tour the veterinary hospital.

Dr Mankowski and I provided an interactive session sharing the life of a veterinary professional and how meaningful our profession is. Afterward, students had a pizza party with us where they asked us fantastic questions about the field and what subjects they should continue to focus their attention on as they enter high school. They were diligently writing notes (yes, that's how passionate they were about this field!), laughing, engaging, and enjoying our company as well as each other.

After showing them an extensive tour of the veterinary hospital, we

also showed the students the onsite farm! The veterinary hospital sits on a large farm full of beautiful animals that include goats, chickens, pigs, emus, sheep, cows, alpacas, and zebus. Not only that, but we also showed the students how to pet, feed, and care for these farm animals.

It was one thing for them to observe us, but it was another when they *did* something impactful for the animal. To watch these children have these incredible lightbulb moments truly put a tear in my eye.

Some of them said they never had the opportunity to pet animals like they did that day. To summarize what a group of students said when they got on the bus to say goodbye to us, "this was the *best day ever!* We can't wait to become veterinarians!"

Dr Mankowski and I looked at each other, high-fived, thanked the hospital team for being so welcoming to these students, and drove home knowing we affected, inspired, and motivated 80 students to consider entering our glorious field of veterinary medicine.

So, you see, giving thanks is giving back. Give back to a profession that so desperately needs to inspire future veterinary professionals. Whether it be career day in an elementary school, Zoom visits in classrooms, or just an hour of job shadowing, you will truly affect the lives of children.

Have a phone call with them. Talk to them. Make them feel welcome to the supper table of veterinary medicine.

Our profession is unique because it is truly a calling from within. Most of us knew we wanted to become a veterinarian when we were young. I was 6 years old when I knew I wanted to become a veterinarian and never veered off that challenging path.

I invite you to keep your doors, your hearts, and your minds open to students of any age that inquire about the field of veterinary medicine. Every profession has its flaws and ours is no different. However, it is not our duty to discourage, demotivate, or deny anyone from their calling. It is our mission to encourage, motivate, and allow them to feel inspired by us. Remember, we are superheroes to them. Can you imagine a superhero not signing an autograph to a child that looks up to them?

During this time of thanksgiving, please give thanks to a profession that has welcomed you into it when you were young.

Pay it forward.

Let our lives be full of both thanks and giving.


—Adam Christman,  
DVM, MBA  
Chief Veterinary Officer



**NEW Butterfly iQ+ Vet**

Never miss a ***diagnostic*** opportunity.

Expedite care timelines and improve  
outcomes with handheld veterinary imaging.



When your patients don't speak,  
***an image is worth a thousand words.***



Learn more at

[vet.butterflynetwork.com](https://vet.butterflynetwork.com)

For veterinary  
professionals only.



26  
Dermatology



## » Managing superficial pyoderma with light therapy

Phovia is highly effective for treating superficial and deep skin infection treatments.

By Amelia G. White, DVM, MS, DACVD



### Community

#### 3 Chairman's letter

» Celebrating veterinary professionals one initiative at a time

Mike Hennessy Sr

#### 4 From the CVO

» Give thanks. Be thankful.

Adam Christman, DVM, MBA

#### 12 Commentary

» Life as a Black veterinary student

Simone O Spence

#### 60 Products360


» Supplements, innovative devices, and more

### Contributors

#### 65 The dilemma

» Delivering a needed dose of relief to the veterinary community

Marc Rosenberg, VMD





# KEEP YOUR EAR CARE ON BALANCE.



pH balance is vital to both the overall ear environment and how well it responds to topical applications. With pH•notix™, you can now balance pH and clean the ear — all without rinsing — to help manage the toughest ear challenges in dogs.

pH•notix®

PHX-0011-ADVERTe





News

Industry

- 14**
  - » IVPA praises Michigan Supreme Court ruling pertaining to licensed veterinarians
- 15**
  - » FDA's CVM determines TriviumVet's feline HCM program is eligible for expanded conditional approval pathway
  - » Antitol partners with dog rescue advocate Lee Asher
- 16**
  - » AVMA unveils new "Language of Veterinary Care" online tools and breakthrough research
  - » VHRC launches comprehensive clinical research programs
- 17**
  - » AAFCO urges additional research on animal food hemp products
- 18**
  - » Butterfly Network and AVG collaborate to provide breakthrough in ultrasonography to UrgentVet clinics
  - » Morris Animal Foundation announces new equine, animal welfare advisory members

**20**

- » Dechra acquires veterinary marketing and distribution rights for equine ProVet APC

**21**

- » *dvm360*® welcomes 11 new SAP partners globally
- » VetX International discovers link between leadership actions and practice culture

Technology

**22**

- » Embark Veterinary releases first-ever purebred dog DNA kit

- » Cincinnati Zoo collaborates with scientists to assess validity of remote infrared thermography

**24**

- » Zoetis adds digital cytology testing to Vetscan Imagyst

Well-being

**25**

- » Identifying passion and purpose energizes your life

**66**



- » Tap the tax, saving potential of cash balance plans  
**Jason M. O'Dell, MS, CWM;**  
**and Carole C. Foos, CPA**

medicine360

Nutrition

**30**

- » Easy nutritional math? It was my understanding that there would be no math  
**Rebecca A. Packer, DVM, MS, DACVIM (Neurology/Neurosurgery)**

Endocrinology

**32**

- » National Pet Diabetes Month: Raising awareness and making strides  
**Julia Burke, Assistant Editor, *dvm360*®**

Surgery

**34**

- » Gastric dilatation-volvulus: The twisted truth  
**Elisa M. Mazzaferro, DVM, PhD, MS, DACVECC**

Emergency & critical care

**40**

- » Managing head trauma in veterinary care  
**Kate Boatright, VMD**

Integrative medicine

**42**

- » Product comparison in an unregulated industry: Hemp  
**Stephen Cital, RVT, SRA, RLAT, CVPP, VTS-LAM (Res Anesthesia)**

Behavior

**43**

- » Pitfalls in canine socialization  
**Amanda Carrozza**

Dermatology

**44**

- » Managing dermatological conditions with new treatment options  
**Rebecca A. Packer, DVM, MS, DACVIM (Neurology/Neurosurgery)**

Feline behavior

**46**

- » Managing feline stress-related conditions  
**Kate Boatright, VMD**

Supplement

**48**

- » A breakthrough joint supplement for dogs and cats  
**By Janice L Huntingford, DVM, DACVSMR, CVA, CVPP, CCRT, CAVCA**

Vetted™

Practice management

**50**

- » 7 strategies to support work-life balance for your veterinary team  
**Ivan Zakharenkov, DVM, MBA**

**52**

- » From surviving to thriving: The 4 P's of positive leadership  
**Erica Tricarico**

**56**

- » Improving your "human skills" with communication  
**Kate Boatright, VMD**

**57**

- » Veterinary technicians embrace their roles  
***dvm360*® staff**

Stay stronger together in our community


Scan the QR code below for express visit.



twitter  
@dvm360



instagram  
@dvm360mag



facebook  
@dvm360



pinterest  
dvm360.com





# ANTECH<sup>®</sup>

## Healthy pets. Happy pet parents. High-performance practice.



### Get more reliable, efficient, and affordable diagnostics with Antech.

Diagnostics are essential to your practice. Partner with Antech and reclaim valuable time to focus on your patients and their pet parents—and yourself.

**Reliable** Trusted by thousands of veterinarians, Antech delivers fast and accurate results.

**Efficient** Optimized, time-saving workflows for wellness testing, routine diagnostics, and specialty tests.

**Affordable** We help you minimize operational costs and deliver optimal quality.

### Experience Antech's flexible, can-do spirit.

CALL **1-800-872-1001** VISIT **q-r.to/antech-dvm-1121**

 **Better diagnostics. Better medicine.™**

© 2021 Antech Diagnostics, Inc. All rights reserved. Antech and the Antech logo are the registered trademarks of Antech Diagnostics, Inc. or its affiliates. 101321





# EDITORIAL ADVISORY BOARD



**Christopher J. Allen, DVM, JD**

President, Associates in Veterinary Law, PC

Endwell, NY  
info@veterinarylaw.com



**Liz Bales, VMD**

Writer, speaker, and featured expert in all things cat

Philadelphia, PA



**Marty Becker, DVM**

Founder, Fear Free Adjunct professor, Washington State,

Colorado State, and the University of Missouri Colleges of Veterinary Medicine North Idaho Animal Hospital Sandpoint, ID  
fearfreepets.com



**Jan Bellows, DVM, DAVDC, DABVP**

All Pets Dental Weston, FL

allpetsdental.com  
dentalvet@aol.com



**Ashley Bourgeois, DVM, DACVD**

Animal Dermatology Clinic Portland, OR

@TheDermVet



**Priscilla Bowens, DVM, MPH, JD**

Public health researcher, health preparedness

educator, and health care legal counsel Fort Worth, TX; @drpetnugget



**Bo Brock, DVM**

Brock Veterinary Clinic Lamesa, TX



**Elizabeth "Betsy" Charles, DVM, MA**

Executive director, Veterinary Leadership Institute

Adjunct professor, Washington State University Pullman, WA



**Kelly Cairns, DVM, DACVIM, MS**

Vice president of medical excellence and education, Pathway Vet Alliance

Chicago, IL



**Jenifer Chatfield, DVM, DACZM, DACVPM**

Dr. Jen the vet Tampa, FL



**Stephen Cital, RVT, SRA, RLAT, VCC, CVPP, VTS-LAM**

Anesthesia, pain

management, and cannabinoid expert San Jose, CA



**Steve Dale, CABC**

Radio show host, blogger, and animal behavior expert stevedalepetworld.com

Chicago, IL



**Jackie Dueñas, DVM**

Associate veterinarian, Sunset Animal Clinic Miami Florida, FL



**David Dycus, DVM, MS, CCRP, DACVS-SA**

Medical director, Nexus Veterinary Specialists

Chief of orthopedic surgery, Nexus Veterinary Bone & Joint Center Cofounder/codirector, Veterinary Sports Medicine & Rehabilitation Institute Baltimore, MD  
@Ortho\_Vet



**Amanda Dykstra, DVM, MPH, DABVP**

Certified diplomate, American Board of

Veterinary Practitioners, specializing in shelter medicine Shelter consultant and owner of a nonprofit group working to improve access to care in Appalachia Knoxville, TN



**Ryan Frazier, LVT**


Program chair, Washington State Association of Veterinary Technicians.

Member at Large, National Association of Veterinary Technician in America Committee member, Education and Events, PrideVMC Lynwood, WA



**Bash Halow, LVT, CVPM**

Halow Consulting bashhalow.com New York, NY



**Liz Hughston, MEd, RVT, CVT, LVT, VTS (SAIM) (ECC)**

Relief technician, trainer, and consultant San Francisco

Bay Area San Jose, CA  
facebook.com/VetTechXpert



**Boaz Man, DVM**

Owner and medical director Boca Midtowne Animal Hospital

Boca Raton, FL  
bocamidtownevet.com



**Charles D. McMillan, DVM**

Veterinarian, IndeVets Atlanta, VA



**Shawn Messonnier, DVM**

Paws & Claws Holistic Animal Hospital Plano, TX

pawsandclawsanimalhospital.com



**Chris Pachel, DVM, DACVB, CABC**

Animal Behavior Clinic Vice president of

veterinary behavior Co-owner of Instinct Portland Portland, OR



**Kathryn Primm, DVM, CVPM**

Owner, founder, manager, and chief veterinarian

Applebrook Animal Hospital Ooltewah, TN



**Marc Rosenberg, VMD**

Medical director Voorhees Veterinary Center Voorhees, NJ

mrosenberg27@comcast.net



**Emily Seidl, DVM**

Animal Welfare Association Voorhees, NJ



**Christina V. Tran, DVM**

Associate professor and clinical relations lead veterinarian, University of

Arizona College of Veterinary Board of Directors, Rarebreed Veterinary Partners

Past president and founding board member, Multicultural Veterinary Medical Association Chandler, AZ



**Fred Winger, VMD, MS, DACVIM (Neurology)**

CARE Charlotte Animal Referral & Emergency, Charlotte NC Owner, 3D Veterinary Printing, LLC Founding treasurer, Veterinary Neurosurgical Society Adjunct professor, University of Missouri Charlotte, NC



## Mission

Through its extensive network of news sources, **dvm360** provides unbiased multimedia reporting on all issues affecting the veterinary profession.

## Content

Chief Veterinary Officer **Adam Christman, DVM, MBA**  
Vice President, Content **Colleen Hall**  
Associate Editorial Director **Kristen Crossley**  
Director, Veterinary Education **Renea Lewis**  
Associate Editor **Kelsey Gustafson**  
Assistant Editors **Caitlin McCafferty, Julia Burke**  
Copy Chief **Jennifer Potash**  
Copy Supervisor **Paul Silverman**  
Medical and Scientific Quality Review Editor **Stacey Abels, PhD**  
Senior Copy Editors **Marie-Louise Best, Kelly King**  
Copy Editors **Cheney Baltz, Georgina Carson, Kirsty Mackay, Ron Panarotti, Yasmeen Qahwash**  
Creative Director, Publishing **Melissa Feinen**  
Art Director **Wassana Techadilok**

## Live Events

Director, Conference, Convention, and Expo Services  
**Purti R. Bali, CMP, HMCC**  
Director of Operations **Tom Brown**

## Sales

Vice President, Sales, MJH Life Sciences™ **John Hydrusko**  
**Senior National Accounts Manager**  
**Christina Urie** curie@mjlifesciences.com  
**National Accounts Managers**  
**Angie Homann** ahomann@mmhgroup.com  
**Chris Hurrey** churrey@mjlifesciences.com  
**Andre Wooley** awooley@mmhgroup.com  
Sales and Marketing Coordinator **Melanie Gutierrez**  
Books/Resource Guide Sales **Kristina Bildeaux**  
(507) 895-6758 kbildeaux@mmhgroup.com

## Corporate

President & CEO **Mike Hennessy Jr**  
Vice Chairman **Jack Lepping**  
Chief Financial Officer **Neil Glasser, CPA/CFE**  
Executive Vice President, Global Medical Affairs & Corporate Development **Joe Petroziello**  
Senior Vice President, Content **Silas Inman**  
Senior Vice President, Operations **Michael C. Ball**  
Vice President, Human Resources & Administration **Shari Lundenberg**  
Vice President, Mergers & Acquisitions **Chris Hennessy**  
Executive Creative Director, Creative Services **Jeff Brown**

Chairman & Founder **Mike Hennessy Sr**

AN **MJH** life sciences™ BRAND



2 Clarke Drive, Suite 100, Cranbury, NJ 08512

**Subscriber Services:** Visit [dvm360.com](http://dvm360.com) to request or change a subscription, or email our Customer Service Department at [mmhinfo@mmhgroup.com](mailto:mmhinfo@mmhgroup.com).

**Reprints:** Contact John Hydrusko at (609) 716-7777 or [jhydrusko@mmhgroup.com](mailto:jhydrusko@mmhgroup.com).

**Books and Resource Guides:** Visit [industrymatter.com](http://industrymatter.com).

**List Rental Sales:** Email our Customer Service Department at [mmhinfo@mmhgroup.com](mailto:mmhinfo@mmhgroup.com).

**Editorial Office:** MultiMedia Healthcare LLC, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512.

**Websites:** [dvm360.com](http://dvm360.com); [fetchdvm360.com](http://fetchdvm360.com).



# A HARDY SKIN BARRIER: the best defense against allergens



**NEW!**

# DERMAQUIN<sup>®</sup>

SKIN SUPPORT SUPPLEMENT

with hardy kiwi

Available in SOFT CHEWS for small/medium and large dogs  
To learn more, visit [DERMAQUIN.COM](http://DERMAQUIN.COM)

**nutramax**<sup>®</sup>  
LABORATORIES  
VETERINARY SCIENCES, INC.  
010.1421.00





## Life as a Black veterinary student

Being Black in an (almost) all-White profession isn't easy, but it does offer an opportunity to be a catalyst for change.

By Simone O. Spence

Initially, my journey from Paterson, New Jersey, to the Royal Veterinary College in London, England, seemed like the hardest task of my life. Just like all my peers, I worked hard to get good grades, took the Graduate Record Examinations, spent a fortune on applications, and underwent a whirlwind of interviews. I felt overwhelmed by the entire process, as I am sure others can relate, and had insecure moments where self-doubt crept in. Some of that fear was centered on the usual questions of, “Are my grades good enough?” and “Do I have enough experience?”

However, another fear set in that many of my peers would never have to worry about: Am I prepared to undergo the unique challenges I will

face as a minority in this profession?

The subject of diversity in veterinary medicine has been discussed time and time again. African Americans constitute a tiny percentage of the profession. Being accepted into veterinary school became a terrifying accomplishment for me because I would soon have to walk the path of the few.



Simone O. Spence

Now that I am in my second year of veterinary school, I can see the road that led me here was not nearly as difficult as I thought, and it was only the beginning of my adventure. Moving to a new country a year ago was exciting but terrifying, especially with being thousands of miles away from my family and friends. In addition, my first year of veterinary school was packed full

of general, scientific, and biological information that we must learn to set a foundation for our future clinical years. My classmates and I are also dealing with the unique stress that COVID-19 presents to our learning and lack of social interactions.

With the demands of keeping on top of my coursework, the stress of being away from my family, and restrictions due to COVID-19, I need to remind myself why I am here to keep the self-doubt at bay. Creating uncertainty over noncorrelating factors, such as our intellectual ability and the color of our skin, is an unfortunate human error, but I recognize the unique opportunity that I have to be an example for young, prospective Black veterinary students. Although my fear of being one of the few Black students in my veterinary classes brought on many insecurities,

I now see it as a gift to share my experience and journey with others.

It can be scary trying to achieve what seems impossible when there is a lack of familiarity, and the absence of other students of color around you. Before moving to London, I had hopes that this city's diverse atmosphere might also be displayed within my veterinary program. Unfortunately, this is not the case. I have come to terms that this is the current reality of our profession, but change must be made. I take pride in the fact that though I may be in the minority, I am a trailblazer. I've become my own self-supporter, pushing myself through all the difficulties of being a second-year veterinary student. I'm excited to help pave the way for the Black students and veterinarians yet to come. [dvm360](#)





# vetmedin®

(pimobendan) CHEWABLE TABLETS

## FOR THE HEART *from the start.*

- In clinical studies, dogs treated with VETMEDIN lived almost twice as long from the start of treatment,<sup>1</sup> and required less intensification of therapy to maintain quality of life, than those treated with an ACE inhibitor<sup>2</sup>
- In the US, VETMEDIN has supported over 1 million dogs<sup>3</sup>
- Recommended by the ACVIM as part of standard treatment for dogs with congestive heart failure<sup>4</sup>



Studies show using VETMEDIN from the start gives dogs with CHF the opportunity for better days and longer lives.<sup>5</sup>

**IMPORTANT SAFETY INFORMATION:** VETMEDIN is for use in dogs with clinical evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. **For more information, please see full prescribing information.**

**References:** <sup>1</sup> Häggström J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. *J Vet Intern Med.* 2008;22(5):1124–1135. <sup>2</sup> Häggström J, Boswood A, O'Grady M, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. *J Vet Intern Med.* 2013;27(6):1441–1451. <sup>3</sup> The number of dogs treated with VETMEDIN in the US is estimated by IDEXX Laboratories, Inc. based on transaction data from a representative sample of US veterinary practices. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA. <sup>4</sup> Keene BW, Atkins CE, Bonagura JD, Fox PR, Häggström J, Fuentes VL, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. *J Vet Intern Med.* 2019, 33:1127–1140. <sup>5</sup> Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. *J Am Anim Hosp Assoc.* 2006;42(4):249–261.

VETMEDIN® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.  
©2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0293-2019-V3.



TOGETHER, WE ARE MORE THAN MEDICINE.





# IVPA praises Michigan Supreme Court ruling pertaining to licensed veterinarians

The ruling provides veterinarians the opportunity to use relevant experts in license defense cases.



The Independent Veterinary Practitioners Association (IVPA)—the first nonprofit association committed to uniting independently owned and locally operated veterinary practices—commended the Michigan Supreme Court’s ruling to protect licensed professionals, including veterinarians, stating that all disciplinary actions must be based on expert testimony instead of the reviewing board’s assumptions or perceptions.

According to a news release from the organization, this ruling offers veterinarians with active disciplinary cases the chance to use specialized experts to help defend their license for providing animal care.

“This legislation allows veterinarians to present medical evidence to fairly defend themselves when faced with disciplinary action,” said Jeffrey Powers, DVM, IVPA member and owner of Veterinary Clinics North with 2 Michigan locations, in the release. “Relying on expert testimony will ensure fair and balanced review of the facts of the case to protect animals, individuals, and health care providers alike,” Powers added.

The ruling guarantees the state of Michigan will continuously coincide with the more reasoned and appropriate principles applied throughout many other states nationwide.

“We’re grateful to have worked with the IVPA to ensure that licensed professionals in Michigan are afforded fair rulings based on reliable and trustworthy testimony from experts,” said Christopher Patterson, partner at Fahey Schultz Burzych Rhodes. “We consider this ruling a win not just for IVPA members, but for the idea that licensing processes should be fair and based on reliable evidence.” *dvm360*

## REFERENCE

Independent Veterinary Practitioners Association commends Michigan Supreme Court ruling as it pertains to licensed veterinarians. News release. Independent Veterinary Practitioners Association. September 20, 2021. Accessed September 21, 2021.


159637-002

## VETMEDIN® (pimobendan)

**Chewable Tablets**  
Cardiac drug for oral use in dogs only

**Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**Description:** VETMEDIN (pimobendan) is supplied as oblong half-scored chewable tablets containing 1.25, 2.5, 5 or 10 mg pimobendan per tablet. Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic drug with vasodilative properties. Pimobendan exerts a stimulatory myocardial effect by a dual mechanism of action consisting of an increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (Type II). Pimobendan exhibits vasodilating activity by inhibiting phosphodiesterase III activity. The chemical name of pimobendan is 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazole-5-yl]-5-methyl-3(2H)-pyridazinone. The structural formula of pimobendan is:



**Indications:** VETMEDIN (pimobendan) is indicated for the management of the signs of mild, moderate, or severe (modified NYHA Class II<sup>a</sup>, III<sup>b</sup>, or IV<sup>c</sup>) congestive heart failure in dogs due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM). VETMEDIN is indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.

<sup>a</sup> A dog with modified New York Heart Association (NYHA) Class II heart failure has fatigue, shortness of breath, coughing, etc. apparent when ordinary exercise is exceeded.

<sup>b</sup> A dog with modified NYHA Class III heart failure is comfortable at rest, but exercise capacity is minimal.

<sup>c</sup> A dog with modified NYHA Class IV heart failure has no capacity for exercise and disabling clinical signs are present even at rest.

**Dosage and Administration:** VETMEDIN should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening). The tablets are scored and the calculated dosage should be provided to the nearest half tablet increment.

**Contraindications:** VETMEDIN should not be given in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.

**Warnings:** Only for use in dogs with clinical evidence of heart failure. At 3 and 5 times the recommended dosage, administered over a 6-month period of time, pimobendan caused an exaggerated hemodynamic response in the normal dog heart, which was associated with cardiac pathology (See **Animal Safety**).

**Human Warnings:** Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans.

**Precautions:** The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than AVVI or DCM. The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches.

**Adverse Reactions:** Clinical findings/adverse reactions were recorded in a 56-day field study of dogs with congestive heart failure (CHF) due to AVVI (256 dogs) or DCM (99 dogs). Dogs were treated with either VETMEDIN (175 dogs) or the active control enalapril maleate (180 dogs). Dogs in both treatment groups received additional background cardiac therapy (See **Effectiveness** for details and the difference in digoxin administration between treatment groups).

The VETMEDIN group had the following prevalence (percent of dogs with at least one occurrence) of common adverse reactions/new clinical findings (not present in a dog prior to beginning study treatments): poor appetite (36%), lethargy (33%), diarrhea (30%), dyspnea (29%), azotemia (14%), weakness and ataxia (13%), pleural effusion (10%), syncope (9%), cough (7%), sudden death (6%), ascites (6%), and heart murmur (3%). Prevalence was similar in the active control group. The prevalence of renal failure was higher in the active control group (4%) compared to the VETMEDIN group (1%).

Adverse reactions/new clinical findings were seen in both treatment groups and were potentially related

to CHF, the therapy of CHF, or both. The following adverse reactions/new clinical findings are listed according to body system and are not in order of prevalence: CHF death, sudden death, chordae tendineae rupture, left atrial tear, arrhythmias overall, tachycardia, syncope, weak pulses, irregular pulses, increased pulmonary edema, dyspnea, increased respiratory rate, coughing, gagging, pleural effusion, ascites, hepatic congestion, decreased appetite, vomiting, diarrhea, melena, weight loss, lethargy, depression, weakness, collapse, shaking, trembling, ataxia, seizures, restlessness, agitation, pruritus, increased water consumption, increased urination, urinary accidents, azotemia, dehydration, abnormal serum electrolyte, protein, and glucose values, mild increases in serum hepatic enzyme levels, and mildly decreased platelet counts.

See Table 1 for mortality due to CHF (including euthanasia, natural death, and sudden death) and for the development of new arrhythmias (not present in a dog prior to beginning study treatments) by treatment group and type of heart disease (AVVI or DCM) in the 56-day field study.

**Table 1: CHF Death and New Arrhythmias in the 56-Day Field Study**

	VETMEDIN® Group	Active Control Group
<b>Dogs that died due to CHF</b>	14.3% n = 175	14.4% n = 180
	9 of 126 dogs with AVVI	16 of 130 dogs with AVVI
	16 of 49 dogs with DCM	10 of 50 dogs with DCM
<b>Dogs that developed new arrhythmias<sup>a</sup></b>	39.4% n = 175	45.0% n = 180
	45 of 126 dogs with AVVI	59 of 130 dogs with AVVI
	24 of 49 dogs with DCM	22 of 50 dogs with DCM

<sup>a</sup> New arrhythmias included supraventricular premature beats and tachycardia, atrial fibrillation, atrioventricular block, sinus bradycardia, ventricular premature beats and tachycardia, and bundle branch block

Following the 56-day masked field study, 137 dogs in the VETMEDIN group were allowed to continue on VETMEDIN in an open-label extended-use study without restrictions on concurrent therapy. The adverse reactions/new clinical findings in the extended-use study were consistent with those reported in the 56-day study, with the following exception: One dog in the extended-use study developed acute cholestatic liver failure after 140 days on VETMEDIN and furosemide.

In foreign post-approval drug experience reporting, the following additional suspected adverse reactions were reported in dogs treated with a capsule formulation of pimobendan: hemorrhage, petechia, anemia, hyperactivity, excited behavior, erythema, rash, drooling, constipation, and diabetes mellitus. To report suspected adverse reactions, to obtain a Safety Data Sheet (SDS), or for technical assistance, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact the FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/reportanimalae>.

**Clinical Pharmacology:** Pimobendan is oxidatively demethylated to a pharmacologically active metabolite which is then conjugated with sulfate or glucuronic acid and excreted mainly via feces. The mean extent of protein binding of pimobendan and the active metabolite in dog plasma is >90%. Following a single oral administration of 0.25 mg/kg VETMEDIN tablets the maximal mean (± 1 SD) plasma concentrations (C<sub>max</sub>) of pimobendan and the active metabolite were 3.09 (0.76) ng/ml and 3.66 (1.21) ng/ml, respectively. Individual dog C<sub>max</sub> values for pimobendan and the active metabolite were observed 1 to 4 hours post-dose (mean: 2 and 3 hours, respectively). The total body clearance of pimobendan was approximately 90 mL/min/kg, and the terminal elimination half-lives of pimobendan and the active metabolite were approximately 0.5 hours and 2 hours, respectively. Plasma levels of pimobendan and active metabolite were below quantifiable levels by 4 and 8 hours after oral administration, respectively. The steady-state volume of distribution of pimobendan is 2.6 L/kg indicating that the drug is readily distributed into tissues. Food decreased the bioavailability of an aqueous solution of pimobendan, but the effect of food on the absorption of pimobendan from VETMEDIN tablets is unknown.

In normal dogs instrumented with left ventricular (LV) pressure transducers, pimobendan increased LV dP/dt<sub>max</sub> (a measure of contractility of the heart) in a dose dependent manner between 0.1 and 0.5 mg/kg orally. The effect was still present 8 hours after dosing. There was a delay between peak blood levels of pimobendan and active metabolite and the maximum physiologic response (peak LV dP/dt<sub>max</sub>). Blood levels of pimobendan and active metabolite began to drop before maximum contractility was seen. Repeated oral administration

of pimobendan did not result in evidence of tachyphylaxis (decreased positive inotropic effect) or drug accumulation (increased positive inotropic effect). Laboratory studies indicate that the positive inotropic effect of pimobendan may be attenuated by the concurrent use of a β-adrenergic blocker or a calcium channel blocker.

**Effectiveness:** In a double-masked, multi-site, 56-day field study, 355 dogs with modified NYHA Class II, III, or IV CHF due to AVVI or DCM were randomly assigned to either the active control (enalapril maleate) or the VETMEDIN (pimobendan) treatment group. Of the 355 dogs, 52% were male and 48% were female; 72% were diagnosed with AVVI and 28% were diagnosed with DCM; 34% had Class II, 47% had Class III, and 19% had Class IV CHF. Dogs ranged in age and weight from 1 to 17 years and 3.3 to 191 lb, respectively. The most common breeds were mixed breed, Doberman Pinscher, Cocker Spaniel, Miniature/Toy Poodle, Maltese, Chihuahua, Miniature Schnauzer, Dachshund, and Cavalier King Charles Spaniel. The 180 dogs (130 AVVI, 50 DCM) in the active control group received enalapril maleate (0.5 mg/kg once or twice daily), and all but 2 received furosemide. Per protocol, all dogs with DCM in the active control group received digoxin. The 175 dogs (126 AVVI, 49 DCM) in the VETMEDIN group received pimobendan (0.5 mg/kg/day divided into 2 portions that were not necessarily equal, and the portions were administered approximately 12 hours apart), and all but 4 received furosemide. Digoxin was optional for treating supraventricular tachyarrhythmia in either treatment group, as was the addition of a β-adrenergic blocker if digoxin was ineffective in controlling heart rate. After initial treatment at the clinic on Day 1, dog owners were to administer the assigned product and concurrent medications for up to 56±4 days.

The determination of effectiveness (treatment success) for each case was based on improvement in at least 2 of the 3 following primary variables: modified NYHA classification, pulmonary edema score by a masked veterinary radiologist, and the investigator’s overall clinical effectiveness score (based on physical examination, radiography, electrocardiography, and clinical pathology). Attitude, pleural effusion, coughing, activity level, furosemide dosage change, cardiac size, body weight, survival, and owner observations were secondary evaluations contributing information supportive to product effectiveness and safety.

Based on protocol compliance and individual case integrity, 265 cases (134 VETMEDIN, 131 active control) were evaluated for treatment success on Day 29. See Table 2 for effectiveness results.

**Table 2: Effectiveness Results for the 56-Day Field Study**

	VETMEDIN® Group	Active Control Group
<b>Treatment Success on Day 29</b>	80.7% n = 134	76.3% n = 131
	88 of 101 dogs with AVVI	77 of 100 dogs with AVVI
	20 of 33 dogs with DCM	23 of 31 dogs with DCM
<b>Treatment Success on Day 56</b>	71.1% n = 113	67.2% n = 110
	66 of 85 dogs with AVVI	56 of 85 dogs with AVVI
	13 of 28 dogs with DCM	17 of 25 dogs with DCM
<b>No increase in furosemide dose between Day 1 and Day 29</b>	78.3% n=130	68.6% n=126

At the end of the 56-day study, dogs in the VETMEDIN group were enrolled in an unmasked field study to monitor safety under extended use, without restrictions on concurrent medications.

VETMEDIN was used safely in dogs concurrently receiving furosemide, digoxin, enalapril, atenolol, spironolactone, nitroglycerin, hydralazine, diltiazem, antiparasitic products (including heartworm prevention), antibiotics (metronidazole, cephalaxin, amoxicillin-clavulanate, fluoroquinolones), topical ophthalmic and otic products, famotidine, theophylline, levofloxacin sodium, diphenhydramine, hydrocodone, metoclopramide, and butorphanol, and in dogs on sodium-restricted diets.

**Palatability:** In a laboratory study, the palatability of VETMEDIN was evaluated in 20 adult female Beagle dogs offered doses twice daily for 14 days. Ninety percent (18 of 20 dogs) voluntarily consumed more than 70% of the 28 tablets offered. Including two dogs that consumed only 4 and 7% of the tablets offered, the average voluntary consumption was 84.2%.

**Animal Safety:** In a laboratory study, VETMEDIN chewable tablets were administered to 6 healthy Beagles per treatment group at 0 (control), 1, 3, and 5 times the recommended dosage for 6 months. See Table 3 for cardiac pathology results. The cardiac pathology/histopathology noted in the 3X and 5X dose groups is typical of positive inotropic and vasodilator drug toxicity in normal dog hearts, and is associated with exaggerated hemodynamic responses to these drugs. None of the dogs developed signs of heart failure and there was no mortality.

**Table 3: Incidence of Cardiac Pathology/Histopathology in the Six-month Safety Study**

Severe left ventricular hypertrophy with multifocal subendocardial ischemic lesions	One 3X and two 5X dogs <sup>a</sup>
Moderate to marked myxomatous thickening of the mitral valves	Three 5X dogs
Myxomatous thickening of the chordae tendineae	One 3X and two 5X dogs
Endocardial thickening of the left ventricular outflow tract	One 1X and 3X, and two 5X dogs
Left atrial endocardial thickening (jet lesions) in 2 of the dogs that developed murmurs of mitral valve insufficiency	One 3X and two 5X dogs
Granulomatous inflammatory lesion in the right atrial myocardium	One 3X dog

<sup>a</sup> Most of the gross and histopathologic findings occurred in these three dogs

Murmurs of mitral valve insufficiency were detected in one 3X (Day 65) and two 5X dogs (Days 135 and 163). These murmurs (grades II-III or VI) were not associated with clinical signs.

Indirect blood pressure was unaffected by VETMEDIN at the label dose (1X). Mean diastolic blood pressure was decreased in the 3X group (74 mmHg) compared to the control group (82 mmHg). Mean systolic blood pressure was decreased in the 5X group (117 mmHg) compared to the control group (124 mmHg). None of the dogs had clinical signs of hypotension.

On 24-hour Holter monitoring, mean heart rate was increased in the 5X group (101 beats/min) compared to the control group (94 beats/min). Not counting escape beats, the 3X and 5X groups had slightly higher numbers of isolated ventricular ectopic complexes (VES). The maximum number of non-escape VES recorded either at baseline or in a control group dog was 4 VES/24 hours. At either Week 4 or Week 20, three 3X group dogs had maximums of 33, 13, and 10 VES/24 hours, and two 5X group dogs had maximums of 22 and 9 VES/24 hours. One 1X group dog with no VES at baseline had 6 VES/24 hours at Week 4 and again at Week 20. Second-degree atrioventricular heart block was recorded in one 3X group dog at Weeks 4 and 20, and in one dog from each of the 1X and 5X groups at Week 20. None of the dogs had clinical signs associated with these electrocardiogram changes.

Treatment was associated with small differences in mean platelet counts (decreased in the 3X and 1X groups), potassium (increased in the 5X group), glucose (decreased in the 1X and 3X groups), and maximum blood glucose in glucose curves (increased in the 5X group). All individual values for these variables were within the normal range. Three 1X and one 5X group dogs had mild elevations of alkaline phosphatase (less than two times normal). Loose stools and vomiting were infrequent and self-limiting.

**Storage Information:** Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).

## How Supplied:

VETMEDIN® (pimobendan) Chewable Tablets: Available as 1.25, 2.5, 5 and 10 mg oblong half-scored chewable tablets - 50 tablets per bottle.

NDC 0010-4490-01-1.25 mg - 50 tablets  
NDC 0010-4482-01-5 mg - 50 tablets  
NDC 0010-4481-01-2.5 mg - 50 tablets  
NDC 0010-4479-01-10 mg - 50 tablets

Approved by FDA under NADA # 141-273

## Marketed by:

Boehringer Ingelheim Animal Health USA, Inc. Duluth, GA 30096

VETMEDIN® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH used under license.

© 2020 Boehringer Ingelheim Animal Health USA Inc. All rights reserved.

448005-01  
Revised 06/2020

US-PET-0205-2021



# FDA's CVM determines TriviumVet's feline HCM program is eligible for expanded conditional approval pathway

The company was granted permission to pursue conditional approval because the CVM recognizes there is no current approved animal drug in the United States for treating feline HCM.

By dvm360° staff

**T**riviumVet, an Ireland-based animal health research and development company, announced that the United States Food and Drug Administration's (FDA) Center for Veterinary Medicine (CVM) has deemed it can pursue the expanded conditional approval pathway for its feline hypertrophic cardiomyopathy (HCM) therapeutic candidate Felycin—a patented, delayed-release rapamycin formulation.

Under the 2018 reauthorization of the FDA's Animal Drug User Fee Act, Congress permitted the FDA a limited expansion of the conditional approval pathway for certain new animal drugs. According to a company release,<sup>1</sup> conditional approval allows drug sponsors to legally market a product after proving that the drug is safe, manufactured in accordance with rigorous standards, and there is a reasonable expectation of effectiveness for use while completing the critical clinical studies.

With TriviumVet granted permission to pursue conditional approval, CVM understands there is no

existing approved animal drug in the United States for treating feline HCM—a serious, life-threatening disease that affects about 15% of cats.<sup>2</sup>

“We are very pleased with this positive response from CVM because it establishes a pathway to first conditional and then full approval, potentially expediting access to the drug for millions of at-risk patients. We are excited to share results of our clinical work early next year and intend to submit our final study report to CVM once these results are available,” said TriviumVet CEO Louise Grubb, MBS, BSc, in the release.<sup>1</sup>

“At TriviumVet we strive to produce treatments for clinical unmet needs and feline HCM is one of the diseases that must urgently be addressed. The interest in this treatment was highlighted in our December 2020 survey of US veterinarians carried out by Brakke Animal Health where 80% of respondents were likely to prescribe a novel product to their HCM patients,” she added.

TriviumVet is conducting clinical research in client-owned cats to analyze Felycin's effectiveness

in treating HCM. Previous results from laboratory animal studies and effects demonstrated in human organ transplant patients imply Felycin has the potential to slow or reverse the adverse cardiac remodeling underlying the disease process in HCM, according to the release.<sup>1</sup>

Preclinical investigations have demonstrated repeated dosing with Felycin is well tolerated by healthy cats at multiples of the intended therapeutic dose. [dvm360°](#)

## REFERENCES

1. FDA's Centre for Veterinary Medicine deems TriviumVet's feline HCM program eligible for expanded conditional approval pathway. News release. TriviumVet. September 16, 2021. Accessed September 17, 2021. [www.prnewswire.com/news-releases/fdas-centre-for-veterinary-medicine-deems-triviumvets-feline-hcm-program-eligible-for-expanded-conditional-approval-pathway-301378597.html](http://www.prnewswire.com/news-releases/fdas-centre-for-veterinary-medicine-deems-triviumvets-feline-hcm-program-eligible-for-expanded-conditional-approval-pathway-301378597.html)
2. Client information sheet: feline hypertrophic cardiomyopathy. NC State Veterinary Hospital. Accessed September 17, 2021. [https://cvm.ncsu.edu/wp-content/uploads/2020/07/Feline-Hypertrophic-Cardiomyopathy-client-handout-6.29.2020.pdf#:~:text=Feline%20Hypertrophic%20Cardiomyopathy%20\(HCM\)%20is,pressure%20or%20an%20overactive%20thyroid](https://cvm.ncsu.edu/wp-content/uploads/2020/07/Feline-Hypertrophic-Cardiomyopathy-client-handout-6.29.2020.pdf#:~:text=Feline%20Hypertrophic%20Cardiomyopathy%20(HCM)%20is,pressure%20or%20an%20overactive%20thyroid)

# Antinol partners with dog rescue advocate Lee Asher

By dvm360° staff

**V**etz Petz, exclusive distributors of the pet joint health supplement Antinol, announced its partnership with Lee Asher, founder of The Asher House, a 501(c)(3) organization committed to pet rescue. The partnership will spotlight the supplement's transformational effect on dogs while informing pet parents of the significance of maintaining canine joint health and mobility.

“Every day, I see firsthand how the discomfort that comes along with aging and activity impact my

dogs' joint health and mobility,” said Asher in a news release. “I think all pet owners would benefit from a better understanding of how we can help our dogs continue to be happy, comfortable, and active even as they age. I'm excited to share my dogs' Antinol journey over the coming months.”

After the official launch of Antinol within the United States this summer, Vetz Petz is introducing a nationwide initiative, Keeping Happiness in Motion, that urges pet owners to play a role in improving canine quality of

life. The initiative will include Asher documenting the before-and-after mobility transformational journey of his 5 rescue dogs as they take Antinol daily over several months.

What's more, Asher's journey will be showcased through a series of videos on his Instagram—@TheAsherHouse—and through Antinol's social channels, @Antinol\_USA on Instagram and AntinolUSA on Facebook. Pet parents are also encouraged to participate in the initiative by sharing content demonstrating their pet's journey of

“keeping happiness in motion” on social media.

“Our goal is to make everyday moments better for longer through tackling joint and mobility discomfort for pets of all shapes and sizes,” said Kevin Cook, Vetz Petz founding partner. “We know Lee shares in this passion and commitment, and we're so excited to share the mobility transformational journeys of Lee's amazing rescue pups with our audience and his, and share our Keeping Happiness in Motion movement with pet owners across the US.” [dvm360°](#)

## REFERENCE

- Leading pet joint health supplement Antinol announces partnership with dog rescue advocate Lee Asher, founder of The Asher House. News release. Vetz Petz. September 8, 2021. Accessed September 13, 2021.



## AVMA unveils new "Language of Veterinary Care" online tools and breakthrough research

These resources will enhance the personal connections and communication between veterinary professionals and clients, educate pet owners on the need to prioritize wellness visits, and much more.

By *dvm360*® staff

The American Veterinary Medical Association (AVMA) has released "Language of Veterinary Care," a set of comprehensive new online tools to help veterinarians effectively communicate to pet parents about the value of preventive care and the importance of wellness visits.

According to an AVMA news release, these resources emphasize personal connections and improved communication by enabling veterinary professionals to use "language that works" when conversing with clients about why and when they should go to the veterinarian, the various services available, and the costs of care.

"Pet owners want to do what's best for their animals," said José Arce, DVM, president of the AVMA, in the release. "Our goal is to help our members better engage with their clients so pet owners bring their animals in for regular checkups and follow their veterinarians' recommendations. Improved communications can also help alleviate some of the pressures that veterinarians, clinic staffs, and pet owners are experiencing because of the [COVID-19] pandemic."

Although most pet parents get regular veterinary care for their animals and have confidence in their veterinarians, research conducted by AVMA discovered that some owners still do not seek regular veterinary care for their pets; the main reasons cited involved affordability and value perception challenges, according to the release.

To help combat these hurdles, AVMA teamed up with a language strategy firm to investigate how veterinary teams can better connect with clients. The research offered insight from pet owners regarding their preference in communication and

what resonates most with them during visits—finding its valued relationships and personalized care. With assistance from Synchrony's products, CareCredit and Pets Best Insurance Services, AVMA is developing a series of content pieces available to members for translating this research into actionable information for veterinary use.

"Language matters and we are excited to support this initiative to help veterinarians communicate the importance of wellness care in ways that resonate with pet owners," said Boo Larsen, general manager of veterinary medicine at Synchrony. "We are thrilled to sponsor this groundbreaking study because of its emphasis on building stronger communication between veterinarians and their clients to support personalized recommendations and trusted relationships. This meshes perfectly with our commitment to strengthening the veterinary/client/patient bond by weaving cost and financial choices into the relationship to keep the focus on the pet's care."

"We are very grateful to Synchrony for helping to bring this far-reaching and thorough research into the spotlight, and for supporting these path-breaking new initiatives that will benefit animals, clients, and veterinarians alike," remarked Arce. *dvm360*®

### REFERENCE

Groundbreaking new Language of Veterinary Care research finds that pet owners value relationship and personalized care when interacting with veterinary teams. News release. American Veterinary Medical Association. September 20, 2021. Accessed September 20, 2021. [www.avma.org/news/press-releases/american-veterinary-medical-association-unveils-new-tools-and-resources-help](http://www.avma.org/news/press-releases/american-veterinary-medical-association-unveils-new-tools-and-resources-help)

## VHRC launches comprehensive clinical research programs

Findings will help accelerate advances in pet products, medications, therapies, and devices.

By *dvm360*® staff

Veterinary Health Research Centers LLC (VHRC) is introducing clinical research programs with a worldwide network of trial sites to power studies leading to safe, effective pet products, medications, therapies, and devices.

According to a company news release, VHRC Certified Practices offers solutions for pharmaceutical companies, entrepreneurs, and innovators, with the goal being efficient, cost-effective clinical trials.

"Data-driven evidence is critical today in demonstrating efficacy of advanced treatment options before they are approved," said VHRC founder Joel Ehrenzweig in the release. "Using companion animals with naturally occurring ailments like kidney and heart disease, cancer, and obesity makes sense because the response to many treatments is similar in dogs, cats, and individuals."

Comprising general practices and specialty hospitals with advanced equipment and expert skill sets, this exclusive network of veterinary clinical trial sites enables VHRC to deliver results from proof of concept to commercialization, according to the release.

"Each VHRC Certified Practice site receives advanced GCP/EDC and technology-specific training as part of a rigorous site validation process prior to the initiation of each project," said Rob Hunter, PhD, chief science and regulatory officer at VHRC, in the release. "VHRC Certified Practices include acclaimed regional referral centers and niche specialists that can focus on fulfilling often esoteric patient enrollment requirements."

Ongoing trials at VHRC for B-Cure Lasers ([www.bcurelaservet.com](http://www.bcurelaservet.com)) are focused on treating knee, spine, and hip joint pain as well as gingivitis, particularly in senior dogs and cats. *dvm360*®

### REFERENCE

Veterinary Health Research Centers launches clinical research programs for animal health, pharma and medical device companies. News release. Veterinary Health Research Centers. September 23, 2021. Accessed September 29, 2021. <https://www.biospace.com/article/veterinary-health-research-centers-launches-clinical-research-programs-for-animal-health-pharma-and-medical-device-companies/>



# AAFCO urges additional research on animal food hemp products

Using these products before extensive studies and legal approval processes can negatively affect ranchers' access to markets, animal health, and ultimately human health.

By dvm360® staff

The Association of American Feed Control Officials (AAFCO) is calling for action on hemp and its by-products—including whole hemp plants, hemp seed oil, cannabidiol, and other cannabinoids—in livestock feed and pet food. AAFCO, which provides ingredient guidance for feed regulators, is urging the hemp and feed industries to continue studying the safety and efficacy of these products as nutritional ingredients.

AAFCO can use those findings to formally define the ingredients and offer standards for pet and livestock feed, the organization said in a news release. “We understand the hemp industry is eager to enter the animal food market, but we are concerned that not enough research has been completed on these products,” said Susan M. Hays, AAFCO executive director, in the release. “That’s why we are urging the hemp industry to conduct appropriate research and submit their results to us for review as a normal step in our ingredient approval process.”

Although the 2018 United States Farm Bill legalized growing hemp, any feed ingredient—including hemp products—is under the jurisdiction of the United States Food and Drug Administration (FDA). Because research is required to identify the levels of Δ-9-tetrahydrocannabinol (THC) and other cannabinoids in hemp and the effects on intended uses and species, it is not known whether hemp products are safe for animal consumption.

“Allowing hemp by-products to be used for animal nutrition before

rigorous research and legal approval processes have been completed could have adverse impacts on ranchers’ access to markets, on animal health, and ultimately on human health when hemp-fed animal products enter the human food chain,” Hays said.

Supporters of hemp in feed advocate passing state legislation to enable in-state use of hemp as a feed ingredient, but there is no national approval for such a move based on a comprehensive scientific review of its safety.

According to the release, AAFCO is concerned that welcoming hemp products to market through varying state laws, without research and review, will result in inconsistent manufacturing methods, unsupported marketing claims, and restriction of interstate and international markets.

The organization urges lawmakers to collaborate with stakeholders including the FDA, United States Department of Agriculture, the National Association of State Departments of Agriculture, livestock and dairy associations, consumer advocacy groups, and AAFCO itself within the review and approval process for hemp and its by-products concerning animal nutrition. AAFCO said it can guide hemp producers through the submission and review process. [dvm360®](#)

#### REFERENCE

AAFCO calls for hemp industry action on hemp products in animal food. News release. Association of American Feed Control. September 20, 2021. Accessed September 21, 2021. [www.prnewswire.com/news-releases/aafco-calls-for-hemp-industry-action-on-hemp-products-in-animal-food-301380249.html](http://www.prnewswire.com/news-releases/aafco-calls-for-hemp-industry-action-on-hemp-products-in-animal-food-301380249.html)



**Earn your end-of-year veterinary CE credits in person and enjoy San Diego.**

Join us in San Diego for high-impact CE classes created by veterinary professionals for veterinary professionals—and reconnect with peers, friends, faculty and exhibitors!

You'll leave with the inspiration to tackle your toughest practice problems—and provide animals with the love and care they deserve.

Register today by visiting the link below or scanning the QR code.  
[fetchdvm360.com](http://fetchdvm360.com)



San Diego, CA | Dec. 2-5, 2021

@fetchdvm360



**Paw Finders**  
THE ONLY TAG YOU NEED.™

**RABIES TAG & LOST PET RECOVERY ALL IN ONE TAG.**

- QR contains pet owner's contact info
- Easy to use vet portal for tag registration
- Less calls to your vet's office about lost pets
- SAME COST AS CURRENT RABIES TAG  
\$2.99 registration fee can be passed along to the pet owner in the vaccine price.

For more info about Paw Finders visit **PAWFINDERS.COM**

PATENT PENDING  
A PRODUCT OF NATIONAL BAND & TAG CO.



## Butterfly Network and AVG collaborate to provide breakthrough in ultrasonography to UrgentVet clinics

By dvm360® staff

**B**utterfly Network, Inc. and American Veterinary Group (AVG) have teamed up to equip all UrgentVet clinics with the Butterfly iQ Vet—a single-probe, whole-body ultrasound system designed for all animals.

According to a company news release, UrgentVet is owned and operated by AVG and is the first dedicated urgent care practice for pets. The partnership with Butterfly Network was finalized after an iQ Vet was used in UrgentVet clinics.

“With COVID-19–related restrictions in our clinics, the volume of work has been felt by our team. We are a tech-focused, forward-thinking organization striving to continue to offer care in the way we always

envisioned it—fast and expertly done,” said UrgentVet founder Jim Dobies, DVM, in the release.

“Prior to using the Butterfly iQ Vet, we were using an ultrasound [system] that was more expensive and not as portable. The Butterfly technology was perfectly suited to what we do. In an acute setting, the Butterfly iQ Vet is fantastic. It can go anywhere,” Dobies said.

The Butterfly iQ Vet is user-friendly for staff new to ultrasonography and helps with scans done by UrgentVet practice members. Additionally, Dobies said the real-time diagnostics within the examination room have helped demonstrate to owners what their pets are experiencing.

In addition, iQ Vet has been used by veterinarians to offer diagnostic insights and better care to all species. According to the release, patented Ultrasound-on-Chip technology lets Butterfly iQ Vet leverage the power of a semiconductor chip, pairing this with intuitive software accessible on a compatible mobile device or tablet (UrgentVet uses it most frequently with an iPad).

“Veterinary urgent care clinics are busier than ever. This is an important time to offer our powerful diagnostic tool, iQ Vet, that allows for fast and easy assessment,” said Darius Shahida, Butterfly Network’s chief strategy officer and chief business development officer.

“The iQ Vet makes [ultrasonography] as convenient as using a stethoscope, which is critically important for urgent care clinics. We are proud to support UrgentVet as the organization grows and expands,” he added. [dvm360®](#)

### REFERENCE

Butterfly Network, American Veterinary Group collaborate to equip all UrgentVet clinics with point-of-care ultrasound. News release. Butterfly Network, Inc. September 23, 2021. Accessed September 27, 2021.

## Morris Animal Foundation announces new equine, animal welfare advisory members

By dvm360® staff

**M**orris Animal Foundation, a nonprofit organization in Denver, Colorado, funding scientific research to advance animal health and well-being, has announced 4 new members of its equine scientific advisory board and 1 of its animal welfare advisory board.

“We are honored to welcome our new advisory board members and appreciate the depth of international experience they bring, particularly in this year’s equine research focus area of colic,” said Janet Patterson-Kane, PhD, BVSc, chief scientific officer at Morris Animal Foundation, in a news release.

Individuals on the equine scientific advisory board are volunteer experts in their industry who help ensure fair, unbiased funding decisions to improve horse health worldwide. Those on the animal welfare advisory board review approved studies to guarantee they advance health while protecting animal welfare.

Joining the equine scientific advisory board team are:

**Debra Archer, PhD, BVM&S, CertESTS, DipECVS, MRCVS:** Archer is a professor of equine surgery at the University of Liverpool’s Philip Leverhulme Equine Hospital in the United Kingdom and is the University of Liverpool’s lead

for veterinary clinical research. Her clinical interests include all areas of equine surgery and emergency care, with special interest in colic. Archer is lead investigator of the International Colic Surgery Audit, involving multiple clinics worldwide, and a large, multicenter clinical trial (CHARIOT lidocaine trial).

**Sarah Freeman, PhD, BVetMed CertVA, CertVR, CertES (Soft Tissue), DipECVS MRCVS Associate:** Freeman is a professor of veterinary surgery at the University of Nottingham in the United Kingdom. Freeman’s research interests include wound management, end-of-life decision-making, and clinical disease in horses, specifically colic and musculoskeletal disease. She leads the Nottingham Equine Colic Project that assists owners and veterinarians with early recognition and assessment of equine colic.

**Pat Harris, PhD, MA, VetMB, DipECVCN, MRCVS:** Harris is a specialist in veterinary clinical and comparative nutrition and serves as director of science for MARS Horsecare, head of the WALTHAM Equine Studies Group at the Waltham Petcare Science Institute and scientific adviser for MARS EQUESTRIAN Sponsorship.

She collaborates with experts on equine health and nutrition research at institutes and universities worldwide.

**Mathijs Theelen, DVM, BKO, ECEIM:** Theelen is a specialist in equine internal medicine and head of the foal intensive care unit at Utrecht University’s Equine Hospital in the Netherlands. His clinical interests include antimicrobial susceptibility and resistance in horses and foals, and the role of the gut microbiome in overall equine health.

Joining the animal welfare advisory board team is: **Kat Littlewood, BVSc (Dist), PGDipVCSc (Dist), AFHEA, MANZCVS (Animal Welfare):** Littlewood is a veterinarian in the Animal Welfare Science and Bioethics Centre at Massey University in New Zealand. Littlewood’s research interests include animal welfare and behavior, veterinary ethics, human behavior change for animals, and end-of-life decision-making. [dvm360®](#)

### REFERENCE

Morris Animal Foundation welcomes new equine and animal welfare advisory members. News release. Morris Animal Foundation. September 20, 2021. Accessed September 29, 2021. [www.morrisanimalfoundation.org/article/new-animal-welfare-and-equine-advisory-board-members](http://www.morrisanimalfoundation.org/article/new-animal-welfare-and-equine-advisory-board-members)



**Elura™**  
(capromorelin oral solution)

Elura helps cats with CKD maintain  
or gain weight to keep them

*feline fabulous*



It can be hard to watch cats with chronic kidney disease (CKD) waste away. Prescribe Elura at the first sign of weight loss in your feline CKD patients.

MORE THAN 8/10 CATS  
GAINED WEIGHT\*1

UNIQUE MOA MIMICS  
THE NATURALLY  
OCCURRING  
HORMONE GHRELIN

SAFE TO USE DAILY  
AND APPROVED FOR  
LONG-TERM USE

ORAL SOLUTION WITH  
LOW DOSING VOLUME

## INDICATION

For the management of weight loss in cats with chronic kidney disease.

## IMPORTANT SAFETY INFORMATION

For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin, or in cats with hypersomatotropism (acromegaly). Elura may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration, or hepatic dysfunction. Elura has not been evaluated in cats younger than 5 months of age, or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy. Please see accompanying brief summary for product safety information.

\*Compared to 4/10 control cats. A multi-center, placebo-controlled, randomized and masked field study including 176 cats with CKD and at least 5% unintended loss of body weight (as compared to the highest weight in the medical records for the 3 years preceding enrollment). Study period was 56 days (Day 0 – Day 55). Primary endpoint was percent change in weight from Day 0 to Day 55. CKD, chronic kidney disease.

1. Elura Freedom of Information Summary. NADA 141-536. 2020.

© 2021 ELANCO OR ITS AFFILIATES. ELURA, ELANCO AND THE DIAGONAL BAR LOGO ARE TRADEMARKS OF ELANCO OR ITS AFFILIATES. PM-US-21-0733

**Elanco™**



# Elura™

(capromorelin oral solution)

20 mg/mL  
For oral use in cats only

**CAUTION:**

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Before using Elura, please consult the product insert, a summary of which follows:

**INDICATION:**

For management of weight loss in cats with chronic kidney disease.

**DOSAGE AND ADMINISTRATION:**

Administer ELURA orally at a dose of 2 mg/kg (0.9 mg/lb) or 0.1 mL/kg (0.045 mL/lb) body weight once daily.

**CONTRAINDICATIONS:**

ELURA should not be used in cats that have a hypersensitivity to capromorelin.

**WARNINGS:**

Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans.

**For oral use in cats only.**

Do not use in cats with hypersomatotropism (acromegaly). ELURA may increase serum glucose for several hours after dosing. Use in cats with current or historical diabetes mellitus has not been evaluated and use may not be appropriate.

**PRECAUTIONS:**

Use with caution in cats that may have cardiac disease or severe dehydration. ELURA causes transient decreases in heart rate and blood pressure up to 4 hours following dose administration. Some cats may exhibit clinical signs of bradycardia or hypotension following administration of ELURA. Use with caution in cats with hepatic dysfunction. Capromorelin is metabolized in the liver in humans and dogs and similar metabolism is expected in the cat. The safe use of ELURA has not been evaluated in cats younger than 5 months old. The safe use of ELURA has not been evaluated in cats that are pregnant, lactating, or intended for breeding.

**ADVERSE REACTIONS:**

Safety was evaluated in a 56-day field effectiveness study in 176 client-owned cats (118 administered ELURA, 58 administered vehicle control) that received at least one dose. Cats enrolled had  $\geq 5\%$  unintended weight loss and a history of chronic kidney disease (CKD). Cats had a mean age of 15 years and at enrollment 11.4% of the cats were in Stage 1 CKD, 66.5% were in Stage 2, 21.0% were in Stage 3, and 1.1% were in Stage 4. Cats enrolled in the study had a variety of comorbid conditions: dental disease (88.1%), moderate or severe muscle loss (43.2%), heart murmur (28.4%), history of vomiting or underlying gastrointestinal disease (28.4%), hyperthyroidism (13.6%) and hypertension (9.7%).

**Table 1: Adverse Reactions in the Field Effectiveness Study**

Adverse Reaction	ELURA (n=118)	Vehicle Control (n=58)
Vomiting	35 (29.6%)	13 (22.4%)
Hypersalivation	25 (21.2%)	0 (0.0%)
Inappetence	22 (18.6%)	7 (12.0%)
Behavior Change <sup>a</sup>	17 (14.4%)	3 (5.2%)
Lethargy	16 (13.6%)	6 (10.3%)
Anemia	11 (9.3%)	1 (1.7%)
Dehydration	11 (9.3%)	2 (3.4%)
Stage of CKD Increased <sup>b</sup>	10 (8.5%)	3 (5.2%)
Diarrhea	9 (7.6%)	2 (3.4%)
Urinary Tract Infection	8 (6.8%)	2 (3.4%)
Hyperglycemia	8 (6.8%)	2 (3.4%)
Upper Respiratory Infection	7 (5.9%)	1 (1.7%)
Hypercalcemia	7 (5.9%)	0 (0.0%)

Adverse Reaction	ELURA (n=118)	Vehicle Control (n=58)
Facial Skin Lesion	6 (5.1%)	3 (5.2%)
Hyperkalemia	5 (4.2%)	0 (0.0%)
Ataxia	4 (3.4%)	0 (0.0%)
Diabetes Mellitus	1 (0.8%)	0 (0.0%)
Congestive Heart Failure	1 (0.8%)	0 (0.0%)

Note: If an animal experienced the same event more than once, only the first occurrence was tabulated.

<sup>a</sup> Behavior change included hiding from the owner (8 ELURA, 1 vehicle control); owner reported difficulty administering medication (7 ELURA, 1 vehicle control); and redirected aggression to another household cat (2 ELURA, 1 vehicle control).

<sup>b</sup> Two ELURA and 1 vehicle control cat increased by two CKD stages; 8 ELURA and 2 vehicle control cats increased one CKD stage. It could not be determined if the progressive renal disease was the natural course of the pre-existing disease or treatment related.

Hypersalivation was generally associated with dosing and resolved within a few minutes.

Nine cats (8 ELURA and 1 vehicle control) either died or were euthanized during or shortly after the study. Six ELURA cats were euthanized or died from decompensated CKD. One ELURA cat was euthanized after study withdrawal on Day 33 for declining quality of life and recent identification of a new mass. One ELURA cat acutely declined and was euthanized for findings of nodules in both kidneys and diagnosis of sarcoma. The vehicle control cat was euthanized for acute onset of right hindlimb paresis and suspected embolic event. Two additional cats were diagnosed with neoplasia during the study (one ELURA cat with unspecified soft tissue sarcoma and one control cat with mammary adenocarcinoma) but completed the study. In voluntary post-approval reporting for extra-label use of a capromorelin product for dogs, the following adverse events have been reported in cats (listed in decreasing order of reporting frequency): bradycardia, lethargy, hypersalivation, hypotension, behavior change, and vomiting.

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US, Inc. at 1-888-545-5973.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>.

**EFFECTIVENESS:**

Effectiveness was demonstrated in a multicenter, prospective, masked, randomized, vehicle-controlled field study. The study enrolled 176 client-owned cats with  $\geq 5\%$  unintended weight loss and a history of chronic kidney disease. The cats enrolled included 96 females and 80 males of various breeds, 4.4 - 22.1 years old with a mean age of 15 years and weighing 1.81 - 6.76 kg. CKD stage was determined based on creatinine at screening according to the International Renal Interest Society (IRIS) 2015 guidelines. All stages were enrolled. Cats were administered ELURA at 2 mg/kg or a matched volume of control once daily by mouth for 56 days. The control was the solution without capromorelin (vehicle control). The primary effectiveness variable was the percent change in body weight from Day 0 to Day 55. Effectiveness was evaluated in 112 cats: 71 cats administered ELURA and 41 cats administered vehicle control. There was a statistically significant difference between the percent change in weight for the ELURA group (+5.2%) compared to the vehicle control group (-1.6%) at Day 55 ( $p < 0.0001$ ). Secondary analysis for percent change in weight at Day 15 and Day 27 demonstrated cats in the ELURA group gained weight throughout the study.

**STORAGE CONDITIONS:**

Store at or below 86°F (30°C)

**HOW SUPPLIED:**

20 mg/mL flavored oral solution in a 15 mL bottle with an oral dosing syringe.

Approved by FDA under NADA # 141-536.

Manufactured for: Elanco US Inc, Greenfield, IN 46140 USA

REV. DATE-10/2020

ELURA, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

PA402828X



W2a

# Dechra acquires veterinary marketing and distribution rights for equine ProVet APC

The global specialist in veterinary pharmaceuticals will have an exclusive license for equine ProVet APC and ProVet BMC.

By *dvm360* staff

Dechra Veterinary Products recently announced its acquisition of an exclusive license from Hassinger Biomedical for equine ProVet APC (Autologous Platelet Concentrate) and ProVet BMC (Bone Marrow Concentrate).

“ProVet APC has become the most highly sought-after regenerative system for equine athletes,” said Amy Hassinger, CEO of Hassinger Biomedical, in a news release. “We believe Dechra is especially poised through its experience in the veterinary sector to meet the growing global demand by veterinarians and their clients for the ProVet APC and BMC Regenerative Therapy System.”

According to the release, the 2 patented medical devices concentrate platelets or bone marrow in 90 seconds with a processing time of 2.5 minutes. The technology found within ProVet APC has been found to consistently deliver 6 to 8 mL of a 7.8 higher concentration of platelet-rich plasma and can have a healing concentrate obtained from 54 mL of whole blood in the 60 mL system.

“The medical industry has long recognized that harnessing the growth factors found in platelets positively enhances healing results and reduces recovery time in soft tissue injuries,” said Mike Eldred, president of Dechra North America, in the release.

“These 2 products will be great additions to our equine product line and further strengthen our market position in veterinary regenerative medicine,” he continued.

Additionally, the acquisition of equine ProVet APC products will further accompany Dechra's Orthokine Vet IRAP joint therapy and offer veterinarians a comprehensive tool for their regenerative medicine needs. *dvm360*

**REFERENCE**

Dechra acquires exclusive license from Hassinger Biomedical for equine ProVet APC. News release. Dechra Veterinary Products. September 22, 2021. Accessed September 27, 2021.



## dvm360® welcomes 11 new SAP partners globally

This group includes the company's first international inductees, exemplifying its dedication to veterinary medicine globally.

By dvm360® staff

dvm360® welcomed 11 new partners to its Strategic Alliance Partnership (SAP) program. The group is the organization's first to include international inductees, demonstrating the company's commitment to the global industry of veterinary medicine.

According to a company news release, the evolving SAP program features organizations dedicated to offering expert insights and research on animal health, pet care products, real-time regulation updates for veterinary clinics, and veterinary medicine news.

The new members reflect the company's core values of advancing veterinary medicine worldwide. They are: Ask Jan for Help, LLC; Bond Vet; Companion Animal Euthanasia Training Academy; Companion Consultancy; FirstVet; MedVet; Mount Laurel Animal Hospital; NorthStar VETS; Pawsibilities Vet Med; The Veterinary Cooperative; and TEEF for Life.

"We are thrilled to welcome the first international group of strategic alliance partners, who will help us continue to raise the standards of animal care," said Mike Hennessy Jr, president and CEO of MJH Life Sciences™, parent company of dvm360®. "We are looking forward to collaborating on initiatives that give back to the animal care community."

The SAP program offers global reach and visibility to partnering advocacy organizations, medical associations, and veterinary schools. Additionally, the program enables dvm360® to create cooperation and open exchange of information between trusted veterinary practitioners to support the profession. The company works with its affiliates to cross-collaborate and spotlight diverse veterinary communities. [dvm360®](#)

### REFERENCE

dvm360® welcomes eleven new global Strategic Alliance Partnership (SAP) members. News release. dvm360®. October 1, 2021. Accessed October 4, 2021. [https://www.prnewswire.com/news-releases/dvm360-welcomes-eleven-new-global-strategic-alliance-partnership-sap-members-301389388.html?tc=eml\\_cleartime](https://www.prnewswire.com/news-releases/dvm360-welcomes-eleven-new-global-strategic-alliance-partnership-sap-members-301389388.html?tc=eml_cleartime)



## VetX International discovers link between leadership actions and practice culture

The United Kingdom-based veterinary consultancy company collected data from 2 veterinary conferences to demonstrate a connection between how veterinary practice leaders behave and the climate in their clinics.

By dvm360® staff

VetX International—a United Kingdom-based veterinary consultancy, community, and education platform—conducted research that uncovered a direct correlation between leadership and practice culture. The study collected data from veterinary leaders including practice owners and managers during a dvm360® Fetch conference and the Society of Practising Veterinary Surgeons-Veterinary Management Group Congress 2020.

According to a VetX International news release, the data explored veterinary leaders' ability to successfully address toxic behaviors, implement core values, hire and retain staff, and manage their own time, along with how these variables impact overall practice culture. Additionally, the study strived to establish steps leaders can take to streamline practice operations amid an international industry shortage.

The study results reported by researchers Dave Nicol, BVMS, Cert Mgmt MRCVS, founder of VetX International; and Dermot McNerney, BVSM, BVSc, head of veterinary partnerships at VetX International, indicated 4 actions that can have a heavy influence on the quality of workplace culture:

- Implementing a clear vision in practice
- Addressing and resolving inappropriate staff behavior
- Effectively managing leaders' time to be able to perform nonclinical activities
- Recruiting clinical talent effectively

Additionally, 3 out of 4 respondents reported struggling with finding time to work on leadership priorities, while 40% had difficulty with managing and addressing toxic behaviors and 65.2% found attracting and retaining new talent to be challenging.<sup>1</sup>

"We've long suspected that time-poor leaders were causing untold long-term harm to their practice performance by neglecting essential leadership activities in favor of more urgent clinical ones," Nicol said in the release. "The implications for such choices are now clear: good leadership simply cannot be left to chance. We're really proud of the fact that we've been able to show not just that these factors matter, but also show what things in particular leaders should be doing with their time to help grow healthy cultures that support practice objectives."

Overall, Nichol and McNerney hope the findings help leaders discover new methods for curtailing clinical work, forging and communicating an impactful vision, hiring and retaining the right individuals to match the clinic's vision, and dealing with toxic behaviors that can degrade workplace culture. [dvm360®](#)

### REFERENCE

1. Study reveals definitive link between leadership actions & vet practice culture. News release. Basepaws. September 28, 2021. Accessed October 5, 2021.



# Embark Veterinary releases first-ever purebred dog DNA kit

This comprehensive kit employs individualized health insights and information that can ultimately help extend dogs' lives by 3 years.

By *dvm360*® staff

Embark Veterinary, Inc has released its breakthrough DNA test for purebred dogs. Forged by veterinarians and geneticists, the kit provides purebred owners with unique, actionable health information to help pinpoint diagnostic, monitoring, and treatment plans that can easily be shared with a veterinarian.

According to a company news release, Embark discovered that over 50% of tested dogs are either at risk for—or carriers of—genetic health complications, and that more

than 1 in 3 owners have documented updating their dog's care after receiving test results.

"Until now, there has not been a dog DNA product on the market specifically designed for purebred dogs, but every dog owner deserves the most accurate and detailed data on their dog's health," said Ryan Boyko, Embark CEO and cofounder. "Not only will this test better inform owners, veterinarians, and breeders, but it will accelerate our health discovery engine and improve insights into breed-specific

health conditions and traits, fueling discoveries that will help extend dogs' lives by 3 years within the decade."

Embark says this is the only dog DNA test available that gives owners a critical canine health metric: Embark's Genetic Diversity Score. According to the release, this score analyzes the stretches of DNA in a dog's genome to compute a precise measure of inbreeding, offering owners the most predictive score for identifying future health and longevity.

"We see that highly genetically diverse dogs live on average 2 to 3 years longer than dogs with low genetic diversity and have fewer health problems over their lifetime," said Adam Boyko, Embark chief science officer and cofounder. "Although owners can't change their dog's genetics, they can be vigilant about their dog's care and exercise knowing their dog's unique health risks."

The DNA test is available for \$199 on Embark's website or at Amazon (a launch offer code—FALL30—can be used on Embark's website to save \$50). *dvm360*®

#### REFERENCE

Embark Veterinary launches first-ever DNA test for purebred dog owners. News release. Embark Veterinary, Inc. October 4, 2021. Accessed October 5, 2021. [www.prnewswire.com/news-releases/embark-veterinary-launches-first-ever-dna-test-for-purebred-dog-owners-301391854.html](http://www.prnewswire.com/news-releases/embark-veterinary-launches-first-ever-dna-test-for-purebred-dog-owners-301391854.html)

# Cincinnati Zoo collaborates with scientists to assess validity of remote infrared thermography

The partnership will explore the benefits of using remote infrared thermography for a variety of threatened or endangered species.

By *dvm360*® staff

The Center for Conservation and Research of Endangered Wildlife (CREW) at Cincinnati Zoo & Botanical Garden announced it will be cooperating with scientists from Woods Hole Oceanographic Institution (WHOI)—a private nonprofit research and higher education facility dedicated to studying marine science and engineering—to prove the benefits of using remote infrared thermography (IRT) when performing noninvasive checkups.

"We are using thermal imaging to collect body temperature and heart/respiration rates on a variety of animals, including birds, reptiles, and mammals," said Erin Curry, PhD, a reproductive physiologist at CREW,

in an organizational release. "At the same time, we are using traditional methods to obtain vital signs and comparing the results."

Although IRT has been used and has proved to be accurate when measuring heart rate in humans and large domestic animals, this will be the first time the technology is used to help threatened or endangered species. The team's goal is to gather a minimum of 50 different animal species at Cincinnati Zoo, accounting for variables such as fur length, head size, and the presence of fat and blubber, to validate the technology. At present the results are optimistic, with heart rates authenticated in a gorilla, bongo, sloth, and tenrec.

"Once we validate it, we can use it in zoos for noninvasive health checks," said Caroline Rzucidlo, MS, a PhD student in the Massachusetts Institute of Technology-WHIO Joint Program. "We also hope to attach it to a drone and fly it over wild populations of animals to get some basic health metrics without having to disturb them. We can compare those metrics over time to monitor animals' responses to environmental changes."

An additional goal for the team is to also use IRT for reproductive monitoring. According to the release, pregnancy diagnosis, estrus detection, and changes in testicular thermal signatures may shed some light on the reproductive status,

improve animal management, and deliver more accurate timing of semen collection procedures and artificial insemination.

"Projects like this reinforce the Cincinnati Zoo & Botanical Garden's reputation as a global leader in innovative conservation research," said Thane Maynard, Cincinnati Zoo director. "I hope this technology will eventually be used to improve the health of animal populations all over the world, in zoos and in the wild!" *dvm360*®

#### REFERENCE

Cincinnati Zoo tests new technology to assess animal health from a distance. News release. Cincinnati Zoo & Botanical Garden. August 16, 2021. Accessed August 31, 2021. <http://cincinnatizoo.org/news-releases/cincinnati-zoo-tests-new-technology-to-assess-animal-health-from-a-distance/>





# JUST DROP IT.

THE FIRST  
FDA-APPROVED  
EYE DROP  
EMETIC FOR  
DOGS

## Clevor<sup>®</sup> (ropinirole ophthalmic solution)

When dogs eat something potentially poisonous or harmful, you need to act quickly. Clevor is a selective emetic with a fast onset of action and short duration of vomiting. A convenient, single-use dropper provides one injectionless treatment for a dog.

**Clevor - a new way to induce emesis in dogs.**



CLEVOR<sup>®</sup> is indicated for the induction of vomiting in dogs.

**IMPORTANT SAFETY INFORMATION:** Do not use in dogs with central nervous system depression or seizures. Do not use in cases of ingestion of sharp foreign objects, corrosive agents (acids or alkalis), volatile substances or organic solvents. CLEVOR<sup>®</sup> should not be administered in cases with corneal ulceration, ocular irritation, or ocular injury. Do not use when there is a known sensitivity to ropinirole or the inactive ingredients. **ADVERSE REACTIONS MAY INCLUDE:** Transient mild or moderate hyperemia of the eye, ocular discharge, protrusion of the 3rd eyelid and blepharospasm, transient mild lethargy and increased heart rate. Not recommended for use in breeding, pregnant or lactating dogs. CLEVOR<sup>®</sup> has not been evaluated in dogs with heart or liver impairments or dogs younger than 4.5 months or less than 4 pounds. Dopamine antagonists, neuroleptics and other medicines with antiemetic properties may reduce the effectiveness of ropinirole. CLEVOR<sup>®</sup> should be administered by a veterinary professional. Gloves and protective eyewear should be worn when administering. Not for use in humans. Keep out of reach of children.

**For additional product safety information, see brief on following page or visit:**  
<https://www.vetoquinolusa.com/clevor-info>

CLEVOR<sup>®</sup> is a trademark of Orion Corporation Orion Pharma. It is developed and manufactured by Orion Corporation Orion Pharma and distributed by Vetoquinol USA, Inc. under license from Orion Corporation Orion Pharma.

CVR-0003-IORTRN 2/2021 v1





# Zoetis adds digital cytology testing to Vetscan Imagyst

By *dvm360*® staff

Zoetis recently announced the addition of digital cytology testing to Vetscan Imagyst—its multipurpose diagnostics technology platform launched in September 2020. With this innovation, Vetscan Imagyst now employs a network of expert remote pathologists along with artificial intelligence (AI) technology for fecal testing.

According to a company news release, Zoetis remains dedicated to developing additional innovative applications for Vetscan Imagyst so veterinarians can offer enhanced patient care. “Every veterinarian knows the importance of easy and rapid access to specialists when diagnosing and treating our patients,” said Richard E. Goldstein, DVM, DACVIM (SAIM), DECVIM-CA,

vice president and chief medical officer of global diagnostics at Zoetis. “Now with the new digital cytology solution available from Vetscan Imagyst, we are virtually placing a board-certified, clinical pathologist right ‘down the hall’ from every veterinarian.”

This digital cytology application also grants instant access to expert clinical pathologists for analyzing samples including cells from blood, internal organs, or bodily fluids, allowing fast, minimally invasive diagnosis of cancer, infection, inflammation, and more. With a quick, accurate review of common cytology specimens (eg, fine needle aspirates), Vetscan Imagyst helps veterinarians provide same-day diagnosis and treatment, when necessary.

Vetscan Imagyst offers first-of-its-kind technology with its digital cytology feature, including the following benefits:

- **Provides multiple applications in a single platform** with digital cytology and AI fecal testing results and can add future applications
- **Occupies less space** with a small in-office footprint and a compact scanner that can be easily added to any practice
- **Offers veterinary customers access to expert clinical pathologists** within the Zoetis network as needed
- **Accelerates the future of animal care** by updating the way and the speed with which diagnostic tests can be delivered

Vetscan Imagyst advances the process for clinical pathology review, displaying results within hours. Submissions are prepared in clinic using traditional means; however, they are submitted digitally instead of sending physical slides to a laboratory.

“We are excited to build on the incredible momentum that began

with the AI fecal analysis launch,” said Lisa Lee, senior vice president and head of global diagnostics at Zoetis. “Vetscan Imagyst has been a significant part of the Zoetis portfolio and continues to evolve to meet diagnostic needs in practices around the world.

“The unique multipurpose technology has added immense value to veterinary clinics, facilitating fast, more accurate results, leading to quicker diagnoses and decisions that ultimately strengthen the bond of trust between veterinarians and their clients,” she added.

This addition demonstrates Zoetis’ commitment to innovation and persistent drive to “meet the unmet needs of its veterinary customers.” Vetscan Imagyst is at the forefront of in-clinic diagnostics and will continue to feature more advanced applications that will benefit veterinarians, their patients, and pet parents. *dvm360*®

## REFERENCE

Zoetis adds digital cytology testing to Vetscan Imagyst, its multi-purpose diagnostics technology platform. News release. Zoetis. October 5, 2021. Accessed October 5, 2021.

## CLEVOR® (ropinirole ophthalmic solution)

30 mg/mL

For ophthalmic use in dogs only

Single use dropper

**BRIEF SUMMARY:** Before using CLEVOR® (ropinirole ophthalmic solution), please consult the product insert, a summary of which follows:

### CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

### INDICATION:

For induction of vomiting in dogs.

### DOSAGE AND ADMINISTRATION:

**This product should be administered by veterinary personnel.**

#### Dosing Instructions:

Administer the appropriate number of eye drops topically according to Table 1. The number of eye drops administered corresponding to body weight results in a target dose of 3.75 mg/m<sup>2</sup> (dose band 2.7 - 5.4 mg/m<sup>2</sup>). If the dog does not vomit within 20 minutes of the first dose, then a second dose may be administered.

#### Dose Administration

4 - 11.1 lbs (1.8 - 5 kgs), 1 drop. Example: 1 drop into either left or right eye. 11.2 - 22.1 lbs (5.1 - 10 kgs), 2 drops. Example: 1 drop into each eye. 22.2 - 44.1 lbs (10.1 - 20 kgs), 3 drops. Example: 2 drops in one eye and 1 drop in the other eye. 44.2 - 77.2 lbs (20.1 - 35 kgs), 4 drops. Example: 2 drops in each eye. 77.3 - 132.3 lbs (35.1 - 60 kgs), 6 drops. Example: an initial dose of 2 drops in each eye, followed 2 minutes later by 1 drop in each eye. 132.4 - 220.5 lbs (60.1 - 100 kgs), 8 drops. Example: an initial dose of 2 drops in each eye, followed 2 minutes later by 2 drops in each eye.

Wear gloves and protective eye wear when handling or administering this product to prevent accidental exposure.

- Open the dropper by twisting off the tail.

- Keep the dog’s head steady in a slightly upright position.
- Hold the dropper in an upright position without touching the eye.
- Rest your finger on the forehead of your dog to maintain the distance between the dropper and the eye.
- Squeeze the prescribed number of drops in to the eye(s).
- CLEVOR is a single use dropper and is light sensitive.
- After administration, with gloves on, return the dropper to the aluminum pouch and place in the carton.
- If the dog does not vomit, a second dose can be given 20 minutes after administration of the first dose.
- This second dose is the same number of drops as the first dose.
- Thirty minutes after opening, with gloves on, dispose of dropper, aluminum pouch, and carton.

Refer to the **Animal Safety Warnings** section for treatment of protracted vomiting.

### CONTRAINDICATIONS:

Do not use in dogs with central nervous system depression or seizures.

Do not use in cases of ingestion of sharp foreign objects, corrosive agents (acids or alkalis), volatile substances or organic solvents. Do not use in cases with corneal ulceration, ocular irritation, or ocular injury. Do not use when there is a known sensitivity to ropinirole or the inactive ingredients.

### WARNINGS:

#### Human Safety Warnings:

**Not for use in humans. Keep out of reach of children.**

Wear gloves and protective eye wear when handling or administering this product to prevent accidental exposure. In case of accidental eye, oral or skin exposure, flush with water. If wearing contact lenses, eyes should be rinsed first, then remove contact lenses and continue rinsing. Remove contaminated clothing. Ropinirole is a dopamine agonist. **Seek medical attention if accidental**

### exposure occurs and show the package insert or label to the physician.

Exposure to this drug may cause adverse reactions such as headache, nausea, vomiting, dizziness, orthostatic hypotension, and sleepiness. Avoid contact with the product if pregnant, planning to become pregnant, or breast-feeding, as exposure has been shown to have adverse effects on embryo-fetal development based on rodent studies.

### Animal Safety Warnings:

This product should be administered by veterinary personnel.

Dogs should be monitored for CLEVOR-associated clinical signs, including protracted vomiting, salivation, muscle tremors, evidence of abdominal discomfort, lethargy, transient tachycardia, transient decrease in blood pressure and signs of ocular irritation, including conjunctival hyperemia, mild blepharospasm, and protrusion of the third eyelid. These clinical signs are related to the pharmacological action of ropinirole.

To stop protracted vomiting, administer metoclopramide (dopamine D2 antagonist) at a dose of 0.5 mg/kg intravenously (IV) or subcutaneously (SQ). Metoclopramide also decreases the prevalence of most CLEVOR-associated clinical signs.

### PRECAUTIONS:

The safe use of CLEVOR has not been evaluated in dogs with cardiac disease or cardiovascular compromise. CLEVOR can cause transient tachycardia and transient decreased systolic blood pressure.

The safe use of CLEVOR has not been evaluated in dogs with hepatic impairment. CLEVOR is metabolized by the liver. The safe use of CLEVOR has not been evaluated in dogs younger than 4.5 months of age and weight less than 4 pounds.

The safe use of CLEVOR has not been evaluated in dogs that are pregnant, lactating, or intended for breeding.

### ADVERSE REACTIONS:

Safety was evaluated during a field study that enrolled 132 dogs (100 in the CLEVOR group and 32 in the vehicle control group).

CLEVOR was administered as drops into the eyes at the dose as directed by the dosing table (see **DOSAGE AND ADMINISTRATION**). The following table shows the number of dogs exhibiting ocular, systemic, and clinical pathology adverse reactions.

Adverse Reactions Reported During the Study (all dogs): Ocular organ system were conjunctival hyperemia, protrusion of the third eyelid, conjunctival discharge, blepharospasm, conjunctival swelling, scratching/rubbing of eyes, corneal ulceration and corneal fluorescein uptake without corneal ulceration. Systemic organ system were lethargy, tachycardia (>160 beats per minute), vomiting duration longer than one hour, salivation, trembling, diarrhea or soft stool, anxious and borborygmi. Clinical pathology organ system were crystalluria, pyuria, increased liver enzymes, decreased blood glucose and increased prothrombin time.

To report suspected adverse events call 1(800) 835-9496, for technical assistance or to obtain a copy of the SDS, contact Vetoquinol USA, Inc. at 1 (800) 267-5707 or [www.vetoquinolusa.com](http://www.vetoquinolusa.com).

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at [www.fda.gov/reportanimalae](http://www.fda.gov/reportanimalae).

CLEVOR is a trademark of Orion Corporation

Manufactured by: Orion Corporation

Distributed by: Vetoquinol USA, Inc.

Ft. Worth, TX (USA) 76137

1 (800) 267-5707 [www.vetoquinolusa.com](http://www.vetoquinolusa.com)

Issued 06/2020

Approved by FDA under NADA # 141-534



## Well-being

&gt; Continued from cover page

White discussed what makes up passions and purpose, and she urged attendees to reflect on these to ensure that they are staying true to who they are.

### Determining your passions and purpose

#### Your passions

White defined a passion as a topic or activity that you enjoy, comes naturally to you (ie, a gift or talent), energizes you, and makes time seem to pass quickly when you are engaging in it. She encouraged attendees to dedicate a few minutes to pondering about things that do this for them, noting they don't have to be related to veterinary medicine.


*By realizing that others have a need to be valued, seen, heard, and cared for, you can design the life you want to lead and contribute to a rewarding, profitable profession.*

—Patricia D. White, DVM, MS, DACVD, CPC

“Your passions can change over time, but it's important to recognize what they are,” White said. “Pay attention to these things that light you up, then make a movement toward [them] or find out how to pull [them] into your life and incorporate [them] in what you do.”

#### Your purpose—your “big why”

Next, White said, it's critical to clarify your purpose by answering these 4 questions: What do you love? What are you good at? What does the world need from you? What can you get rewarded for? She then described your purpose as a unique combination of your passions and skills aligned with your values that typically



serves as the solution to a problem faced by a certain group of the population. Although being a veterinarian may be your answer to achieving your purpose, purpose usually involves all aspects of your life.

“When you have clarity on your ‘big why,’ it means you have clarity on the deepest meaning of what you do—that what you are doing is moving you in the direction of living your passions and how you are getting there is in alignment with your core values,” White remarked.

She then emphasized that when these key characteristics of yours all line up, you will be happy, productive, and purposeful.

#### The benefits of passion and purpose on well-being

White shared that along with promoting your emotional and mental well-being, remaining true to your passions and purpose also promotes your physical well-being. For instance, if you stray from these things, your physical self will display signs of discomfort such as low energy or chronic fatigue, the feeling of being trapped, stomach discomfort or digestive disorders, forgetfulness or inability to concentrate, headaches, anxiety, depression, insomnia, addiction, or aches and pains.

However, if you follow your passions and move toward your purpose, you will experience lightness, freedom, and joy; have abundant energy; sleep better; and have less stress and better health.

“[Achieving] this [involves] work, but when you get [your passions and purpose] clear and start to change your intention and in every moment you get to choose, you can start to shift your life into that positive place,” White said, adding, “You have to make a change, but that change comes slowly and it starts in the center with who you are.”

#### Passion and purpose for your personal and professional life

It's critical to engage at the clinic each day from a place of passion and purpose rather than from a place of what you think you should do because of external influences or other beliefs. When you stay in line with your passions you develop a sustainable foundation; sustainability is the first step toward growth, and growth often results in profit, White said. Plus, when your ideas are completed with more purpose and meaning, you have the motivation and emotional energy required to venture outside your comfort zone and get inspired to

transition from aspiration to achievement in your personal and professional life.

#### Takeaways

To live a life of success and be fulfilled as a heart-centered veterinarian in the clinic and beyond, start by pinpointing your passions and purpose, then ensure you incorporate these aspects into your daily life. Not only will this make a major difference in your life, White said, but it will also likely positively affect those around you, including the clients and patients you work with and your loved ones.

“When your goal is driven by passion and purpose, your core values are reflected in everything you do and you can't help but create an experience that adds values to others that you will be rewarded for and is fun,” White concluded. dvm360®



View more conference content on our website  
[dvm360.com/latest-conference](https://dvm360.com/latest-conference).



## Dermatology

&gt; Continued from cover

deeper regions of the epidermis and hair follicle epithelium, increase in number, and enhance inflammation.

Classical clinical lesions of superficial pyoderma include papules and pustules that may eventually progress to alopecia, epidermal collarettes, scales, and crusts. Often the skin is erythematous and pruritic. Chronic cases may demonstrate lichenification, hyperpigmentation, and scarring alopecia from long-standing inflammation and infection.<sup>2</sup> Cats may develop even more unique cutaneous reaction patterns and skin lesions—especially when allergic skin disease is present—including miliary dermatitis, eosinophilic plaques, rodent ulcers, and eosinophilic granulomas.<sup>5</sup>

Identifying and addressing the primary disease is paramount in achieving complete, permanent resolution of the superficial pyoderma. Therefore, treatment is multifactorial and aimed at addressing the primary disease, reducing skin inflammation, and treating the infection directly. Current guidelines for the treatment of superficial pyoderma in dogs recommend the use of topical antimicrobials as sole therapy whenever possible; however, overuse of systemic antibiotics remains common.<sup>2,13-16</sup>

Topical therapy has many benefits including direct antimicrobial effects without use of an antibiotic, reduction in antibiotic-resistant bacterial populations, restoration of the normal skin barrier, enhancement of skin hydration, physical removal of keratinous debris, and removal of offending allergens from the haircoat.<sup>2,14</sup> However, topical therapy is met with challenges that impede clinical application. Adherence is the biggest concern when recommending topical therapy to pet owners. Frequent bathing or application of medicated solutions to the skin can be difficult when busy owner lifestyles combine with a nonadherent patient. Skin inflammation can be painful and animals may be resistant to topical therapy. Cats are fastidious groomers and may lick away a medicated topical therapy before it can achieve appropriate contact time. Additionally, some topical agents can cause oral erosions and ulcerations or even gastrointestinal disturbance

when groomed off. For these reasons, systemic antibiotics continue to be a common prescribing practice for superficial pyoderma.

All antibiotic use, despite duration or frequency, contributes to the development of antibiotic-resistant bacterial populations on the animal and in the environment.<sup>17-19</sup> From that very first dose, bacteria are constantly evolving to implement inherent and acquired resistance mechanisms necessary for survival. One well-recognized mechanism is oxacillin resistance through the *mecA* gene, which produces a penicillin-binding protein receptor with poor affinity for  $\beta$ -lactam antibiotics.<sup>2,14,15,20-23</sup> Even more concerning than these oxacillin-resistant strains are those that develop multidrug resistance, which is defined as resistance to 3 or more antibiotic drug classes. This may happen over time with repeated antibiotic exposure or after a single dose of certain antibiotics such as fluorinated quinolones.<sup>2,20,23-25</sup> The continued emergence of antibiotic-resistant bacteria inhibits the successful treatment of bacterial infections in pets and humans. As veterinarians consider how their antibiotic use contributes to this growing pandemic, they must look for alternative, safe, effective, affordable, and convenient antibacterial treatment modalities.

**Phovia as a solution**

Investigation into the photobiological effects of light therapy has been ongoing for the past 50 years. Photobiomodulation (PBM) therapy is a type of light treatment that uses visible or near infrared light to promote therapeutic benefits including induction of tissue healing and regeneration and inhibition of biological responses that induce pain or inflammation. The treatment distance, wavelength, fluence, pulse parameters, spot size, and irradiation time influence the effects of light energy on tissue. Visible light with wavelengths ranging from 400 to 700 nm can stimulate positive photobiomodulatory effects that promote wound healing, reduce inflammation and pain, modulate stem cell populations, and reduce bacterial contamination of wounds.<sup>26,27</sup>

Once visible light enters the skin, it is absorbed by the cells and initiates

chemical changes dependent on the wavelength (or color) of light and the chromophore within the skin.<sup>27</sup> Within each cell, membrane-bound organelles called mitochondria contain chromophores that absorb the light energy and begin making energy (adenosine triphosphate; ATP) via activation of cytochrome c oxidase. Outcomes of the mitochondrial respiratory pathway activation include stimulation of secondary messenger pathways, production of transcription factors and growth factors, and increased ATP production. However, excessive light energy exposure will overstimulate mitochondrial respiration and cause expenditure of all ATP reserves, which creates oxidative stress resulting in damaging elevations of nitric oxide, production of harmful free radicals, and activation of cytotoxic mitochondrial-signaling pathways leading to apoptosis.<sup>27,28</sup> This is why creating PBM therapy protocols is important for targeting the beneficial effects while avoiding unintended harm.

Specific benefits of light energy within the visible light spectrum can be broken down into each color of light. Blue light (400-500 nm) has a lower penetration depth and primarily interacts with keratinocytes, reduces bacterial adhesion and growth, and increases intracellular calcium and osteoblast differentiation.<sup>29-31</sup> Green light (495-570 nm) affects the superficial tissue and alters melanogenesis, reduces hyperpigmentation of the skin, and reduces tissue swelling.<sup>29,30</sup> Red light (600-750 nm) penetrates deeper into the dermis and subcutis where it acts on cellular mitochondria to reduce inflammation and promote collagen synthesis through fibroblast proliferation and production of transforming growth factor- $\beta$ , fibroblast growth factor, platelet derived growth factor, and others.<sup>26-28,32,33</sup> Red light has proliferative effects on mesenchymal stem cells and induces proliferation of epithelial colony forming units important for tissue repair and regeneration.<sup>34,35</sup>

Phovia, sold by Vetoquinol, is a form of fluorescent PBM therapy utilizing a blue light emitting diode (LED lamp, 400-460 nm) and topical photoconverter gel that

emits low-energy fluorescent light (510-600 nm) when illuminated by the LED lamp.<sup>36,37</sup> This interaction results in the formation of multiple wavelengths of visible light, each with a unique depth of penetration and effect on the tissue as described above. Application is fast and simple. The affected skin may be clipped free of hair and cellular debris removed with gentle cleaning. The skin is allowed to dry before application of the photoconverter gel. Just prior to application, 1 ampule of fluorescence chromophore gel is added to 1 container of photoconverter carrier gel and mixed thoroughly. The mixture is applied in a 2-mm layer to the affected skin, and the LED lamp is held 5 cm above the lesion and used to illuminate the area for 2 minutes. The gel is wiped away using saline-soaked gauze. The application can be repeated immediately after 5 to 10 minutes of rest or a second application can occur a few days later. Twice-weekly applications are continued until the wound is healed. Appropriate eyewear is required to protect the operator from the intensely bright light. Application is pain free and stress free for the patient, so sedation is not typically required.

**Benefits of Phovia**

Phovia shows great promise as a safe, effective therapy for treatment of numerous inflammatory dermatoses in dogs including superficial pyoderma,<sup>38</sup> deep pyoderma,<sup>39</sup> perianal fistula,<sup>40</sup> interdigital dermatitis,<sup>41</sup> calcinosis cutis,<sup>42</sup> acute traumatic wounds,<sup>43</sup> chronic wounds,<sup>37</sup> surgical wounds,<sup>44</sup> and otitis externa.<sup>45</sup> Phovia as a sole therapy speeds time to healing by 36% in canine superficial pyoderma as compared with dogs receiving oral antibiotics alone.<sup>38</sup> In one study, dogs with superficial pyoderma were treated with Phovia alone or with an oral antibiotic alone. Dogs treated twice weekly with Phovia demonstrated complete clinical healing in about 2.3 weeks ( $P < .05$ ) whereas dogs receiving oral antibiotic healed in about 3.75 weeks.<sup>38</sup> Additionally, Phovia speeds time to healing by nearly 50% in deep pyoderma when used with an oral antibiotic (5.7 weeks of treatment) >>



# *SLOW TO HEEL. FAST TO HEAL.*



## **DEEP, QUICK SKIN REPAIR.**

Even our furry friends with selective hearing can heal skin lesions twice as fast. With Phovia Fluorescent Light Therapy System.



**PHOVIA™**

An accelerated dermatology system.



Dermatology

> Continued from page 26

compared with dogs receiving only oral antibiotic (11.7 weeks of treatment).<sup>39</sup> The ability of this fluorescent PBM therapy to eliminate or significantly reduce duration of exposure to antibiotics will decrease the spread of antibiotic-resistant bacterial strains within pets and humans.

Phovia's high safety profile makes it a beneficial tool to implement in everyday practice. Training the veterinary team to communicate therapy benefits with clients as well as to perform treatments is fast and easy. Training the veterinary technicians to perform treatments will give the veterinarian time to examine other patients. A single back-to-back application takes about 15 minutes, so pet owners can be in and out of the clinic quickly; however, the 2 weekly treatments can be separated by a few days if the veterinarian prefers to evaluate the patient more frequently. Additionally, when used as a sole therapy, clients are not required to administer oral or topical medications at home. This greatly improves treatment adherence and success. Instruct clients to use once-daily smartphone photos to document improvement at home. This can be useful when deciding how many treatments to perform. Most cases of superficial pyoderma will resolve completely by the third treatment.<sup>38</sup> It is a good idea to communicate to clients that 3 to 4 weekly treatments may be required.

Conclusion

Phovia is a versatile, innovative therapeutic approach to numerous types of dermatitis.<sup>36</sup> It is easy to implement in general practice, and is safe, pain free, and affordable. Phovia is highly effective for superficial and deep skin infections and eliminates the need for clients to administer numerous at-home treatments. This greatly improves the pet-owner bond and treatment outcomes by promoting adherence. Phovia accelerates time to wound healing, which decreases duration of antibiotic exposure and may reduce risk of antibiotic resistance development in these cases.<sup>2,13,36-39</sup> Phovia's efficacy against antibiotic-susceptible and antibiotic-resistant bacteria shows promise as an

alternative therapeutic approach that promotes the principles of antimicrobial stewardship.<sup>36</sup> If you are interested in purchasing this medical device for your practice, contact your Vetoquinol service representative. [dvm360®](#)

*Amelia G. White, DVM, MS, DACVD is an associate clinical professor of dermatology at Auburn University College of Veterinary Medicine.*

REFERENCES

1. Hill PB, Lo A, Eden CAN, et al. Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. *Vet Rec.* 2006;158(16):533-539. doi:10.1136/vr.158.16.533
2. Hillier A, Lloyd DH, Weese JS, et al. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). *Vet Dermatol.* 2014;25(3):163-e43. doi:10.1111/vde.12118
3. Diesel A. Cutaneous hypersensitivity dermatoses in the feline patient: a review of allergic skin disease in cats. *Vet Sci.* 2017;4(2):25. doi:10.3390/vetsci4020025
4. Halliwell R, Pucheu-Haston CM, Olivry T, et al. Feline allergic diseases: introduction and proposed nomenclature. *Vet Dermatol.* 2021;32(1):8-e2. doi: 10.1111/vde.12899
5. Santoro D, Pucheu-Haston CM, Prost C, Mueller RS, Jackson H. Clinical signs and diagnosis of feline atopic syndrome: detailed guidelines for a correct diagnosis. *Vet Dermatol.* 2021;32(1):26-e6. doi: 10/1111/vde.12935
6. Ravens PA, Xu BJ, Vogelnest LJ. Feline atopic dermatitis: a retrospective study of 45 cases (2001-2012). *Vet Dermatol.* 2014;25(2):95-102, e27-e28. doi: 10.1111/vde.12109
7. Woolley KL, Kelly RF, Fazakerley J, Williams NJ, Nuttall TJ, McEwan NA. Reduced in vitro adherence of *Staphylococcus* species to feline corneocytes compared to canine and human corneocytes. *Vet Dermatol.* 2008;19(1):1-6. doi: 10.1111/j.1365-3164.2007.00649.x
8. Yu HW, Vogelnest LJ. Feline superficial pyoderma: a retrospective study of 52 cases (2001-2011). *Vet Dermatol.* 2012;23(5):448-e86. doi:10.1111/j.1365-3164.2012.01085.x
9. Nocera FP, Ambrosio M, Fiorito F, Cortese L, De Martino L. On gram-positive- and gram-negative-bacteria-associated canine and feline skin infections: a 4-year retrospective study of the University Veterinary Microbiology Diagnostic Laboratory of Naples, Italy. *Animals (Basel).* 2021;11(6):1603. doi: 10.3390/ani11061603
10. Medleau L, Blue JL. Frequency and antimicrobial susceptibility of *Staphylococcus* spp isolated from feline skin lesions. *J Am Vet Med Assoc.* 1988;193(9):1080-1081.
11. Chermprapai S, Ederveen THA, Broere F, et al. The bacterial and fungal microbiome of the skin of healthy dogs and dogs with atopic dermatitis and the impact of topical antimicrobial therapy, an exploratory study. *Vet Microbiol.* 2019;229:90-99. doi: 10.1016/j.vetmic.2018.12.022
12. Weese JS. The canine and feline skin microbiome in health and disease. *Vet Dermatol.* 2013;24(1):137-145, e31. doi: 10.1111/j.1365-3164.2021.01076.x
13. Divala TH, Corbett EL, Stagg HR, et al. Effect of the duration of antimicrobial exposure on the development of antimicrobial resistance (AMR) for macrolide antibiotics: protocol for a systematic review with a network meta-analysis. *Syst Rev.* 2018;7(1):246. doi: 10.1186/s13643-018-0917-0

14. Morris DO, Loeffler A, Davis MF, Guardabassi L, Weese JS. Recommendations for approaches to methicillin-resistant staphylococcal infections of small animals: diagnosis, therapeutic considerations and preventative measures.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. *Vet Dermatol.* 2017;28(3):304-e69. doi: 10.1111/vde.12444
15. Palma E, Tiloca B, Roncada P. Antimicrobial resistance in veterinary medicine: an overview. *Int J Mol Sci.* 2020;21(6):1914. doi: 10.3390/ijms21061914
16. Summers JF, Hendricks A, Brodbelt DC. Prescribing practices of primary-care veterinary practitioners in dogs diagnosed with bacterial pyoderma. *BMC Vet Res.* 2014;10:240. doi: 10.1186/s12917-014-0240-5
17. Lloyd DH. Reservoirs of antimicrobial resistance in pet animals. *Clin Infect Dis.* 2007;45(suppl 2):S148-S152. doi: 10.1086/519254
18. Pomba C, Rantala M, Greko C, et al. Public health risk of antimicrobial resistance transfer from companion animals. *J Antimicrob Chemother.* 2017;72(4):957-968. doi: 10.1093/jac/dkw481
19. Zur G, Gurevich B, Elad D. Prior antimicrobial use as a risk factor for resistance in selected *Staphylococcus pseudintermedius* isolates from the skin and ears of dogs. *Vet Dermatol.* 2016;27(6):468-e125. doi: 10.1111/vde.12382
20. Descloux S, Rossano A, Perreten V. Characterization of new staphylococcal cassette chromosome *mec* (SCC*mec*) and topoisomerase genes in fluoroquinolone- and methicillin-resistant *Staphylococcus pseudintermedius*. *J Clin Microbiol.* 2008;46(5):1818-1823. doi: 10.1128/JCM.02255-07
21. Krapf M, Muller E, Reissig A, et al. Molecular characterisation of methicillin-resistant *Staphylococcus pseudintermedius* from dogs and the description of their SCC*mec* elements. *Vet Microbiol.* 2019;233:196-203. doi: 10.1016/j.vetmic.2019.04.002
22. van Duijkeren E, Catry B, Greko C, et al; Scientific Advisory Group on Antimicrobials (SAGAM). Review on methicillin-resistant *Staphylococcus pseudintermedius*. *J Antimicrob Chemother.* 2011;66(12):2705-2714. doi: 10.1093/jac/dkr367
23. Yoo JH, Yoon JW, Lee SY, Park HM. High prevalence of fluoroquinolone- and methicillin-resistant *Staphylococcus pseudintermedius* isolates from canine pyoderma and otitis externa in veterinary teaching hospital. *J Microbiol Biotechnol.* 2010;20(4):798-802.
24. Hassanzadeh S, Ganjloo S, Pourmand MR, Mashhadi R, Ghazvini K. Epidemiology of efflux pumps genes mediating resistance among *Staphylococcus aureus*; a systematic review. *Microb Pathog.* 2020;139:103850. doi: 10.1016/j.micpath.2019.103850
25. Ihrke PJ, Papich MG, DeManuelle TC. The use of fluoroquinolones in veterinary dermatology. *Vet Dermatol.* 1999;10:193-204.
26. Wang ZX, Kim SH. Effect of photobiomodulation therapy (660 nm) on wound healing of rat skin infected by *Staphylococcus*. *Photobiomodul Photomed Laser Surg.* 2020;38(7):419-424. doi: 10.1089/photob.2019.4754
27. Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. *Photochem Photobiol.* 2008;84(2):450-462. doi: 10.1111/j.1751-1097.2007.00286.x
28. Zein R, Selting W, Hamblin MR. Review of light parameters and photobiomodulation efficacy: dive into complexity. *J Biomed Opt.* 2018;23(12):1-17. doi: 10.1117/1.JBO.23.12.120901
29. Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Photobiomodulation (blue and green light) encourages osteoblastic-differentiation of human adipose-derived stem cells: role of intracellular calcium and light-gated ion channels. *Sci Rep.* 2016;6:33719. doi: 10.1038/srep33719
30. Serrage H, Heiskanen V, Palin WM, et al. Under the spotlight: mechanisms of

- photobiomodulation concentrating on blue and green light. *Photochem Photobiol.* 2019;18(8):1877-1909. doi: 10.1039/c9pp00089e
31. de Sousa NTA, Santos MF, Gomes RC, Brandino HE, Martinez R, de Jesus Guirro RR. Blue laser inhibits bacterial growth of *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*. *Photomed Laser Surg.* 2015;33(5):278-282. doi: 10.1089/pho.2014.3854
32. Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Red (660 nm) or near-infrared (810 nm) photobiomodulation stimulates, while blue (415 nm), green (540 nm) light inhibits proliferation in human adipose-derived stem cells. *Sci Rep.* 2017;7(1):7781. doi: 10.1038/s41598-017-07525-w
33. Fekrazad R, Sarrafzadeh A, Kalhori KAM, Khan I, Arany PR, Giubellino A. Improved wound remodeling correlates with modulated TGF-beta expression in skin diabetic wounds following combined red and infrared photobiomodulation treatments. *Photochem Photobiol.* 2018;94(4):775-779. doi: 10.1111/php.12914
34. Fekrazad R, Asefi S, Allahdadi M, Kalhori KAM. Effect of photobiomodulation on mesenchymal stem cells. *Photomed Laser Surg.* 2016;34(11):533-542. doi: 10.1089/pho.2015.4029
35. Khan I, Arany PR. Photobiomodulation therapy promotes expansion of epithelial colony forming units. *Photomed Laser Surg.* 2016;34(11):550-555. doi: 10.1089/pho.2015.4054
36. Marchegiani A, Spaterna A, Cerquetella M. Current applications and future perspectives of fluorescence light energy biomodulation in veterinary medicine. *Vet Sci.* 2021;8(2):20. doi: 10.3390/vetsci8020020
37. Scapagnini G, Marchegiani A, Rossi G, et al. Management of all three phases of wound healing through the induction of fluorescence biomodulation using fluorescence light energy. SPIE Proceedings Volume 10863, Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases II; 108630W (2019).
38. Marchegiani A, Fruganti A, Cerquetella M, Tambella AM, Laus F, Spaterna A. Klox fluorescence biomodulation system (KFBS), an alternative approach for the treatment of superficial pyoderma in dogs: preliminary results. *BSAVA Conference Proceedings 2018.* 2018:442.
39. Marchegiani A, Fruganti A, Spaterna A, Cerquetella M, Tambella AM, Paterson S. The effectiveness of fluorescent light energy as adjunct therapy in canine deep pyoderma: a randomized clinical trial. *Vet Med Int.* 2021;2021:6643416. doi: 10.1155/2021/6643416
40. Marchegiani A, Tambella AM, Fruganti A, Spaterna A, Cerquetella M, Paterson S. Management of canine perianal fistula with fluorescence light energy: preliminary findings. *Vet Dermatol.* 2020;31(6):460-e122. doi: 10.1111/vde.12890
41. Marchegiani A, Spaterna A, Cerquetella M, Tambella AM, Fruganti A, Paterson S. Fluorescence biomodulation in the management of canine interdigital pyoderma cases: a prospective, single-blinded, randomized and controlled clinical study. *Vet Dermatol.* 2019;30(5):371-e109. doi: 10.1111/vde.12785
42. Apostolopoulos N, Mayer U. Use of fluorescent light energy for the management of bacterial skin infection associated with canine callosities cutis lesions. *Vet Rec Case Rep.* 2020;8(4). doi: org/10.1136/vetreccr-2020-0001285
43. Marchegiani A, Spaterna A, Piccionello AP, Meligrana M, Fruganti A, Tambella AM. Fluorescence biomodulation in the management of acute traumatic wounds in two aged dogs. *Vet Med (Praha).* 2020;65:215-220. doi: org/10.17221/131/2019-VETMED
44. Salvaggio A, Magi GE, Rossi G, et al. Effect of the topical Klox fluorescence biomodulation system on the healing of canine surgical wounds. *Vet Surg.* 2020;49(4):719-727. doi: 10.1111/vsu.13415
45. Tambella AM, Attili AR, Beribe F, et al. Management of otitis externa with an led-illuminated gel: a randomized controlled clinical trial in dogs. *BMC Vet Res.* 2020;16(1):91. doi: 10.1186/s12917-020-02311-9



# Proven Accuracy and Precision\*



## Made Specially for Dogs and Cats with Diabetes!™

In a recent clinical study, the Test Buddy™ System results were found to have greater accuracy than a leading competitor.

The results from the Test Buddy™ System were compared to the results from laboratory equipment to prove accuracy and precision within the accuracy acceptance criteria listed in EN ISO 15197:2003.



### Canine Results

Test Buddy™ System:

**95%**

Leading Competitor:

**83.1%**



### Feline Results

Test Buddy™ System:

**96%**

Leading Competitor:

**73.6%**

Percent of results within  $\pm 15$  mg/dL or  $\pm 20\%$  of the reference sample.



Scan here to access the full clinical study.

Order today! For more product information, contact 1-800-877-6161.

Brought to you by

**Healthy Tracks™**  
for Pets

[www.healthy-tracks.com](http://www.healthy-tracks.com)



STRATEGIC  
**ALLIANCE**  
PROGRAM

Bronze Member



### Download App for FREE!

Allows pet parents to sync glucose results from the Test Buddy™ meter memory to certain mobile devices, and share their pet's results with their veterinarian.



## Easy nutritional math?

It was my understanding that there would be no math

Help conquer your fear of math with these simple and effective formulas that offer a more personalized approach to your patient's nutrition plan.

By Rebecca A. Packer, DVM, MS, DACVIM  
(Neurology/Neurosurgery)



**A**re you intimidated by math? Do you find nutrition discussions difficult?

During her talk at the Fetch dvm360® conference Robin Saar, RVT, VTS (Nutrition), puts these fears to rest by breaking down the math and presenting strategies for establishing client trust during nutrition discussions.

There are many aspects of veterinary nutrition that affect our patients throughout their lives, including weight loss, weight gain, gestation, lactation, neonates, and starvation cases. Saar presents approaches to all of these situations and breaks down the math into manageable pieces. Applying these formulas will allow you to provide more personalized care to your patients.

### Energy requirements

The most common math involved in veterinary nutrition is calculating energy requirements for various situations. The resting energy requirement (RER) is one of the basic calculations used in many applications. The RER is the requirement when the patient is awake but at rest. The formula to

calculate RER is  $BW^{0.75} \times 70$ , where BW is body weight in kilograms. Although there is a linear formula for RER ( $RER = 70 + [30 \times BW]$ ), Saar does not recommend its use, as it is not accurate for pets less than 2 kg or more than 30 kg. These days most smartphone calculators have the xy button (x to the power of y), where you enter the BW, push the xy button, and then enter 0.75, then multiply that result by 70.

To calculate the maintenance daily requirements (MER) we use the RER multiplied by a factor. In her Fetch presentation, Saar presents a detailed chart for the appropriate factors to use when calculating MER based on whether the patient's activity is light/moderate/active, whether they are obese prone, whether the patient is intact or neutered, whether they need to lose weight or gain weight, and whether the patient is a dog or cat. From this chart, Saar highlights that cats tend to be slightly lower in their requirements than dogs and that neutered pets have lower energy requirements than intact pets.

When calculating the MER for weight loss, the factor is 1.0, effectively equivalent to the RER in these cases. Saar points out that for

weight loss calculations, the BW used in the calculations should be the current weight, not the ideal or goal weight. She explains that this is partly because it is difficult to determine what the ideal body weight actually is, and partly because when using a regular diet for weight loss, cutting back calories will also result in reducing nutrients. Using the current weight avoids the risk of providing too few nutrients. This formula should be recalculated using updated weights frequently throughout the process of weight loss, so MER can be readjusted for the current weight. When calculating MER for weight gain, however, you should use the patient's ideal weight (not current weight) so you can ensure that you are meeting adequate nutritional requirements.

In some cases, you may find that you need to calculate daily energy requirements (DER). DER is slightly different from MER. When using MER, the presumption is that energy requirements are similar every day. DER is used when there are specific short-term increases in requirements, such as in the case of sled dogs on long (100-mile) runs, gestation, or lactation, neonatal or

pediatric animals, or certain disease states. Think of a DER as a special need for a lot of extra calories "on that day." There are simple formulas for these DER calculating (if you are 16 weeks or younger,  $DER = RER \times 3.0$ ; if 17 weeks or older,  $DER = RER \times 2.0$ ); however, there are much more specific ways to calculate energy requirements for these situations that provide personalized care for each patient given their needs. Saar calls these "Robin's Fun Equations." They are a bit more complicated but can still be broken down into manageable steps, and provide a very tailored, personalized approach to caring for a patient. She presents these situations in detail in her Fetch seminar.

For example, when calculating the DER of a puppy, it is far more accurate to use the following equation:  $DER = 130 \times BWC^{0.75} \times 3.2 (2.71828 - 0.87[BWC/BWE] - 0.1)$  where BWC is current body weight, BWE is the expected adult body weight, and 2.71828 is a constant rather than to simply multiply RER by a generic factor. This more complicated formula considers that very young neonates have high energy requirements but lower body weight,



and then as they grow their energy requirements increase, and then ultimately as they become closer to their adult weight, their energy requirements are lower. The formula for a kitten is very similar, but does have some minor differences:  $DER = 100 \times BWC^{0.67} \times 6.7$  ( $2.71828 - 0.189[BWC/BWE] - 0.66$ ).

### Calculating feeding requirements

By considering the current and expected weights, the feeding requirements increase at first with growth and weight gain, then decrease as you approach the expected adult weight.

Gestation is another life stage in which personalized nutrition can help your patients, although there is no need to increase DER until 5 weeks post-breeding. Again, there are minor differences between the formulas for dams ( $DER = 130 \times BW^{0.75} + [26 \times BW]$ ) and queens ( $DER = 140 \times BW^{0.67}$ ). For dams, this formula equates to an increase in MER by about 25% to 60%, and about 40% to 50% in queens. The goal during gestation is to maintain a normal body condition throughout pregnancy.

Lactation is another life stage that requires additional nutrition. Saar describes that lactation is one of the highest energy demands that an animal can have. The calculated DER for lactation is dependent on the number of puppies or kittens nursing. With 1 puppy the  $DER = 3.0 \times RER$ ; however, each additional puppy the factor of increase is an additional 0.5. For lactating queens, the DER is calculating per kitten by weekly intervals. For example, during weeks 1 to 2 of nursing, the DER for the queen is  $RER + 30\%$  per kitten. In week 3 this factor is 45% per kitten, week 4 is 55% per kitten, week 5 is 65% per kitten, and week 6 is 90% per kitten.

Once these temporary phases are no longer active, energy requirements return to the typical MER formulation.

In terms of disease states, tracking weight loss and calculating the percent loss over time can be useful as an indicator of disease. An unexplained weight loss of 5% or more should result in further scrutiny as to any known factors or

perhaps diagnostic tests to determine potential causes. An unexplained weight loss of greater than 10% is concerning. For smaller patients, a small change in body weight can be easily overlooked despite being a significant percentage change, so it is worth reweighing in a month to see if the trend is ongoing or perform further diagnostic testing to evaluate potential causes.

Other disease states that require tailored nutritional plans include patients at a risk for refeeding syndrome. An example of this would be a pet who was lost and then found a week or two later, thin and dehydrated. Blood work at first may appear normal. But if you offer food after a period of starvation, the body's compensatory physiological processes that allow you to survive starvation will respond poorly to the abundance of food, and a day or two later result in electrolyte derangement and clinical signs. Refeeding, after these compensatory processes have been established and ongoing, acts as a trigger for cells to reuptake these electrolytes and glucose that previously had been shifted to the vasculature, and then blood concentrations of these substances get depleted. Although this sounds fairly complex, it is easy to combat these processes with a strict feeding plan. Saar presents a nutritional plan that is successful not only for refeeding after starvation, but also for diarrhea, diet changes, and other similar situations.

### Calculating volume

After calculating all these detailed energy requirements for specific patients in very specific situations, we still need to know what amount of food we feed. This can be calculated on a volume basis by using the kcal/cup data from each food, or by weight using the kcal/kg data. For foods where the amount of kcal/cup is not available, Saar shows us how to calculate this by using the metabolizable energy from the ingredients. NFE (nitrogen-free extracts) are carbohydrates. Proteins have nitrogen, so nitrogen-free extracts are carbohydrates.  $NFE = 100\% - \% \text{ crude protein} - \% \text{ crude fat} - \% \text{ crude fiber} - \% \text{ moisture} - \% \text{ ash}$ . Note that ash is not typically

## The most common math involved in veterinary nutrition is calculating energy requirements for various situations.

—Robin Saar, RVT, VTS (Nutrition)

listed but is 2.5% for canned diets and 8% for kibble. Metabolizable energy (ME) =  $10([8.5 \text{ kcal/g} \times \% \text{ crude fat}] + [3.5 \text{ kcal/g} \times \% \text{ crude protein}] + [3.5 \text{ kcal/g} \times \% \text{ crude NFE}])$ . Adding these components gives kcal per kilogram of food. From here owners could then weigh the amount of food given instead of measuring it.

### Nutrition plan adherence

All of these methods of calculating energy requirements are really interesting nutritionally, and it is great to create such tailored plans for our patients, but how do we encourage owners to follow through? Saar presents several strategies for building trust and compliance:

- Develop trust. Why do some owners trust a 16-year-old pet store employee more than their veterinarian with years of training and a degree behind them? We need to build trust, and Saar reminds us that one of the best ways to develop trust is to share stories. Share client stories related to the recommendations you are making. Talk about other peoples' experiences so they know there were others who did well and had good experiences on the diet you recommend. Then transfer that trust and information seamlessly to the rest of the team. Once you have your discussion and make your recommendation, communicate with the next person in line (the technician, the receptionist checking them out, etc). Clients want to see that we are all a team and organized, and not failing to share info or providing different opinions.
- Understand and listen to our clients. Sure, we know medicine and clients should know that,

but in this day and age, they also hear all sorts of extraneous information. It helps to be sure to listen to what owners want. If they talk about kibble vs canned food, be sure to listen. If they talk about needing the convenience of getting food at the grocery store or having difficulty driving to the pet store across town, be sure to listen to these things. Do they talk about preferring homemade or fresh foods vs others? Pay attention to these details and adapt your conversation and recommendations to their needs.

- Give 1 clear recommendation. Saar realizes that we may have several options, but by already listening to owners you should have a clear recommendation that suits their needs and preferences. And reiterate this out loud so they hear it: "I have thought about your pet's needs and the information you told me, and here is what I recommend."
- Treat it like a prescription. "This will improve your pet's health, so this is what we recommend."
- Be open to offer another recommendation depending on the client's needs in case there are other factors that affect your recommendation. [dvm360®](#)

*Packer is an associate professor of neurology/neurosurgery at Colorado State University College of Veterinary Medicine and Biomedical Sciences in Fort Collins and is board certified in neurology by the American College of Veterinary Internal Medicine. She is active in clinical and didactic training of veterinary students and residents and has developed a comparative neuro-oncology research program at Colorado State University.*





## NATIONAL PET DIABETES MONTH: Raising awareness and making strides

A general overview of canine and feline diabetes, plus the efforts the Diabetes PetCare Alliance is making to diagnose affected pets and provide clients with the proper resources.

*By Julia Burke, Assistant Editor*

November marks National Pet Diabetes Month. Consequently, awareness is being raised about this lifelong condition affecting approximately 1 in 300 adult dogs and 1 in 230 cats in the United States<sup>1,2</sup> to ensure veterinarians provide companion animals with proper diagnosis and treatment options so they can live fulfilling lives.

Diabetes keeps pets from producing or utilizing insulin appropriately, which prevents the conversion of food to energy; as a result, extra sugar remains in the blood resulting in lethargy and other health-related complications.<sup>3</sup> Though this disease has no cure, it can be managed with treatment and monitoring so pets can continue to thrive.

### Risk factors for diabetes

Although canines and felines can acquire diabetes at any age, diabetic dogs are usually between 4 and 14 years and receive diagnosis from 7 to 10 years, whereas cats with diabetes are typically older than 6 years old.<sup>4</sup> In dogs, diabetes occurs in females twice more than males.<sup>4</sup> Additionally, a study from the *Journal of the American Veterinary Association*<sup>5</sup> revealed that certain canine breeds were at higher risk for developing diabetes including Samoyeds, miniature schnauzers, miniature poodles, and pugs.

Another risk factor is obesity, and aging dogs and cats may develop other diseases (eg, canine hyperadrenocorticism, feline hyperthyroidism, pancreatitis, heart disease,

kidney disease; and urinary tract and skin infections) that may lead to diabetes, or that can greatly affect their response to treatment.<sup>4</sup> Additionally, long-term use of medications including corticosteroids is a diabetes risk factor.<sup>4</sup>

### Signs of diabetes

Early diagnosis is critical to helping pets live longer, healthier lives. According to the American Veterinary Medical Association,<sup>4</sup> hallmark signs of pet diabetes include the following:

- Excessive thirst and increased urination
- Weight loss (though appetite may increase)
- Decreased appetite
- Cloudy eyes (particularly in dogs)



- Chronic or recurring infections (eg, skin and urinary tract infections)

### Diabetes diagnosis and treatment

The treatment for diabetes is typically straightforward—through a general health examination, a urine test for glucose or ketones, or a blood test that detects glucose levels.<sup>3</sup> However, additional blood tests can rule out other medical conditions, and urine cultures can eliminate the possibility of a urinary tract infection.<sup>4</sup>

Advise pet owners to manage their pets' lifelong diabetes with daily doses of insulin, glucose monitoring, attention to diet and exercise, and regular veterinary checkups. The main goal of monitoring diabetes involves keeping a pet's blood sugar near normal levels and avoiding life-threatening levels that are too high or too low. Each patient is unique, so they will require an individualized treatment plan consisting of a new diet and medications.<sup>4</sup>

### Diabetes PetCare Alliance

The Diabetes PetCare Alliance is a partnership between Merck Animal Health, Zoetis, Purina Pro Plan Veterinary Diets, and veterinary professionals nationwide. It has been working since 2014 to inform clients about diabetes and facilitate the screenings for thousands of pets.<sup>6</sup>

Veterinary practices that joined the alliance gained access to downloadable resources for educating clients and raising awareness of the condition, thus increasing the number of pets screened for the disease during National Pet Diabetes Month and beyond. Clients whose pets receive diabetes diagnoses will get a free diabetes management kit which includes<sup>6</sup>:

- One AlphaTRAK 2 Blood Glucose Monitoring System from Zoetis
- One 6-pound bag of Purina Pro Plan Veterinary Diets DM Dietetic Management, Feline Formula for cats, or Purina Pro Plan Veterinary Diets EN Gastroenteric Fiber Balance Dry Formula for dogs
- One 10 mL vial of Vetsulin (porcine insulin zinc suspension) from Merck Animal Health

Although clinic enrollment occurred from September 1, 2021 to October 31, 2021, clients with companion animals receiving diabetes diagnoses are eligible to receive the kits from November 1, 2021, to December 31, 2021.

### Takeaways

Although diabetes is a lifelong condition, early detection and proper treatment can allow pets to continue to lead happy lives. The Diabetes PetCare Alliance is helping pet parents across the nation identify diabetes in their beloved companion animals, so they can jumpstart treatment and keep pets healthy. *dvm360*<sup>®</sup>

### REFERENCES

1. McCann TM, Simpson KE, Shaw DJ, Butt JA, Gunn-Moore DA. Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative risk factor analysis. *J Feline Med Surg* 9:289-299, 2007. doi:10.1016/j.jfms.2007.02.001
2. Catchpole B, Ristic JM, Fleeman LM, Davison LJ. Canine diabetes mellitus; can old dogs teach us new tricks? *Diabetologia*. 2005;48(10):1948-1956, 2005. doi:10.1007/s00125-005-1921-1
3. Pets with diabetes can live happy, healthy lives. Pet Diabetes Month. Accessed October 5, 2021. <https://usa.petdiabetesmonth.com/>
4. Diabetes in pets. American Veterinary Medical Association. Accessed October 5, 2021. [www.avma.org/resources/pet-owners/petcare/diabetes-pets](http://www.avma.org/resources/pet-owners/petcare/diabetes-pets)

5. Hess RS, Kass PH, Ward CR. Breed distribution of dogs with diabetes mellitus admitted to a tertiary care facility. *J Am Vet Med Assoc*. 2000 May 1;216(9):1414-1417. doi:10.2460/javma.2000.216.1414. PMID: 10800511.

6. Enrollment opens next month for the 2021 Diabetes PetCare Alliance Program. *dvm360*<sup>®</sup>. August 5, 2021. Accessed October 5, 2021. [www.dvm360.com/view/enrollment-opens-next-month-for-the-2021-diabetes-petcare-alliance-program](http://www.dvm360.com/view/enrollment-opens-next-month-for-the-2021-diabetes-petcare-alliance-program)

Available to ship today!

# BUPRENORPHINE

0.5 mg/mL, 10 mL or 50 mL

INJECTION  
SOLUTION



- ✓ Manufactured following cGMP, the same regulations used by pharmaceutical companies
- ✓ Tested for potency and sterility
- ✓ Available for hospital administration

Order today!

888.508.5032

Not available in AL, ME, MN or ND.




THE FUTURE OF COMPOUNDING IS MANUFACTURING™



FDA Registered Facility | [epicurpharma.com](http://epicurpharma.com)



# Gastric dilatation-volvulus: The twisted truth

Rapid stabilization, surgical intervention, and intensive postoperative care are key to successful GDV management.

By Elisa M. Mazzaferro, DVM, PhD, MS, DACVECC

**G**astric dilatation-volvulus (GDV) is a common life-threatening emergency for which immediate recognition, stabilization, and surgical intervention remain the only option for therapy. Despite numerous advances in emergency and critical care, the exact etiology of this condition remains elusive. GDV is most common in large and giant purebred dogs but can occur in any size and breed of dog as well as in human and nonhuman primates, cats,<sup>1</sup> guinea pigs, and other species.

Advances have been made in identifying genetic predisposition in breeds such as the Great Dane, leading to the possibility of eliminating predisposed dogs from the breeding population.<sup>2</sup> Despite this, other risk factors including large thoracic depth to width ratios, advanced age,<sup>3</sup> stretched hepatosplenic ligaments, barometric pressure change, dietary fat content, meal and dry particle food size, foreign body ingestion,<sup>4</sup> patient temperament, prior splenectomy,<sup>5-8</sup> raising or lowering food bowls, and postprandial activity have also been

implicated as potential causes for GDV; however, studies have shown conflicting results.<sup>9</sup>

## PATHOPHYSIOLOGY

Independent of risk factors, GDV is a process in which instability of the gastric fundus, along with delayed gastric emptying and gas or fluid distension, results in 180° to 270° rotation of the stomach around its mesenteric vascular axis.<sup>10</sup> Some dogs may experience intermittent rotation and repositioning, but in the majority of cases, once mispositioned the dilated, rotated stomach compresses the caudal vena cava and diminishes venous return to the right heart, ultimately affecting cardiac preload and output.<sup>11</sup> Lack of perfusion to the stomach, along with decreased cardiac output, rapidly results in clinical signs associated with distributive and cardiogenic shock. Prompt recognition and early intervention are required to improve chances of a successful outcome.

## CLINICAL SIGNS AND DIAGNOSTIC TESTING

Characteristic clinical signs of GDV include unproductive retching, ptyalism, abdominal distension, and restlessness,

and stretching. For confirmation, the right lateral abdominal radiograph is the most rewarding to demonstrate a classic appearance of dorsocranial displacement of the pylorus with gas distension of the gastric fundus and compartmentalization. In some instances, the presence of fluid or 360° rotation can make a diagnosis of GDV more challenging. In such instances, evaluation of contralateral and ventrodorsal abdominal radiographs may be required. Thoracic radiographs often reveal dilation of the esophagus with a small caudal vena cava and microcardia. Because of the lack of cardiac preload, the cardiac silhouette may be elevated from the sternum.<sup>12</sup>

In the patient with GDV, a minimum database should be obtained, consisting of a PCV/TS, venous electrolytes, acid-base status, and lactate concentration. Although the initial PCV/TS is not prognostic, patients with GDV can have rupture of the short gastric vessels or concurrent splenic torsion, resulting in absolute or relative anemia that may require transfusion of red blood cell products. Additional information gained by the animal's acid-base status and lactate concentration is also important and can be prognostic. Plasma lactate levels greater than 7 to 9 mmol/L have been associated with the presence of gastric necrosis and may be prognostic of survival in initial studies.<sup>13,14</sup> Lactate clearance, or a drop in lactate to less than 40% to 50% of baseline, or by more than 4 mmol/L

with therapy, has more accurately been predictive of survival.<sup>15-17</sup> Serum spec cPL (canine pancreatic lipase) immunoreactivity may also be elevated in dogs with GDV, suggesting simultaneous pancreatic injury.<sup>18</sup> Prolonged coagulation times, an elevated D-dimer level, and lower fibrinogen concentration as well as Protein C and antithrombin activity have all been noted in dogs that do not survive postoperatively.<sup>17</sup>

## STABILIZATION AND PREOPERATIVE CARE

Once a diagnosis of GDV is made, timing is critical in providing supportive care and initiating immediate surgical intervention. Placement of large bore intravenous catheters into the cephalic or lateral saphenous veins allows administration of crystalloid fluids. Isotonic crystalloids (Normosol-R, Plasma-Lyte A, 0.9% saline) should be administered in incremental boluses, starting with a quarter of the patient's calculated shock volume. In dogs, this is roughly 22 mL/kg (or take the patient's body weight in pounds and add a zero for the quarter shock volume) and should be administered as rapidly as possible. Once the calculated volume has been infused, reevaluation of the patient's perfusion parameters (heart rate, blood pressure, capillary refill time, mucous membrane color) should be performed to determine whether to continue additional fluid boluses or to add a colloid such as hydroxyethyl starch (5-10 mL/kg) for additional vascular support. Gastric decompression by trocarisation or orogastric tube placement should be performed to alleviate gastric dilation and improve cardiac preload.<sup>19</sup> Many dogs with GDV are bacteremic at the time of diagnosis due to bacterial translocation.<sup>20</sup> Preoperative administration of a first-generation







# Choose ThyroKare™ today!

**ThyroKare™ (levothyroxine sodium tablets), USP**

Approved by FDA under NADA # 141-539

## **Why choose ThyroKare™?**

- ThyroKare is offered in 9 different strengths from 0.1 mg to 1.0 mg in 0.1 mg increments
- 180 count bottle offers 50% more than the competition
- ThyroKare is available in 180 and 1000 count bottles to meet specific prescription quantity needs
- Color-coded bottles for ease and accuracy in dispensing
- Meets all USP standards
- Made in the USA



*To learn more, call 800.525.2022 or 859.254.1221, email [ThyroKare@NEOGEN.com](mailto:ThyroKare@NEOGEN.com) or visit [ThyroKare.com](http://ThyroKare.com).*

© NEOGEN Corporation, 2021. NEOGEN and NEOGENVet are registered trademarks and ThyroKare is a trademark of NEOGEN Corporation, Lansing 48912 U.S. All other trademarks are property of their respective companies.




## ThyroKare™ (levothyroxine sodium tablets), USP

NEOGEN Vet

For oral use in dogs only

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** ThyroKare (levothyroxine sodium tablets), USP contains synthetic L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic levothyroxine sodium is identical to the hormone produced in the thyroid gland of a dog. Levothyroxine sodium has an empirical formula of  $C_{15}H_{10}I_4NNaO_4 \cdot H_2O$ , molecular weight of 798.85 g/mol (anhydrous) and structural formula as shown:



**INDICATION:** For replacement therapy for diminished thyroid function in dogs.

**DOSAGE AND ADMINISTRATION:** The initial dose is 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) body weight twice daily. To minimize day-to-day variations in serum total thyroxine (TT4) concentrations (see **CLINICAL PHARMACOLOGY**), owners should consistently administer ThyroKare either with or without food. To maintain serum levothyroxine sodium concentrations over time, therapeutic monitoring should be conducted every 4 weeks until an adequate maintenance dose is established and then as needed for continued maintenance.

When switching from another levothyroxine sodium formulation to ThyroKare, monitor serum TT4 concentrations and clinical response due to potential differences in recommended starting doses and potential differences in bioavailability.

**CONTRAINDICATIONS:** Do not use in dogs with thyrotoxicosis, acute myocardial infarction, or uncorrected adrenal insufficiency.

### WARNINGS:

**User Safety Warnings:** Not for human use. Keep out of reach of children. In the event of accidental ingestion, seek medical advice immediately and show the product label to the physician. Wash hands after handling.

**Animal Safety Warnings:** Keep ThyroKare in secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

**PRECAUTIONS:** Use with caution in dogs with clinically significant cardiovascular disease, diabetes mellitus, or other conditions for which an increased metabolic rate might prove hazardous. Dogs with underlying cardiovascular disease that are diagnosed with hypothyroidism should be closely monitored during the dose establishment phase. Adjustment of cardiovascular medications or levothyroxine sodium dosage may be needed.<sup>1-4</sup> The safety of ThyroKare has not been evaluated in breeding, pregnant, or lactating dogs.

**ADVERSE REACTIONS:** In a 6-month US field study, the 120 dogs enrolled in the study receiving a minimum of one dose of ThyroKare were evaluated for safety. The percentage of dogs experiencing adverse reactions is presented in Table 1.

Table 1. Percentage of dogs experiencing adverse reactions

Adverse Reaction	Percent	Adverse Reaction	Percent
Polydipsia	30.8	Otitis externa and otorrhea	4.2
Polyuria	20.0	Increased serum alanine aminotransferase (ALT)	4.2
Tachypnea	16.7	Increased serum alkaline phosphatase (ALP)	3.3
Lethargy	11.7	Pruritus, including pinnal	3.3
Anorexia	10.0	Tachycardia	3.3
Emesis	10.0	Aggression	1.7
Muscle tremor/shaking	10.0	Dermatitis and eczema	1.7
Hyperactivity	8.3	Lymphopenia	1.7
Anxiety	5.8	Temporal muscle atrophy	1.7
Desquamation/scaling/seborrhea	5.8	Weight loss	1.7
Diarrhea	5.0	Adipsia	0.8
Polyphagia/increased appetite	5.0	Hypersalivation	0.8
Alopecia and increased shedding	4.2	Hypersensitivity reaction	0.8

Clinical pathology findings were consistent with stimulation of hematopoiesis as a result of replacement therapy with ThyroKare. However, hematocrit and red blood cell counts exceeded the upper limit of the reference range in 6 dogs at the end of the study; 3 of these dogs also had elevated reticulocyte counts. Nine (9) dogs had transient elevations in neutrophil counts exceeding the reference range at Day 28 that resolved by Day 56. Liver enzyme elevations associated with ThyroKare returned to the reference range by Day 168 in 2 of 4 dogs with increased ALP and 4 of 5 dogs with increased ALT, respectively.

One dog was withdrawn from the study at the owner's request because of an elevated TT4 concentration and abnormal behavior. A second dog was removed from the study by request of the investigator due to anemia.

A dog with preexisting hypoalbuminemia exhibited declining serum albumin and total protein concentrations concurrently with prolonged elevated serum TT4 concentrations. Although reducing the ThyroKare dose resulted in serum TT4 levels in the therapeutic range, the dog experienced a serious adverse event that included marked weight loss, hypoalbuminemia, hypoproteinemia, elevated ALP, and hypoglycemia. The dog received supportive veterinary care and completed the study while remaining on the same ThyroKare dose. Serum albumin returned to near baseline and total protein normalized by the end of the study.

## ThyroKare™ (levothyroxine sodium tablets), USP

NEOGEN Vet

Twenty-two (22) individual case reports describing 42 adverse reactions related to the clinical use of ThyroKare in dogs were reported voluntarily to Neogen Corporation (as of 2020). The following adverse events were reported: panting, anxiety, elevated or low serum TT4 concentrations, vomiting, diarrhea, lethargy, unspecified skin issues, folliculitis, hyperpigmentation, hair loss, hiding, polyuria, polydipsia, tachycardia, masseter and temporal muscle atrophy, reduced appetite, polyphagia, and seizure.

**CONTACT INFORMATION:** For a copy of the Safety Data Sheet (SDS) or to report suspected adverse drug events, contact Neogen Corporation at 800.525.2022. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1.888.FDA.VETS or www.fda.gov/reportanimalae.

**CLINICAL PHARMACOLOGY:** Synthetic levothyroxine (T4) is chemically identical to the naturally-occurring thyroxine hormone. Levothyroxine sodium acts, as does endogenous thyroxine, to stimulate metabolism, growth, development, and differentiation of tissues. Levothyroxine sodium is absorbed rapidly from the gastrointestinal tract after oral administration. When ThyroKare (levothyroxine sodium tablets), USP was administered as a single oral dose of 0.1 mg/10 lb (0.022 mg/kg) to 7 thyroidectomized, fasted Beagles, the absolute bioavailability of levothyroxine sodium was low (19%). After 7 days of twice daily dosing, peak serum TT4 concentrations were reached within 1.3 to 4 hours. The mean (± standard deviation) terminal phase half-life was 9.6 (±3.4) hours. Administration of levothyroxine sodium with food reduces oral bioavailability.<sup>5</sup> Levothyroxine sodium is excreted in the feces. Absorption and metabolism of levothyroxine can vary greatly between individual dogs, so therapeutic monitoring of serum TT4 levels is recommended (see **DOSAGE AND ADMINISTRATION**).

**EFFECTIVENESS:** In a US field study, 120 dogs were administered an initial dose of 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) body weight, given twice daily. The dose could be increased or decreased (without a change in frequency) after 4 and 8 weeks and at unscheduled visits, based on clinical findings and serum thyroid (TT4) hormone concentrations.

Treatment success was determined at Day 84 and was defined as no more than two prior dose adjustments and the serum TT4 concentration within the therapeutic range (1.0 to 5.4 µg/dL) when collected 4 to 6 hours post-tablet administration. After 84 ± 5 days of treatment, 87 of 107 evaluable cases (81.3%) were considered treatment successes. During the extended use phase of the study that allowed additional dose adjustments, 87 of 107 evaluable cases (81.3%) were considered treatment successes after 168 ± 5 days of treatment.

Clinical signs of hypothyroidism (lethargy, weight gain, hypercholesterolemia, bradycardia, cold intolerance, and dermatologic conditions such as alopecia, seborrhea, hyperpigmentation, myxedema, hyperkeratosis, scaling, and pyoderma) generally improved during the study.

**ANIMAL SAFETY:** A comprehensive literature review identified publications that reported clinical signs and adverse reactions resulting from oral and parenteral levothyroxine exposure in dogs.

Reported exposure to levothyroxine sodium, even at high-dose multiples, was well tolerated in the dogs included in the studies. Adverse reactions reported in naturally hypothyroid and euthyroid dogs exposed to levothyroxine sodium equivalent to 0.5X to 2X the initial 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) twice daily ThyroKare dose were restlessness, lethargy, hyperactivity, anorexia, polyphagia, polyuria, polydipsia, periodic lateral recumbency, tachypnea, syncope, tachycardia, hyperthermia, pruritus, alopecia, skin scaling, dermatitis, otitis externa, change in coat color, weight loss, vomiting, borborygmus, diarrhea, epistaxis, leukocytosis, and elevated serum total thyroxine. Two studies of naturally hypothyroid dogs reported liver enzyme elevations [ALP, ALT, or aspartate aminotransferase (AST)] related to levothyroxine sodium administration that resolved in most dogs by 10 to 18 weeks after initiation of exposure. In one of the studies, seven dogs had a hematocrit and red blood cell count above the upper reference limit at the end of the study. In a study of euthyroid dogs, exposure to 0.5 mg/m<sup>2</sup> levothyroxine sodium (approximately equivalent to the initial ThyroKare dose) for 8 weeks was associated with a decrease in pituitary thyrotrope volume density and morphologic changes consistent with thyroid gland inactivity. After cessation of treatment, the changes were reversible.

Chronic exposure to 25X the initial dose resulted in transient increases in bone metabolism, but bone turnover returned to near normal levels after two months of continuous exposure. Study dogs also exhibited transient increases in serum phosphorus and calcium, hyperthermia, tachycardia, and tachypnea. Additional adverse reactions reported in experimental studies that evaluated parenteral exposures to levothyroxine (approximately 2.5X to 25X the initial oral daily dose) included cardiovascular and dynamic conduction changes, anorexia, polycythemia, fine muscle tremors, and death.

**STORAGE CONDITIONS:** Store at 20°-25°C (68°-77°F) with excursions allowed between 15° and 30°C (59° and 86°F) and protect from light.

**HOW SUPPLIED:** ThyroKare (levothyroxine sodium tablets), USP is available as colored tablets in nine strengths: 0.1 mg-yellow; 0.2 mg-pink; 0.3 mg-green; 0.4 mg-light pink; 0.5 mg-white; 0.6 mg-dark blue-violet; 0.7 mg-pinkish orange; 0.8 mg-light blue; and 1.0 mg-tan, in bottles of 180 and 1,000 tablet counts.

Approved by FDA under NADA # 141-539

**REFERENCES:** [1]B. Chow and A. French, "Conversion of atrial fibrillation after levothyroxine in a dog with hypothyroidism and arterial thromboembolism," J Small Anim Pract, vol. 55, no. 5, pp. 278-282, 2014. [2]J. A. Flood and J. P. Hoover, "Improvement in myocardial dysfunction in a hypothyroid dog," Can Vet J, vol. 50, pp. 828-834, 2009. [3]D. E. Phillips and K. R. Harkin, "Hypothyroidism and myocardial failure in two Great Danes," J Am Anim Hosp Assoc, vol. 39, pp. 133-137, 2003. [4]J. K. Sangster, D. L. Panciera and J. A. Abbott, "Cardiovascular effects of thyroid disease," Compend Contin Educ Vet, vol. 35, no. 7, p. E1-E10, 2013. [5]G. Le Traon, S. Burgaud and L. J. Horspool, "Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium," J Vet Pharmacol Therap, vol. 31, pp. 95-101, 2008.

Rev. 12/20

NEOGEN  
Manufactured by: Neogen Corporation  
944 Nandino Blvd., Lexington, KY 40511  
800.525.2022 • NEOGEN.com

L784-1220

## MEDICINE | Surgery

> Continued from page 34

cephalosporin (Cefazolin 22 mg/kg IV) is indicated, along with maropitant (1 mg/kg IV) to decrease the risk of postoperative vomiting and subsequent aspiration pneumonia.

### ANALGESIA AND ANESTHESIA

Analgesia in the form of a pure mu opioid such as methadone (0.1-0.2 mg/kg IV, IM) or fentanyl (2-3 µg/kg IV) can be administered prior to anesthetic induction. Opioids such as morphine and hydromorphone have potent emetic properties and so ideally should be avoided. Although the partial agonist buprenorphine may be beneficial at providing analgesia, its avid binding to the mu receptors may compete with more potent mu agonists such as fentanyl, which may be required intraoperatively or postoperatively, so its administration is not ideal.

Drug choices for anesthetic induction should be chosen based on the patient's degree of instability. In stable patients with functional reserves of adrenal norepinephrine, ketamine (0.5 mg/kg IV) and midazolam/diazepam (0.1-0.2 mg/kg IV) may be chosen, because ketamine results in the adrenal release of norepinephrine and an increase in cardiac output. Propofol (4-7 mg/kg IV) with or without a benzodiazepine (midazolam/diazepam) can be used during simultaneous preoxygenation and administration of an intravenous crystalloid fluid bolus to prevent vasodilator-induced hypotension. In the least stable patients, a combination of fentanyl (5-10 µg/kg IV) with a benzodiazepine (midazolam/diazepam) or etomidate (0.2-4 mg/kg IV) with a benzodiazepine can be performed. Once the animal is anesthetized and intubated, a constant rate infusion of fentanyl (10-20 µg/kg/hour) can be administered to reduce the level of gas anesthesia.

### CARDIAC DYSRHYTHMIAS

The presence of preoperative, intraoperative, and postoperative cardiac dysrhythmias is common. Sinus tachycardia can be associated with relative hypovolemia from lack of cardiac preload, blood loss, discomp, or vasodilation from gas anesthesia or inflammatory cytokines and reperfusion injury. Treatment

of sinus tachycardia consists of intravenous crystalloid and colloid boluses, blood products when needed to address blood loss and anemia, and provision of adequate analgesia and anesthesia during surgery. Even in the absence of ventricular dysrhythmias in the preoperative period, early preemptive intervention with lidocaine (2 mg/kg IV, followed by 50 µg/kg/min constant rate infusion) has been shown to decrease the incidence of postoperative ventricular dysrhythmias, acute kidney injury, and hospitalization time.<sup>21</sup>

Ventricular dysrhythmias in the form of unifocal or multifocal ventricular premature contractions (VPCs), ventricular tachycardia, and R-on-T are common and should be addressed whenever they occur during anesthesia. During the postoperative period, lidocaine should be continued for its antiarrhythmic properties as well as provision of analgesia and treatment of reperfusion injury.

### SURGICAL INTERVENTION

At the time of surgery, the stomach should be untwisted into its normal anatomic location. Next, the abdomen should be systematically explored. The spleen and its vascular supply should be carefully evaluated to determine whether torsion or thrombosis are present, necessitating splenectomy. Once a complete exploration of the abdomen has been performed, the stomach should be visualized and palpated for integrity and the presence of necrosis or perforation. When present, small areas of necrosis should be removed, resected, and not invaginated. The need for gastric resection, with or without concurrent splenectomy, has been demonstrated to be a negative prognostic indicator for survival.<sup>22</sup> Multiple gastropexy techniques have been described, including the right paracostal incisional, belt-loop, modified belt-loop, and circumcostal.<sup>23-26</sup> The technique chosen should depend on surgeon preference. Independent of the gastropexy performed, GDV recurrence is rare (< 5% chance of recurrence) when the technique is performed properly.<sup>27</sup> Possible causes of recurrence include too small an area of gastropexy (< 4 cm) or



breakdown of the gastropexy site. Placement of the gastropexy too close to the pylorus also can result in the postoperative complication of delayed gastric emptying.

### POSTOPERATIVE CARE

Postoperative care involves provision of adequate analgesia, ongoing maintenance of fluid balance, treatment of cardiac dysrhythmias, and monitoring for postoperative complications such as ileus, gastrointestinal reflux and feeding intolerance, and disseminated intravascular coagulation.<sup>27</sup> Standard analgesia consists of administration of a pure mu opioid (methadone, fentanyl, hydromorphone) or administration of the partial mu agonist buprenorphine. These can then be transitioned to gabapentin (1.25-4 mg/kg po tid-qd) when administration of oral medication is possible. Because opioid drugs can contribute to postoperative ileus, early transition to other analgesia such as gabapentin is preferred. Intravenous crystalloids, with or without a constant rate infusion of metoclopramide (1-2 mg/kg/day), should be administered to maintain hydration and perfusion. Gastroprotectant therapy in the form of antiemetics (maropitant 1 mg/kg SQ, IV or 2 mg/kg po qd ondansetron 0.1-1 mg/kg IV, po bid-tid) or acid reduction (famotidine 0.5-1 mg/kg IV, po bid; pantoprazole 1 mg/kg IV bid or omeprazole 1 mg/kg po bid) can be administered. Sucralfate (0.5-1 g per dog po tid - qid) and cisapride (0.1-0.5 mg/kg po tid) can be administered in the event of postoperative regurgitation. Careful attention to an animal's acid-base and electrolyte status is warranted, because hypokalemia can predispose a patient to cardiac dysrhythmias. Continuous ECG monitoring for a minimum of 24 hours postoperatively should be performed. If ventricular tachycardia is greater than 160 beats per minute, if there are multifocal VPCs or R-on-T beats present, or if the dysrhythmia is causing hypotension, lidocaine should be administered as previously described. If the ventricular dysrhythmias continue after the patient has been transitioned to oral medications, sotalol (1-2 mg/kg po bid) can be administered at the

time of discharge and continued for 2 weeks until the time of staple/suture removal. In the most complicated cases involving partial gastrectomy, patients should have coagulation tests and a daily platelet estimate on a blood smear performed daily to investigate for disseminated intravascular coagulation (DIC). If DIC is suspected and coagulation times are prolonged, administration of fresh frozen plasma (5-20 mL/kg) should be considered.

### PROGNOSIS

The overall survival for a patient with GDV ranges from 70% to 80% following surgical correction in most studies. Negative prognostic indicators include persistent elevations in lactate that do not drop by at least 40% of baseline following treatment, the need for lidocaine administration,<sup>28,29</sup> and the need for partial gastrectomy with or without concurrent splenectomy.<sup>22</sup>

### PREVENTION

The best method of preventing GDV and its complications is to educate pet owners about prophylactic gastropexy in predisposed large-, giant-, or deep-chested breeds.<sup>24,30-32</sup> Prophylactic gastropexy can be performed as an elective procedure at the same time as a spay or neuter. Midline celiotomy approach as well as laparoscopic and laparoscopic-assisted gastropexy can be performed depending on the resources available, experience, and preference.<sup>30,32</sup> Although minor complications such as incisional infection are possible, the prognosis for recovery and prevention of future GDV is good.<sup>32</sup> dvm360®

### REFERENCES

- Leary ML, Sinnott-Stutzman V. Spontaneous gastric dilatation-volvulus in two cats. *J Vet Emerg Crit Care (San Antonio)*. 2018;28(4):346-355. doi:10.1111/vec.12734
- Harkey MA, Villagran AM, Venkataraman GM, Leisenring WM, Hullar MAJ, Torok-Storb BJ. Associations between gastric dilatation-volvulus in Great Danes and specific alleles of the canine immune-system genes DLA88, DRB1, and TLR5. *Am J Vet Res*. 2017;78(8):934-945. doi:10.2460/ajvr.78.8.934
- O'Neill DG, Case J, Boag AK, et al. Gastric dilatation-volvulus in dogs attending UK emergency-care veterinary practices: prevalence, risk factors and survival. *J Small Anim Pract*. 2017;58(11):629-638. doi:10.1111/jsap.12723
- de Battisti A, Toscano MJ, Formaggini L. Gastric foreign body as a risk factor for gastric dilatation and volvulus in dogs. *J Am Vet Med Assoc*. 2012;241(9):1190-1193. doi:10.2460/javma.241.9.1190
- Sartor AJ, Bentley AM, Brown DC. Association between previous splenectomy and gastric dilatation-volvulus in dogs: 453 cases (2004-2009). *J Am Vet Med Assoc*. 2013;242(10):1381-1384. doi:10.2460/javma.242.10.1381
- Maki LC, Males KN, Byrnes MJ, El-Saad AA, Coronado GS. Incidence of gastric dilatation-volvulus following a splenectomy in 238 dogs. *Can Vet J*. 2017;58(12):1275-1280.
- Grange AM, Clough W, Casale SA. Evaluation of splenectomy as a risk factor for gastric dilatation-volvulus. *J Am Vet Med Assoc*. 2012;241(4):461-466. doi:10.2460/javma.241.4.461
- Goldhammer MA, Haining H, Milne EM, Shaw DJ, Yool DA. Assessment of the incidence of GDV following splenectomy in dogs. *J Small Anim Pract*. 2010;51(1):23-28. doi:10.1111/j.1748-5827.2009.00844.x
- Bell JS. Inherited and predisposing factors in the development of gastric dilatation-volvulus in dogs. *Top Companion Anim Med*. 2014;29(3):60-63. doi:10.1053/j.tcam.2014.09.002
- Czajkowski PS, Hallman RM. Diagnosis of chronic gastric instability using computed tomography in a Great Dane that progressed to gastric dilatation and volvulus: a literature review and case report. *Open Vet J*. 2018;8(2):219-223. doi:10.4314/ovj.v8i2.18
- Sharp CR, Rozanski EA. Cardiovascular and systemic effects of gastric dilatation and volvulus in dogs. *Top Companion Anim Med*. 2014;29(3):67-70. doi:10.1053/j.tcam.2014.09.007
- Green JL, Cimino Brown D, Agnello KA. Preoperative thoracic radiographic findings in dogs presenting for gastric dilatation-volvulus (2000-2010): 101 cases. *J Vet Emerg Crit Care (San Antonio)*. 2012;22(5):595-600. doi:10.1111/j.1476-4431.2012.00802.x
- Zacher LA, Berg J, Shaw SP, Kudej RK. Association between outcome and changes in plasma lactate concentration during presurgical treatment in dogs with gastric dilatation-volvulus: 64 cases (2002-2008). *J Am Vet Med Assoc*. 2010;236(8):892-897. doi:10.2460/javma.236.8.892
- Beer KA, Syring RS, Drobatz KJ. Evaluation of plasma lactate concentration and base excess at the time of hospital admission as predictors of gastric necrosis and outcome and correlation between those variables in dogs with gastric dilatation-volvulus: 78 cases (2004-2009). *J Am Vet Med Assoc*. 2013;242(1):54-58. doi:10.2460/javma.242.1.54
- Mooney E, Raw C, Hughes D. Plasma lactate concentration as a prognostic biomarker in dogs with gastric dilatation and volvulus. *Top Companion Anim Med*. 2014;29(3):71-76. doi:10.1053/j.tcam.2014.09.005
- Green TI, Tonozzi CC, Kirby R, Rudloff E. Evaluation of initial plasma lactate values as a predictor of gastric necrosis and initial and subsequent plasma lactate values as a predictor of survival in dogs with gastric dilatation-volvulus: 84 dogs (2003-2007). *J Vet Emerg Crit Care (San Antonio)*. 2011;21(1):36-44. doi:10.1111/j.1476-4431.2010.00599.x
- Verschoof J, Moritz A, Kramer M, Bauer N. Hemostatic variables, plasma lactate concentration, and inflammatory biomarkers in dogs with gastric dilatation-volvulus. *Tierarztl Prax Ausg K Kleintiere Heimtiere*. 2015;43(6):389-398. doi:10.15654/TPK-150284
- Spinella G, Dondi F, Grassato L, et al. Prognostic value of canine pancreatic lipase immunoreactivity and lipase activity in dogs with gastric dilatation-volvulus. *PLoS One*. 2018;13(9):e0204216. doi:10.1371/journal.pone.0204216
- Goodrich ZJ, Powell LL, Hulting KJ. Assessment of two methods of gastric decompression for the initial management of gastric dilatation-volvulus. *J Small Anim Pract*. 2013;54(2):75-79. doi:10.1111/jsap.12019
- Winkler KP, Greenfield CL, Schaeffer DJ. Bacteremia and bacterial translocation in the naturally occurring canine gastric dilatation-volvulus patient. *J Am Anim Hosp Assoc*. 2003;39(4):361-368. doi:10.5326/0390361
- Bruchim Y, Itay S, Shira BH, et al. Evaluation of lidocaine treatment on frequency of cardiac arrhythmias, acute kidney injury, and hospitalization time in dogs with gastric dilatation-volvulus. *J Vet Emerg Crit Care (San Antonio)*. 2012;22(4):419-427. doi:10.1111/j.1476-4431.2012.00779.x
- Beck JJ, Staatz AJ, Pelsue DH, et al. Risk factors associated with short-term outcome and development of perioperative complications in dogs undergoing surgery because of gastric dilatation-volvulus: 166 cases (1992-2003). *J Am Vet Med Assoc*. 2006;229(12):1934-1939. doi:10.2460/javma.229.12.1934
- Allen P, Paul A. Gastropexy for prevention of gastric dilatation-volvulus in dogs: history and techniques. *Top Companion Anim Med*. 2014;29(3):77-80. doi:10.1053/j.tcam.2014.09.001
- Benitez ME, Schmiedt CW, Radlinsky MG, Cornell KK. Efficacy of incisional gastropexy for prevention of GDV in dogs. *J Am Anim Hosp Assoc*. 2013;49(3):185-189. doi:10.5326/JAAHA-MS-5849
- Formaggini L, Degna MT. A prospective evaluation of a modified belt-loop gastropexy in 100 dogs with gastric dilatation-volvulus. *J Am Anim Hosp Assoc*. 2018;54(5):239-245. doi:10.5326/JAAHA-MS-6596
- Przywara JF, Abel SB, Peacock JT, Shott S. Occurrence and recurrence of gastric dilatation with or without volvulus after incisional gastropexy. *Can Vet J*. 2014;55(10):981-984.
- Bruchim Y, Kelmer E. Postoperative management of dogs with gastric dilatation and volvulus. *Top Companion Anim Med*. 2014;29(3):81-85. doi:10.1053/j.tcam.2014.09.003
- Mackenzie G, Barnhart M, Kennedy S, DeHoff W, Schertel E. A retrospective study of factors influencing survival following surgery for gastric dilatation-volvulus syndrome in 306 dogs. *J Am Anim Hosp Assoc*. 2010;46(2):97-102. doi:10.5326/0460097
- Rivier P, Furneaux R, Viguier E. Combined laparoscopic ovariectomy and laparoscopic-assisted gastropexy in dogs susceptible to gastric dilatation-volvulus. *Can Vet J*. 2011;52(1):62-66.
- Loy Son NK, Singh A, Amsellem P, et al. Long-term outcome and complications following prophylactic laparoscopic-assisted gastropexy in dogs. *Vet Surg*. 2016;45(S1):O77-O83. doi:10.1111/vsu.12568
- Coleman KA, Boscan P, Ferguson L, Twedt D, Monnet E. Evaluation of gastric motility in nine dogs before and after prophylactic laparoscopic gastropexy: a pilot study. *Aust Vet J*. 2019;97(7):225-230. doi:10.1111/avj.12829



# Understanding AND diagnosing canine hypothyroidism

By Laura Van Vertloo, DVM, MS, DACVIM

**C**anine hypothyroidism is a slowly progressive disorder resulting from failure of the thyroid gland to secrete amounts of thyroid hormones adequate for maintaining normal organ functions. Although hypothyroidism is relatively common and thyroid hormone testing is readily available, there is a diagnostic challenge because the clinical signs can be subtle and highly variable. Furthermore, there are numerous causes of low thyroid hormone levels in euthyroid dogs. Because of these factors, making a correct diagnosis of hypothyroidism can be difficult.

Canine hypothyroidism usually results from failure of the thyroid gland. This can be due to lymphocytic thyroiditis (destruction of the thyroid gland by inflammation) or idiopathic thyroid atrophy (degeneration of the thyroid gland in the absence of apparent inflammation). Failure of the thyroid gland is termed primary hypothyroidism and accounts for most cases of canine hypothyroidism. Less commonly, there is secondary hypothyroidism, in which the thyroid gland is healthy but the pituitary gland fails to secrete thyrotropin (TSH), resulting in a secondary failure of the thyroid gland to secrete the hormones thyroxine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>).

Primary hypothyroidism affects different breeds; mixed-breed dogs, golden retrievers, Doberman pinschers, and Labrador retrievers are among those most affected. The age at which clinical signs manifest varies but diagnosis at middle-age to senior years is typical. Because it is the most common, the diagnostic approach to primary hypothyroidism will be the focus of this article.

## Clinical signs

Because thyroid hormones affect virtually every organ, the clinical manifestations of disease can be different for each patient. Dogs affected with hypothyroidism often have a decreased metabolic rate resulting in lethargy, dullness, and weight gain without polyphagia. Dermatologic effects are the most common clinical sign of hypothyroidism,



including alopecia, a dull and brittle hair coat, skin hyperpigmentation, and pyoderma. Neurologic (peripheral neuropathies, vestibular disease, myopathy) and cardiovascular effects

(bradyarrhythmia) are less common but do occur. Rarely, dogs with severe, untreated hypothyroidism can develop myxedema coma, characterized by life-threatening hypothermia, bradyarrhythmia, and deterioration in mental state. Myxedema coma is typically the result of untreated hypothyroidism in the face of additional serious illness.

## Clinical pathology

Clinicopathologic changes in hypothyroid dogs are relatively few but characteristic. Hypercholesterolemia is seen in approximately 75% of hypothyroid dogs; some will also have hypertriglyceridemia. Hyperlipidemia can result in the deposition of ocular lipid, which may be recognized on physical examination. A mild, normocytic, normochromic, nonregenerative anemia is seen in approximately one-third of hypothyroid dogs.





## Causes of diagnostic confusion: factors that decrease T4 in euthyroid dogs

It is critically important to remember the factors that can influence thyroid hormone testing, and the following should be carefully considered before making a diagnosis of hypothyroidism.

### Drugs

Various drugs can influence multiple thyroid hormone tests, especially the total T4 (TT4) test. Prednisone, nonsteroidal anti-inflammatory drugs, phenobarbital, and tricyclic antidepressants are some of the more common offenders. If possible, patients should be removed from treatment with these drugs before evaluation for hypothyroidism.

### Breed

Euthyroid sighthounds are known to have TT4 levels below the reference interval. Fortunately, these dogs are rarely affected by hypothyroidism.

### Age

The TT4 level decreases with age and can dip below the reference interval in very elderly dogs.

### Random fluctuations

Occasionally, euthyroid dogs with no other complicating factors can have a TT4 level that transiently drops below the reference interval. This should not be accompanied by clinical signs and repeat evaluation will likely show a TT4 level in the normal range.

### Nonthyroidal illness

Systemic illness, malnutrition, trauma, and surgery can all cause decreased thyroid hormone levels. This is often called euthyroid sick syndrome. Although the mechanism is unclear, the condition is thought to be a physiologic adaptation to stress or illness. Most commonly, the TT4 level is decreased, but the free T4 (fT4) level can also be affected.

## Diagnostic approach: specific thyroid tests

### TT4

The TT4 test includes both bound and unbound (free) T4. T4 is the most abundant hormone secreted by the thyroid gland. This test is used to rule out hypothyroidism. Very few truly hypothyroid dogs will have a normal TT4 level. As mentioned, many factors can cause a low TT4 level in euthyroid dogs. Because of this, a low TT4 level alone should never be used to diagnose hypothyroidism. Additional thyroid diagnostics should be pursued to support the diagnosis before initiating treatment.

### fT4

The fT4 is the small fraction of the total T4 that is biologically active. Because the fT4 level is less affected by nonthyroidal illness (NTI) than TT4 levels are, this test is frequently used as a follow-up to a low TT4 result if there is clinical suspicion of hypothyroidism but NTI is present.

### TSH

The lack of negative feedback to the pituitary gland in primary hypothyroidism will result in increased TSH. Hypothyroid dogs will have a TSH level above the reference interval in about two-thirds of cases. The TSH test is used in combination with low TT4 and/or fT4 test results to support a diagnosis of hypothyroidism.

### Tests for thyroiditis

Some laboratories offer assays for antithyroglobulin, anti-T3, and anti-T4 autoantibodies. Approximately half of dogs with hypothyroidism will have antithyroglobulin antibodies. Anti-T3 and anti-T4 antibodies can also be detected but are less common. These tests can be added to the diagnostic workup of a dog with suspected hypothyroidism to increase confidence in the diagnosis if the combination of TT4 and/or fT4 and TSH levels is equivocal. It is important to note that the absence of these antibodies does not rule out hypothyroidism.

## Diagnostic approach: putting it all together

Because of the numerous factors that complicate thyroid diagnostics, a workup for hypothyroidism should always begin with reasonable clinical suspicion based on history, examination findings, and clinicopathologic parameters. It is important to carefully consider and, when possible, exclude nonthyroidal causes of a low T4 level prior to testing.

Definitive diagnosis of hypothyroidism requires multiple supportive thyroid hormone diagnostics, with the most specific combination of tests being TT4, fT4, and TSH. Because few nonthyroidal factors affect TSH levels, a low TT4 and/or fT4 result in combination with a high TSH level is highly consistent with true hypothyroidism.

Because as many as one-third of hypothyroid dogs will have a TSH level within the reference interval, a normal TSH result cannot be used to rule out hypothyroidism. In these cases, a clinical presentation suspicious for hypothyroidism, exclusion of nonthyroidal factors, a low TT4 and fT4 result, and a TSH level in the middle to upper end of the reference interval are sufficient to diagnose hypothyroidism. In cases with equivocal laboratory findings, finding antithyroglobulin, T3, and T4 antibodies may help increase the suspicion for true hypothyroidism. ■

*Laura R. Van Vertloo, DVM, MS, DACVIM, is an assistant professor of veterinary clinical sciences at Iowa State University, College of Veterinary Medicine in Ames, Iowa.*



# Managing head trauma in veterinary care

Patients presenting with head trauma can be intimidating but can improve immensely with intravenous fluid therapy, supplemental oxygen, and nursing care.

By Kate Boatright, VMD

Head trauma in veterinary patients is an emergency presentation that commonly occurs after a motor vehicle accident or other blunt or penetrating trauma. There are several unique considerations for patients that have sustained head trauma at presentation and during their hospital stay. During a session at the Fetch dvm360® Kansas City conference, Danielle Powers, DVM, DACVIM (Neurology), of the Animal Medical and Surgical Center in Scottsdale, Arizona, discussed management of head trauma for veterinary patients from initial presentation through recovery.

## TRIAGE AND HISTORY

Patients presenting with head trauma should be triaged like any emergency patient. Airway, breathing, and circulatory status should be stabilized while minimizing movement of the patient. Powers reminds clinicians that many of these patients present in shock, and their mentation may improve significantly with the treatment of shock alone.

Ideally the neurological evaluation should be performed prior to administration of medication. Clinicians should assess the pupillary light reflex (PLR), pupil symmetry, ambulatory status, and mentation status of the patient. Use of the Modified Glasgow Coma Score (MGCS) can provide a quantitative evaluation that allows for objective reassessment overtime.

In addition to asking about comorbidities and medications, history taking should include specific questions to assess when the trauma occurred and assess for any loss of consciousness, mentation, and seizure activity following the trauma.

## DIAGNOSTICS

It is essential when handling head trauma patients to minimize stress and prevent the patient from struggling; however, sedation and

general anesthesia are contraindicated in most head trauma cases. Administration of a pure mu opioid can help to address pain and facilitate handling when obtaining diagnostics.

A complete blood count (CBC), serum biochemical profile, and urinalysis should be assessed in these patients. Jugular venipuncture should be avoided when collecting samples as compression of this vein can increase intracranial pressure. Noninvasive blood pressure, preferably with a Doppler, blood gas analysis, and imaging needed to assess other wounds (such as chest radiographs and ultrasonography) should also be performed.

MRI is the imaging modality of choice for brain imaging, but unless the patient is declining, general anesthesia should be avoided. If imaging is deemed necessary, the patient should be cardiovascularly stabilized prior to anesthesia. CT scans are the preferred imaging modality for assessment of skull fractures as radiographs are difficult to interpret and may be inconclusive.

## TREATMENT

Treatment goals for patients with head trauma will vary by the patients' status at presentation and comorbidities. Basic stabilization measures, including placement of a large gauge IV catheter, delivery of intravenous fluids, and supplemental oxygen delivery can improve mentation status significantly in some patients. Pain control is also essential for head trauma patients and pure mu opioids are recommended as they can be easily reversed in the case of declining neurologic or cardiovascular status.

More specific treatment goals include seizure management, controlling increased intracranial pressure, maintaining carbon dioxide levels, and maintaining cerebral perfusion pressure. Powers reminds veterinarians that "by preventing

the hypovolemia and hypoxemia secondary to shock, often the brain function will improve without necessarily treating the brain trauma directly."

*Treatment goals for patients with head trauma will vary by the patients' status at presentation and comorbidities.*

—Danielle Powers, DVM, DACVIM (Neurology)

Administration of steroids is no longer recommended as a first-line therapy as there is limited clinical evidence in human medicine to support their use. Additional treatments including controlled hypothermia and administration of other medications have been discussed in the literature, but results are currently equivocal. Powers feels that "these may or may not be helpful and are clinician's preference when [used] as a treatment for head injury."

In most cases, giving time for the patient to recover is a core part of treatment. During recovery, nursing care is essential to prevent secondary problems such as pressure sores, aspiration pneumonia, urine retention, and corneal ulceration. Oral medications, food, and water should be withheld until the patient is able to swallow on their own.

## PROGNOSIS AND RECOVERY

The prognosis for head trauma patients is variable depending on the severity of the injury and comorbidities. Both primary and secondary brain injuries occur as

a result of head trauma, resulting in immediate and delayed effects. The MGCS can predict prognosis, with lower scores carrying a poorer prognosis. In human medicine, Powers shared that prognosis is "significantly correlated with the level of oxygenation and systolic blood pressure prior to and during medical intervention."

Powers notes that while recovery can be variable, for pets "the degree of recovery may be less important if they can perform tasks required as a companion animal, as opposed to a working animal or person." Quality of life, comfort, and ability to do basic tasks such as eating, drinking, and walking are the most important considerations for companion animals recovering from head trauma.

Owners of pets who have experienced head trauma should be advised that seizure activity can occur up to 4 years after the brain injury, but the longer a patient goes without seizures, the less likely they are to develop.

## TAKE-HOME POINTS

Head trauma is an emergency in veterinary patients. After rapid evaluation, pain medication, gentle handling, IV fluid support, and supplemental oxygen are the most critical things the veterinary team can provide to help facilitate recovery. More specific interventions are available and will vary depending on the degree of the injury. [dvm360®](#)

*Kate Boatright, VMD, a 2013 graduate of the University of Pennsylvania, is a practicing veterinarian and freelance speaker and author in western Pennsylvania. She is passionate about mentorship, education, and addressing common sources of stress for veterinary teams and recent graduates. Outside clinical practice, Boatright is actively involved in organized veterinary medicine at the local, state, and national levels.*



**Entyce**<sup>®</sup>  
(capromorelin oral solution)



# THIS IS MORE THAN A MEAL

Entyce supports dogs facing long-term health challenges by **addressing inappetence**, which is **essential** for improving nutrition.<sup>1</sup>

**Almost seven out of ten\*** owners reported their dog's appetite increased in just four days<sup>2</sup> and dogs can **safely take Entyce throughout their treatment journey.**



**Stamina starts with appetite**

**INDICATION:** For appetite stimulation in dogs.

**IMPORTANT SAFETY INFORMATION:** For use in dogs only. Do not use in dogs that have a hypersensitivity to capromorelin. Use with caution in dogs with hepatic dysfunction or renal insufficiency. The safe use of Entyce has not been evaluated in breeding, pregnant or lactating dogs. The most common adverse reactions included diarrhea, vomiting, elevated blood urea nitrogen, polydipsia, and hypersalivation. Please see accompanying brief summary for prescribing information.

The effectiveness of Entyce has not been evaluated beyond 4 days of treatment in the clinical field study.

\*Compared to 4.5/10 control dogs. Study enrolled client-owned dogs (N=244) with decreased appetite for at least 2 days, including dogs with a variety of comorbid conditions. The dogs were randomized 2:1 to receive Entyce 3 mg/kg (n=171) or vehicle control (n=73) for 4 days. 177 inappetent dogs were assessed for effectiveness. All dogs enrolled in the study were evaluated for adverse reactions throughout the study.<sup>2</sup>

**References:** 1. Zollers B *et al. BMC Vet Res* 2017; 13(10): 1–5. 2. Zollers B *et al. J Vet Intern Med* 2016; 30(6): 1851–1857.

©2021 Elanco or its affiliates. Entyce, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

PM-US-21-1049

**Elanco**



# Product comparison in an unregulated industry: Hemp

As new veterinary CBD products continue to flood the market, understanding what they contain vs what is on the label can be daunting. Fortunately, with a little online legwork, clinicians can arm themselves with objective product information.

By Stephen Cital, RVT, SRA, RLAT, CVPP, VTS-LAM (Res Anesthesia)

## Entyce™

(capromorelin oral solution)

30 mg/mL

For oral use in dogs only

**Appetite Stimulant**

**Caution:**

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Before using Entyce, please consult the product insert, a summary of which follows:

**Indication:**

ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs.

**Dosage and Administration:**

Administer ENTYCE orally at a dose of 3 mg/kg (1.4 mg/lb) body weight once daily.

To administer ENTYCE, gently shake the bottle, and then withdraw the appropriate amount of solution using the provided syringe.

Rinse syringe between treatment doses.

The effectiveness of ENTYCE has not been evaluated beyond 4 days of treatment in the clinical field study (See Effectiveness).

See product insert for complete dosing and administration information.

**Contraindications:**

ENTYCE should not be used in dogs that have a hypersensitivity to capromorelin.

**Warnings:**

Not for use in humans. Keep this and all medications out of reach of children and pets.

Consult a physician in case of accidental ingestion by humans. **For use in dogs only**

**Precautions:**

Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology).

Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology).

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

**Adverse Reactions:**

In a controlled field study, 244 dogs were evaluated for safety when administered either ENTYCE or a vehicle control (solution minus capromorelin) at a dose of 3 mg/kg once daily for 4 days. Enrolled dogs had a reduced or absent appetite for a minimum of 2 days prior to day 0 and had various medical conditions: arthritis (40); gastrointestinal disease (24); allergy (22); dental disease (22); cardiovascular disease (16); renal disease (13); and others. Some dogs may have experienced more than one of the adverse reactions during the study.

The following adverse reactions were observed:

**Table 1: Adverse Reactions reported in dogs administered ENTYCE oral solution compared to vehicle control**

Adverse Reactions	ENTYCE (n = 171) n (%)	Vehicle Control (n = 73) n (%)
<b>GASTROINTESTINAL</b>		
Diarrhea	12 (7.0 %)	5 (6.8 %)
Vomiting	11 (6.4 %)	4 (5.5 %)
Hypersalivation	4 (2.3 %)	0 (0.0 %)
Abdominal discomfort	2 (1.2 %)	0 (0.0 %)
Flatulence	2 (1.2 %)	0 (0.0 %)
Nausea	2 (1.2 %)	0 (0.0 %)
<b>CLINICAL PATHOLOGY</b>		
Elevated blood urea nitrogen	7 (4.1 %)	2 (2.7 %)
Elevated phosphorus	4 (2.3 %)	1 (1.4 %)
Elevated creatinine	1 (0.6 %)	1 (1.4 %)
<b>OTHER</b>		
Polydipsia	7 (4.1 %)	1 (1.4 %)
Lethargy/depression	2 (1.2 %)	0 (0.0 %)

The following adverse reactions were reported in < 1% of dogs administered ENTYCE: hyperactivity, increase fecal volume, increase gut sounds, and polyuria.

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US Inc. at 1-888-545-5973. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>.

**Effectiveness:**

**Laboratory Effectiveness Study:** Twenty four healthy Beagle dogs (6 dogs per sex in each group) with normal appetite were randomized into two groups and dosed daily with ENTYCE (capromorelin oral solution) at 3 mg/kg/day or vehicle control (solution minus capromorelin) to compare food intake over a 4-day period. The dogs were 13 months of age and weighed between 6.5 and 12.5 kg at the time of randomization. Six dogs administered ENTYCE repeatedly exhibited salivation post dosing and two dogs administered vehicle control exhibited salivation only one time on study day 0. Emesis was observed in one dog administered ENTYCE on study day 1. Dogs administered ENTYCE at a dose of 3 mg/kg/day for 4 consecutive days had statistically significantly increased food consumption compared to the vehicle control group ( $p < 0.001$ ).

**Clinical Field Study:** Effectiveness was evaluated in 177 dogs (121 dogs in the ENTYCE group and 56 dogs in the vehicle control group) in a double-masked, vehicle controlled field study. Dogs with a reduced appetite or no appetite, with various medical conditions, for a minimum of 2 days prior to day 0 were enrolled in the study. The dogs ranged in age from 4 months to 18 years. Dogs were randomized to treatment group and dosed once daily for 4 days with ENTYCE at 3 mg/kg or vehicle control. Dogs were assessed for appetite by owners on day 0 and day 3 ± 1 using an “increased”, “no change” or “decreased” scoring system. Dogs were classified as a treatment success if the owner scored their dog’s appetite as “increased” on day 3 ± 1. The success rates of the two groups were significantly different ( $p = 0.0078$ ); 68.6% (n = 83) of dogs administered ENTYCE were successes, compared to 44.6% (n = 25) of the dogs in the vehicle control group.

**Storage Conditions:**

Store at or below 86° F (30° C)

**How Supplied:**

30 mg/mL flavored solution in 10 mL, 15 mL and 30 mL bottles with measuring syringe

Approved by FDA under NADA # 141-457

Manufactured for:

Elanco US Inc.  
Greenfield, IN 46140, USA  
Revised: September 2020

ENTYCE, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.



As veterinary professionals, we have been using nutraceuticals and supplements forever. These products are intended to support (not treat) a function of the body or to promote healthy function of a particular physiologic system. There are many legal nuances that we must be aware of when using these products—so many that it is beyond the scope of this article to discuss them all.

Every year it seems we are introduced to another nutraceutical or supplement and are essentially left to fend for ourselves regarding the quality, efficacy, and proven dosing of these products. Unless you have been living under a rock, you likely have heard of or have had clients ask about a new “wonder” molecule known as cannabidiol (CBD). The fact is that CBD is only 1 of hundreds of molecules known as phytocannabinoids that are produced by both hemp and marijuana plants. However, it is important to understand the difference between hemp products and marijuana. Hemp products contain less than 0.3% Δ-9-tetrahydrocannabinol (THC; the main intoxicating compound in marijuana) and are widely available and legal in many states. Marijuana, on the other hand, is still illegal federally despite varying legal status’ at the state level. We also must be aware of another set of pharmacologically active molecules known as terpenes that can also be found in these products. Terpenes are aromatic molecules that deliver the classic aroma of hemp and marijuana and may also contribute to product efficacy.

Both hemp and marijuana are hot topics in the field of veterinary nutraceuticals/supplements, with many platforms offering continuing education on the topic. However,



many fall short in helping practitioners with choosing a safe, effective and an economical product. With so many choices available at legal recreational dispensaries for marijuana products, to gasoline stations, online vendors, and now sales representatives hitting our clinics, the decision-making can be mind-boggling!

The first step in educating ourselves and helping our patients is knowing what is in these products. This can be achieved by locating a certificate of analysis (COA) by a third-party ISO/IEC 17025 certified laboratory by either directly contacting the company or by perusing a manufacturer's website. Certification with the ISO (International Organization for Standardization) means the company has had its product analyzed to guarantee it contains what the company says it contains.

Myself and many colleagues familiar with cannabinoid containing products often say, "If the company is unwilling to give you a COA, walk away." I take this to heart because this is one of the only ways to arm ourselves against poor-quality products until the United States Food and Drug Administration releases guidelines regarding cannabinoid containing products development and use. There is much information that should be included in a COA, including the cannabinoid levels in mg/mL format to help dose and determine the cost per mg. It also should provide information about what terpenes are present in the product and their concentration and whether there are contaminants such as residual solvents, bacteria, or mycotoxins. Finally, the COA should contain an elemental analysis looking for things like heavy metals. To see what a COA should look like visit, [www.vetcannacademy.com](http://www.vetcannacademy.com).

Although a COA is not a silver bullet, it does raise the question, "Should we be asking for a COA for all of our supplement and nutraceutical products in house?" The answer is probably yes. Aside from a COA, it might also be best to consider using products, not just CBD, with clinical efficacy data, pharmacokinetics data, and safety studies. It is time that we, as the community of individuals selling these types of products, demand better science before carrying them in our practices.

Recently, I helped with a veterinary CBD product study<sup>1</sup> that illuminated the differences in product formulations and the ways in which some companies may deceive us. We found most products did not match what is on the label, with some having less CBD than what is claimed on the bottle and others containing more CBD than what was claimed. We also found heavy metal contaminants in some of the products, with one surpassing what is considered safe by the USP.

If you decide to carry hemp products in your practice, please consider some of the standards of how to assess these products. Your clients, patients, and licensure will thank you. [dvm360](#)

#### REFERENCE

Wakshlag JJ, Cital S, Eaton SJ, Prussin R, Hudalla C. Cannabinoid, terpene, and heavy metal analysis of 29 over-the-counter commercial veterinary hemp supplements. *Vet Med (Auckl)*. 2020;11:45-55. doi:10.2147/VMRR.S248712

# Pitfalls in canine socialization

## Don't let these challenges stand in the way of canine socialization goals.

By Amanda Carrozza

**T**he socialization of dogs is a hot topic in the veterinary industry, according to Christopher L. Pachel, DVM, DACVB, CABC. In a Fetch [dvm360](#) session, Pachel presented the idea that not all techniques are equal because not all canines are the same.

As the lead clinician and owner of Animal Behavior Clinic in Portland, Oregon, Pachel is well versed in providing clients with the best solutions for their pet's behavioral challenges.

"When questioned, many pet owners, trainers, and veterinary team members can list examples of what types of exposures should be included in a socialization program, such as dog-dog play, exposure to children, access to novel objects, and navigating various physical environments," he said.

These exposures may be adequate when viewing socialization through a general lens. However, expand that lens slightly wider and additional windows of opportunity for influencing this developmental stage can be seen. They include genetic influences, prenatal effects, impacts of exposure during the neonatal period, and the behavioral outcomes of ongoing learning.

"This broader lens highlights the aspects of neural and behavioral development that occur both before and after the primary socialization period that typically receives most of the attention within this conversation," Pachel said.

The primary socialization period, he continued, includes the development of motor coordination, seeking out nonmaternal interactions, and making primary associations with physical and social environments. When this process happens smoothly, a puppy is considered socialized.

Recognizing potential roadblocks and their biological or environmental causes can help clinicians tailor a behavioral plan for a patient's specific needs, Pachel said.

### Insufficient socialization

In children, the deprivation of sensory input during pivotal developmental stages can be correlated to disturbances in social and emotional functioning and limbic alterations. This deprivation also shows through patterns of social withdrawal, pathological shyness, explosive emotionality, and the inability to form typical attachments.

Pachel asked, "Could these same

outcomes occur for puppies who experience similar deprivation?"

According to foundational studies of canine behavior and socialization, deficits through the age of 14 weeks are likely to be associated with long-term changes in social behavior.

Those alterations can be specifically correlated with the area of social deprivation (intraspecific, interspecific, and environmental). Interestingly, he pointed out, more recent studies confirm that contact with specific groups of individuals, such as children, during the developmental period from 3 to 12 weeks can help protect against problematic behaviors such as canine aggression or problematic excitability.

To help guide this process for pet owners and animal caregivers, additional studies have quantified the amount of socialization at which these exposures influence long-term social outcomes.

### Trauma

"While there is much research yet to be done on the topic of experiential trauma for developing dogs and puppies, taking a closer look at parallel studies of human development highlights the impact of adverse childhood experiences (ACEs) and the behavior patterns that are more likely to occur in the humans who experienced them during key developmental windows," he said.

For humans, ACEs—such as emotional abuse, physical neglect, or exposure to household mental illness—can be associated with an increased vulnerability to stressors and the development of negative mental health. Those early exposures predict later susceptibility to impaired health and functioning through systems and pathways that also exist within canines and other domestic animals.

### Conditioned arousal

Learning can influence the development of canine behaviors associated with increased arousal. And that arousal can subsequently influence both behaviors and the processes of emotional regulation and learning.

"With repeated exposure to situations in which emotional tolerance is exceeded or the animal is reinforced for displaying behaviors associated with increased arousal, it is possible to influence the speed, intensity, duration, or latency to the recovery of so-called reactive behaviors," Pachel explained. [dvm360](#)



# Managing dermatological conditions with new treatment options

Recent advancements in medications provide antibiotic and antipruritic therapies for pyoderma, pruritus, and atopic dermatitis.

By Rebecca A. Packer, DVM, MS, DACVIM (Neurology/Neurosurgery)

Treatment options for veterinary dermatology patients have advanced significantly in the past several years. Board-certified by the American College of Veterinary Dermatology and the American Board of Veterinary Practitioners, Paul Bloom, DVM, DABVP, DACVD, summarized the latest treatments available for treating pyoderma, pruritus, and otitis, during the Atlantic Coast Veterinary Conference® in Atlantic City, New Jersey. These drugs could be important additions to your treatment arsenal.

In a prepared statement, Bloom separated these new medications into the broad categories of antibiotics and antipruritics. The mainstay of antibiotics for pyoderma has previously been cephalexin, a first-generation cephalosporin. Although this arguably remains the first-line treatment for bacterial folliculitis, the newer antibiotics used to treat pyoderma include the oral antibiotic cefpodoxime and the long-duration injectable antibiotic cefovecin (Convenia; Zoetis), which are both broad-spectrum third-generation cephalosporins. Bloom discussed the potential concerns with using third generation cephalosporins as a first-line treatment.

Cefpodoxime is advertised as a first-line antibiotic for pyoderma; however, the broad-spectrum nature does risk development of resistant bacteria. Whether targeted by the treatment or not, and whether pathogenic or not, resistant bacterial organisms can develop within the broad-spectrum and then, in turn, transfer their resistant genes to other organisms in the environment or other species. The advantage of administering cefpodoxime over cephalexin appears to be primarily logistical, as cefpodoxime is administered once daily, versus cephalexin, which is administered

twice daily. As such, Bloom stated, the risks to developing resistant organisms may not outweigh the logistical benefits, unless the patient already failed treatment with cephalexin.

Similar concerns exist for cefovecin. This parenteral antibiotic has been approved in other countries for treatment of numerous organisms including *Staphylococcus intermedius*, beta-hemolytic *streptococci*, *Escherichia coli*, *Pasteurella multocida*, *Proteus* spp, *Staphylococcus intermedius*, and *Streptococcus canis*. Because of similar risks of potentiating resistant bacteria, Bloom cautioned that cefovecin should be reserved for patients who cannot be medicated orally. Therapeutic concentrations are maintained for approximately 7 to 14 days post injection, with specific therapeutic timing dependent on the specific bacteria and MIC, he said. Although perhaps subtherapeutic, tissue levels persist for up to 65 days. There is question as to whether or not this persistent subtherapeutic tissue concentration will potentiate bacterial resistance even further. Specific concerns exist about potentiation of extended spectrum  $\beta$ -lactamases (Enterobacteriaceae such as *E coli* and *Klebsiella pneumoniae*) that are multidrug resistant. Bloom also reminded us that, with any new therapeutic, long-term adverse effects are not yet fully known.

Available antipruritic medications include oclacitinib (Apoquel; Zoetis), modified cyclosporine (Atopica; Elanco and Cyclavance; Virbac), and lokivetmab (Cytopoint; Zoetis). These 3 medications have different mechanisms of action.

Oclacitinib is a JAK1 pathway inhibitor. JAK1 is an intracellular pathway that is activated when cytokines bind to specific cell membrane receptors. Activation

results in production of various cytokines that trigger and perpetuate pruritus. Oclacitinib therefore inhibits activation of the JAK1 pathway, limiting the amount of proinflammatory and pruritic cytokines produced. It may also be helpful off label for other immune-mediated diseases, including vasculitis, ischemic dermatopathy, pemphigus foliaceus, and discoid lupus erythematosus. Adverse effects appear to be rare, but may include neutropenia or leukopenia, and may reduce seizure threshold.

Bloom reminded us of 1 important factor to be aware of when using oclacitinib; it will mask pruritus regardless of etiology. For example, a patient with sarcoptic mange, flea allergy dermatitis, or bacterial or yeast pyoderma, possibly masking the untreated underlying disease. For this reason, identifying the underlying cause of pruritus is an important component of diagnostic and treatment planning.

Although not new, modified cyclosporines remain highly utilized in dermatology. Bloom cautioned that it is essential to use the modified cyclosporines to achieve consistent absorption. Bloom also recommended using modified cyclosporine in uncomplicated atopic dermatitis, where oclacitinib and lokivetmab have failed. Full therapeutic effect is typically reached within 4 to 6 weeks of administration. Adverse effects appear to be minimal, and consist of gastrointestinal signs, cutaneous papillomatosis, and gingival hyperplasia. Maropitant or ondansetron may help offset vomiting.

Another new medication used in veterinary dermatology is lokivetmab (Cytopoint; Zoetis), a canine monoclonal antibody that binds to and neutralizes IL-31. Bloom noted that, although low amounts of IL-31

are beneficial, higher amounts are detrimental and contribute to the pathogenesis of atopic dermatitis. Lokivetmab is administered via subcutaneous injection, once every 30 to 60 days. As it is a specific canine monoclonal antibody, it can only be used in dogs. Bloom recommended using this drug in cases of pruritus from allergic skin disease, with or without concurrent *Demodex* or bacterial pyoderma or cystitis, or patients with a history of (or current) cancer. Bloom said that cases that failed to respond to either oclacitinib or lokivetmab may respond to the other treatment, due to the different mechanisms of action. As such, if a therapeutic trial with one of these medications is not effective, it is worth trying the other.

Bloom's final update in "new drugs in veterinary dermatology" relates to treatment of otitis. Administering topical ear medications can be tricky for owners, and often treatment is prescribed for 7 to 14 days. This new product contains hydrocortisone aceponate, miconazole, and gentamicin (Easotic; Virbac) and its delivery system is a pump bottle with a flexible tip that allows easy application of the medication deep (but safely) into the ear canal. The pump is metered to allow 1 cc dispensed with each pump, and treatment duration is only 5 days. Bloom's experience with this has been positive, due to both adherence and efficacy.

Dermatological conditions are one of the more common diagnoses requiring veterinary care, and several new treatments have become available over the past few years. Bloom's overview of novel treatments should help all practitioners better understand the options available to care for their patients. [dvm360®](#)

Rebecca A. Packer, DVM, MS, DACVIM (Neurology/Neurosurgery), is an associate veterinarian at BluePearl Specialty and Emergency Pet Hospital in Lafayette, Colorado. She is also the founder and owner of the Pre-Veterinary Mentoring Group, LLC, through which she provides mentorship for preveterinary students, and is the founder and owner of The Pocket Neurologist, LLC, a vet-to-vet teleconsulting service.



Mane-tain your best self!



# ESSENTIAL<sup>®</sup> RANGE

HELPS MANAGE KERATO-SEBORRHEIC DISORDERS  
AND SUPPORT THE BARRIER FUNCTION




INNOVATIONS  
SINCE 2003



EVIDENCE  
BASED  
EFFICACY



TRENDSETTING  
GALENIC  
FORMS



Made in France  
by LDCA



[www.dermoscent.com](http://www.dermoscent.com)

Distributed in the USA  
by Dermoscent Inc.  
[contactUS@dermoscent.com](mailto:contactUS@dermoscent.com)



# Managing feline stress-related conditions

A multipronged approach may be utilized, including ensuring basic needs are met, environmental enrichment, behavior modification, and the considered use of pharmaceuticals or supplements.

By Kate Boatright, VMD



Veterinarians are increasingly aware of the role that stress can play in medical and behavioral conditions in our feline patients. But recognizing signs of stress is only the first step in improving the quality of life for cats experiencing stressors that impact their daily lives. During a session at the Fetch dvm360® Kansas City conference, Christopher Pachel, DVM, DACVB, CABC of the Animal Behavior Clinic in Portland, Oregon discussed practical tips for managing these stress-associated conditions in cats.

## RECOGNIZING STRESS

Cats are notorious for hiding illness, and behavioral changes related to chronic stress may be subtle. At times, pet owners may present the cat to the veterinarian for changes in activity, appetite, or social interaction. In other cases, the cat may be presented for hair loss, inappropriate elimination, upper respiratory infections, or other physical illness. In these cases, it falls on the veterinary team to identify

the presence of stress-related behaviors and potential stressors through careful history taking and educating their clients on the role that stress plays in these medical presentations.

## PRINCIPLES OF BEHAVIORAL TREATMENT PLANS

Pachel encourages practitioners to consider a three-pronged approach to management of stress-associated conditions in cats, including “behavioral modification, environmental management, and ‘medication,’ which may include nutritional support, supplements, pheromones, and pharmaceuticals.” He notes that each patient will have a customized treatment plan and not every prong will be used in all cases.

The Hierarchy of Behavior Change-Procedures, available from the International Association of Animal Behavioral Consultants, discusses a least intrusive, minimally aversive (LIMA) approach to behavioral modification. Pachel reminds veterinarians that before any behavioral

modification is attempted, the pet’s health, nutrition, and environment should be evaluated. Only after disease and pain are addressed and basic physical needs are met can behavioral interventions be successful.

## ENVIRONMENTAL MANAGEMENT

Assessing the cat’s home environment is an important first step in management of environmental factors that may contribute to stress.

Pachel notes that for cats, it is not just about whether a resource (food, water, litter box, and safe hiding locations) is available, but also whether the cat perceives that it is available. He suggests an in-person walk-through or use of telemedicine platforms and owner-recorded video of the home as tools that can be used to assess the home environment. After the assessment, changes to the environment can be discussed that improve resource availability to reduce daily stress.

Addition of enrichment opportunities to a cat’s environment can help to reduce stress.



Vet Pro Infusion Pumps

IV PUMPS DESIGNED TO BE EXTREMELY SMALL BUT VERY EFFECTIVE FOR TODAY'S BUSY VETERINARY CLINIC. LIGHTWEIGHT AND PORTABLE!



4.41" Height  
3.5" Width  
1.57" Depth  
.....  
Only Weighs  
13.76 oz!

VIP 2000 Features

- ▶ High resolution color screen
- ▶ Longer battery life
- ▶ Money saving rechargeable battery
- ▶ Pre-detection of increase in downstream line pressure
- ▶ Post-occlusion bolus reduction system
- ▶ Cage and pole mounts

SKU Number | J1097 Series



SP 3000 Features

- ▶ Auto syringe detection
- ▶ Large LCD display
- ▶ Programmable flow rates and infusion time
- ▶ Operated by battery or AC power

SKU Number | J1096

JORGENSEN LABORATORIES, INC.

Loveland, CO 80538 | 800.525.5614  
www.JorVet.com | Info@JorVet.com

Pachel notes that it may take some trial and observation to find the right type of enrichment for each individual patient, but the results can be highly rewarding. Consider opportunities for the cat to expend energy, engage in species-typical behaviors such as climbing and hunting, and providing mental stimulation. Enrichment can be incorporated into feeding time (ie, use of a food puzzle), training, and more.

*Assessing the cat's home environment is an important first step in management of environmental factors that may contribute to stress.*

—Christopher Pachel, DVM, DACVB, CABC

BEHAVIOR MODIFICATION

While many believe that cats cannot be trained, Pachel states that “behavior modification strategies are absolutely available for cats,” and they “can have a dramatic impact on stress-associated conditions.” There are many specific skills that can be taught to cats using traditional learning techniques, such as habituation, classical conditioning and operant conditioning. Pachel notes that there are species-specific training considerations, including the amount and type of reward and feline body language indicating readiness to progress to more difficult training.

MEDICATION

“Medication” can be delivered to cats in many ways, and may include nutritional support, supplements, pheromones, and pharmacological interventions. For any of these medical interventions, a trial-and-observation approach is often needed. Pet owners should be made aware that the first product selected may not work, but that does not mean any future medications or supplements will be failures as well.

Nutritional support is found in the form of prescription diets with added ingredients to reduce stress levels while support the health of specific systems, including urinary and gastrointestinal. If these diets are found to be helpful, a large advantage over other medication options is the improved adherence seen with administering a diet compared to administration of a pill or supplement.

Supplements and pheromones are available in a wide variety of cat-specific products. Pachel encourages practitioners to get familiar with not only the individual products but their active ingredients, which may aid them in choosing the best product to try for a particular patient. Pheromone products mimic natural feline pheromones and are often delivered to the environment instead of the patient directly, which may make them easier to incorporate into an intervention strategy.

Pharmacological intervention is appropriate for some pets with stress-associated conditions that are motivated by fear, anxiety, stress, and arousal. Pachel states that for behaviors with other motivations, medication is unlikely to help and may, in fact, be contraindicated. If medical therapy is deemed appropriate, veterinarians must consider whether a situational or daily maintenance medication is indicated and the type of medication, including the target neurotransmitter and potential side effects, that will best address the patient's condition.

For any of the medication options, Pachel suggests careful assessment of owner compliance and ability to administer medication when selecting the best product(s) to try. If medication or supplement administration is stressful for pet and owner, long-term use is unlikely, and the added stress of medication administration may negatively affect the patient or harm the bond between pet and owner. Use of compounded medications, feline-friendly medication administration, and positive reinforcement with a high-value reward can all be discussed as options to reduce stress and improve compliance.

TAKE HOME POINTS

A partnership between pet owner and veterinary team is needed to maximize outcomes for stress-related behavioral and medical conditions in feline patients. Once stress-related conditions are recognized, intervention strategies should be designed that include environmental management, behavioral modification, and/or medication. Each cat will require an individualized treatment plan that addresses their specific needs and is feasible for the pet owner to implement. *dvm360*

*Kate Boatright, VMD, a 2013 graduate of the University of Pennsylvania, is a practicing veterinarian and freelance speaker and author in western Pennsylvania. She is passionate about mentorship, education, and addressing common sources of stress for veterinary teams and recent graduates. Outside clinical practice, Boatright is actively involved in organized veterinary medicine at the local, state, and national levels.*



# A breakthrough joint supplement for dogs and cats

*Flexadin Advanced from Vetoquinol is an oral supplement that helps prevent degenerative joint disease and is used as part of a multimodal therapy for managing the condition.*

*By Janice L Huntingford, DVM, DACVSMR, CVA, CVPP, CCRT, CAVCA*



**D**egenerative joint disease (DJD) is the most common orthopedic illness, affecting more than 20% of dogs and cats older than 1 year and more than 80% of those in the senior category. It is characterized by chronic joint pain and stiffness, immobility, and lameness. It decreases quality of life for affected pets.

Management of DJD is multimodal and involves control of clinical symptoms by reducing pain, protecting joints, and improving mobility. Multimodal therapy is achieved through weight loss, exercise, and physical rehabilitation, along with pharmaceuticals and supplements.

Flexadin Advanced from Vetoquinol is a joint supplement that contains a unique active ingredient: undenatured collagen type II (UC-II), which has a different mode of action than is traditionally found in other such products. UC-II forms the major structural component of the hyaline cartilage of articular surfaces and the nucleus pulposus of the intervertebral disc.

Healthy, undamaged cartilage is not seen as foreign by the immune system; however, when DJD occurs, the damaged collagen molecules are released into the synovial fluid. This

stimulates an autoimmune response against the type II collagen, further damaging the hyaline cartilage in the joint and starting a cycle of joint degradation, cartilage damage, and pain. UC-II is believed to affect the gut immune system, inducing oral tolerance to turn off the immune response that targets type II collagen in joint cartilage.

When taken as an oral supplement, small amounts of UC-II are transported across the gut epithelial cells to immune cells in the Peyer patches of the gut-associated lymphoid tissue. Once there, the UC-II activates the T cells to become T regulatory cells. When these T cells encounter natural type II collagen from joints, they secrete anti-inflammatory cytokines that suppress the action of cells that normally would break down type II collagen.<sup>1,2</sup> By inducing oral tolerance, UC-II supplementation initiates anti-inflammatory and cartilage protective pathways that prevent the immune system from further damaging the joint.

In supplement form, UC-II is derived from chicken sternum cartilage and has been shown to be more effective in reducing pain and lameness than glucosamine and chondroitin.<sup>1</sup> UC-II has also been shown to prevent inflammation and cartilage degeneration in supplemented healthy dogs that were strenuously exercised compared with dogs that were not supplemented.<sup>3</sup>

Flexadin Advanced contains 40 mg of UC-II and is easily administered as a single chew to dogs and cats. It is highly palatable and no loading dose is required. Most clients will see some response within 2 to 3 weeks; in some cases it is sooner. Veterinarians should use Flexadin Advanced in their patients with DJD as part of multimodal therapy or to help prevent DJD in very active patients. It is backed by research and is cost-effective, safe, and highly efficacious.



### Case study

Joe, an 11-year-old Labrador retriever mix, was presented for a pain evaluation. Joe was stiff on rising, frequently lying down and panting, and reluctant to play fetch.

Joe was diagnosed with DJD of the hips and lower back. He was started on a nonsteroidal anti-inflammatory drug (NSAID) and pentosan polysulfate sodium (Cartrophen Vet; Biopharm Australia) injections. After 2 weeks, Joe's owner had noticed an improvement. The NSAID was discontinued as Joe had some liver enzyme elevations, and Flexadin Advanced was started. After 4 weeks Joe was back to "acting like a puppy again" and his owners were very pleased. They credited his biggest improvement to the Flexadin Advanced. [dvm360®](#)

### REFERENCES

1. Gupta RC, Canerdy TD, Lindley J, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. *J Anim Physiol Anim Nutr (Berl)*. 2012;96(5):770-777. doi:10.1111/j.1439-0396.2011.01166.x
2. Gencoglu H, Orhan C, Sahin E, Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. *Animals (Basel)*. 2020;10(4):697. doi:10.3390/ani10040697
3. Varney JL, Fowler JW, Coon CN. Undenatured type II collagen mitigates inflammation and cartilage degeneration in healthy Labrador retrievers during an exercise regimen. *Transl Anim Sci*. 2021;5(2):txab084. doi:10.1093/tas/txab084



# THE JOINT SUPPLEMENT YOU CAN RELY ON TO WORK!

A pet's own immune system can aggravate normal joint function. Help your clients maintain healthy cartilage with Flexadin® Advanced with UC-II®.

- ▶ Unique and proprietary form of undenatured type-II collagen, which works differently than traditional supplements
- ▶ Proven in clinical studies
- ▶ Just one chew, once a day
- ▶ Easily accepted by 73% of cats and 94% of dogs
- ▶ No powders or weight-based administration



Get our **FREE** mobility toolkit to share social media posts, articles, and videos with your clients. Visit [vetoquinolusa.com/flexadin](https://vetoquinolusa.com/flexadin) to learn more!



VETTED™ | Practice management

# 7 strategies to support work-life balance for your veterinary team

Top-down actions can provide a tailored work environment, improve employee retention, and strengthen morale and the bottom line.

By Ivan Zakharenkov, DVM, MBA

**W**ork-life balance may seem elusive—always 1 choice or change away from attainment. In fact, it is the result of many mindful decisions to align 3 key priorities: work, self, and others. Achieving that balance leads to a satisfied, meaningful life that fulfills professional and personal goals.

Veterinary medicine often lacks balance. These professionals are selfless individuals committed to caring and advocating for animals, often at the expense of their own health, well-being, and personal time. Veterinarians' exceptional devotion and emotional investment frequently lead to burnout and imbalance, sometimes driving them from the profession. According to the American Veterinary Medical Association's (AVMA) 2020 Census of Veterinarians report, poor work-life balance is the main problem<sup>1</sup> for veterinarians, with 75% naming it the top reason for wanting to leave the profession.

Although self-help resources are available, they are often ineffective in the veterinary work environment. Therefore, practice leaders must prioritize work-life balance. Top-down actions, such as the following 7 strategies, can provide a tailored work environment, improve employee retention, and increase morale, well-being, and the bottom line.

## #1 Do not use a compensation model that incentivizes long hours

For too long, veterinarians have maintained long hours, extra shifts, and high case volume. Many production-based compensation models<sup>2</sup> demand

constant pursuit of targeted goals to meet basic cost-of-living needs and pay off mountainous student debt, to say nothing of achieving financial stability. Veterinarians may forego taking much-needed time off for fear of missing production-based pay targets. New veterinarians are more likely to experience emotional fatigue from a simple salary model that undervalues their workload. They may find themselves overwhelmed and defeated by a strictly commission-based pay scale.

Production-based compensation models that reward effort through commission and bonuses motivate workers but may also trigger unhealthy or unethical competition between veterinarians, leading to increased workplace tension. Monitor staff well-being frequently to ensure employees are not sacrificing their health or that of their patients to sustain an appropriate income.

## #2 Offer flexible scheduling and part-time employment

The AVMA 2020 Economic State of the Veterinary Profession report<sup>3</sup> proves that veterinarians want more life with their practice, but not necessarily a practice life. More veterinarians prefer working fewer hours for less compensation rather than more hours for increased income, according to the report. This preference is not limited to 1 gender—for the fourth year in a row, men and women were more likely to want fewer hours, with women only slightly ahead of men in this wish.

Part-time employees can give a practice much-needed scheduling flexibility by enabling additional appointment slots or expanded hours,

such as late nights or early mornings, without forcing full-time associates into unwanted overtime. The benefits of part-time employees are reflected in the bottom line. Research<sup>4</sup> shows that owners and associates working less than 2000 hours per year—about 40 hours per week—averaged more transactions and better gross revenue per hour than those who work more than 2000 hours per year. The data reinforce the idea that work-life balance is necessary for a sustainable, profitable practice.

## #3 Increase support for parents

For veterinarians with children, work-life balance is a perpetual tug-of-war. Guilt about absence from an area of life can weigh heavily, and the impact of overlap is significant. According to research<sup>5</sup> by *dvm360*<sup>®</sup>, 75% of veterinarians indicated their responsibilities as parents had interfered with their work; 87% stated their work had interfered with their duties as parents.

Parental leave and childcare expenses pose additional economic hurdles for many families on top of veterinary student debt. Practices can showcase their dedication to work-life balance by providing options like the following:

- **Paid parental leave**—Do not make parents choose between their work and their children. With a financial safety net in place, clinicians can step away for planned or emergency family time without guilt and return satisfied and focused.
- **Financial childcare support**—If each paycheck mostly covers day care costs, veterinarians may elect to leave the workforce until their children are of school age.

- **In-hospital day care**—Eliminate staff worries about drop-off, pickup, and coordinating schedules for their children.

## #4 Hire relief vets to balance the workload

The greatest asset of any practice is its workforce; recruiting relief veterinarians can be invaluable in preventing burnout and exhaustion. Relief veterinarians can help most during practice promotions, growth periods with excessive demand, staff shortages, seasonal business, or emergencies. They can provide staff with peace of mind from knowing that someone can share the load, that taking time off will not mean compromising patients or owners, and that veterinarians can temporarily step away to head off burnout.

## #5 Do not promote heroism

Veterinarians often choose their profession because of their compassion, so they cannot resist a call for help or an animal in need—whether that need is urgent or could wait until tomorrow. When you love what you do, there is always a phone call to make, a topic to study, or a patient to see; however, this often comes at the expense of personal responsibilities, interests, time with family, and attention to mental health. An option we are exploring at Galaxy Vets is getting permission from veterinary teams to monitor the number of hours they spend at work through an app on their personal device to ensure they do not overwork.

Celebrating a job well done or an exceptional deed can be motivating, but praiseworthy actions can endorse self-sacrifice. Instead, consider the following strategies:

- Encourage regular breaks and protect that time.
- Ensure staff take a full lunch break.
- Provide employees with a dedicated break area or lounge to escape the clinic's chaos.
- Block off periods on each veterinarian's daily schedule that they can use as they choose.
- Limit the number of consecutive





working hours, just as pilots or truck drivers are obligated to take breaks after a certain number of hours on duty.

Keep tabs on staff members who push through lunches or compromise their break time with interruptions and phone calls; they may need additional encouragement to turn off their “hero mode.”

## #6 Talk—and listen—to your team

Knowing a team’s needs is impossible without listening. Develop a deeper understanding of your team members by learning about their lives outside the hospital. An employee’s personal interests and hobbies may reveal a compromised work-life balance. For example, a colleague who recently mentioned joining a gym but admitted missing the last few sessions may be experiencing workload-related fatigue. A few minor adjustments to hospital routine can create a supportive dialogue. Consider the following strategies:

- **Set boundaries and protect personal time:** Encourage employees to keep personal calendars they can check when asked to take on an extra shift, to ensure they are not sacrificing a personal event for work.
- **Create a hospital vacation calendar:** View vacation as a practice benefit, not a loss; rested employees have improved job satisfaction and performance. Keep track of vacation days with a dedicated calendar to ensure staff are taking enough time off.
  - » **Hold meetings that focus on relationships, not performance:** Conduct regular 1-on-1 check-ins with employees and ask for their honest answers to questions such as:
    - Are you happy?
    - Do you have everything you need?
    - Is there anything I can help you with right now?

Consistent meetings that emphasize employee well-being set the

groundwork for a trusting, productive work relationship.

## #7 Sponsor healthy offsite activities

Demonstrate practice priorities by providing staff with benefits such as gym memberships, yoga classes, or massages. An Apple Watch or fitness tracker can help track sleep, exercise, and water consumption or improve eating habits. When employees see an emphasis on their mental and physical well-being, they not only reap the gift’s benefits but also feel that the practice cares about them.

What gets measured gets improved, so consider employee well-being a vital parameter of your practice and track the data with the same attention level you would give financial reports. Work-life balance metrics should be a big part of overall practice performance evaluation. Employees getting the support they need in this highly demanding profession are more resilient against stressors and more content to stay in your practice.

Although a profound professional commitment is a great asset, sacrificing personal well-being is not healthy. Veterinary professionals should avoid institutions that do not prioritize work-life balance. [dvm360.com](http://dvm360.com)

*Ivan “Zak” Zakharenkov, DVM, MBA, CEO of Galaxy Vets, is a veterinarian, entrepreneur, and passionate advocate for the well-being of veterinary professionals. Twelve years as an emergency department veterinarian inspired him to create Smart Flow, a first-in-the-industry workflow optimization system later acquired by IDEXX. He subsequently founded Veterinary Integration Solutions, an executive consulting firm where he helped veterinary groups systematize acquisition, integration, and improvement of practices with special attention to burnout prevention. Pursuing his goal to make a sizable impact on the veterinary profession, he took the lead in Galaxy Vets, a new veterinary health care system co-owned by its employees with burnout prevention as a strategic priority.*

References available online at [dvm360.com](http://dvm360.com)



# FROM SURVIVING TO THRIVING: The 4 P's of positive leadership

A positive psychology expert shares his framework for leading flourishing veterinary teams.

By Erica Tricarico



In veterinary medicine, professionals often are depleted more than they are fulfilled, according to Josh Vaisman, CCFP, MAPPCCP, cofounder and lead consultant of Flourish Veterinary Consulting. In his lecture at the Fetch dvm360® virtual conference, Vaisman said that everyone in the veterinary profession deserves sustained fulfillment. Positive leadership, he added, is the key to unleashing meaningfulness and bringing out the best in individuals, teams, and organizations.

“I’m on a mission to empower veterinary leaders with evidence-based skills for positive leadership so they can enable positive cultures in their practices and bring out the best in themselves and those they lead,” he said. Here are Vaisman’s 4 P’s of positive veterinary leadership that you can implement at your clinic to cultivate a nurturing environment in which employees feel valued, motivated, and have a “want to” attitude.

## 1 Psychological safety

Psychological safety means creating a practice culture that views mistakes as learning opportunities. Results from a study<sup>1</sup> examining psychological safety in the workplace revealed that it is absent in many workplaces. In the study, higher-performing teams with the best patient outcomes reported more medical errors than the teams with the worst patient outcomes. How can this be? The high-performing teams were not making more mistakes—they were simply more likely to admit making them.

The bottom line? “If the environment makes it unsafe or dangerous to take intrapersonal risks, we will withhold those things. And when we withhold we are not learning, we are not growing, we are not improving—as an individual, as a team, or an organization,” said Vaisman. “We have to have psychological safety in our teams to achieve the level of candor necessary for success and growth.”

According to Vaisman, psychologically safe teams believe the following:

- If I make a mistake, it is not going to be held against me.
- I can discuss difficult topics with my team.
- On my team, everyone’s opinion matters.
- It is safe to ask for help and admit a lack of ability.
- New ideas are welcome.

## 2 Purpose

Purpose is the reason something is done or created. Purpose is also a powerful tool that leaders can use to unlock meaningfulness, said Vaisman.

When an environment generates meaningfulness, employees are much more positively engaged in their work. Having a high level of purpose and meaningfulness is also the No. 1 way to prevent burnout, noted Vaisman. He suggested 2 ways to enable a sense of purpose and meaningfulness at your veterinary practice:

- **Routinely show that all work matters.** We are often good at pointing out the big things like saving a patient’s life, but

the small moments, such as cleaning the examination room between patients, matter too, said Vaisman. Positive leaders help people believe that.

- **Connect all work to a higher purpose.** When purpose is vivid, team members feel that their work matters, they matter, their work is meaningful, and they get to do meaningful things every day, he said.

## 3 Path

Path is about clarifying to empower, said Vaisman.

“From a leadership perspective, clear expectations are very much about putting a pin on the map. Positive leaders enable clear expectations and help teams develop clear expectations internally,” said Vaisman.

When the path is clear, team members agree with statements like the following:

- “I know what is expected of me.”
- “I have meaningful control over my day-to-day work.”
- “I am consistently able to contribute to achieving our goals.”
- “I have the resources I need to succeed.”

## 4 Progress

Progress is about enabling people to experience meaningful growth, contribution, and a sense of value and work, said Vaisman. He suggests 2 ways to bring progress to life:

- **Show appreciation:** Celebrate all things big and small, and reward positive behavior and not just positive results. Express

### Clarifying roles and responsibilities

Vaisman suggests all veterinary professionals want to succeed in their work. To do so effectively, they need to clearly understand what is expected of them, feel a meaningful sense of control over how they achieve those expectations, and be supported by the resources they need to succeed.

To support this, Vaisman discussed RACI, a tool that can help clarify roles, responsibilities, and decision-making authority at your clinic. For each task or project that you are trying to accomplish, answer the following 4 questions:

**R—Who is responsible?** This is the team member (the “doer”) who does the work to complete a task. A task may have more than 1 responsible party.

**A—Who is accountable?** This is the person who owns the final decision on whether a task is completed successfully. “The buck stops here.”

**C—Who is consulted?** These are the people (“in the loop”) to whom questions and concerns about the task should be directed.

**I—Who needs to be informed** throughout the process? These are the team members who need to be kept abreast of task progress and completion (“keep in the picture”).

gratitude, especially during challenging times.

- **Provide support:** Build relationships and connect with your team in meaningful ways, giving them a sense of belonging. Use growth-minded language and productively address shortfalls. When people are appreciated (feel valued) and supported (they feel like they matter), “We are telling them, ‘You are capable. I believe in you,’” said Vaisman. [dvm360®](#)

#### REFERENCE

Edmondson A. Psychological safety and learning behavior in work teams. *Adm Sci Q.* 1999;44(2):350-383. doi:10.2307/2666999.



# Smile!

## Assisi DentaLoop™ Is Here.



# ASSISI DentaLOOP™



### **A Drug-Free Solution Specially Designed for Use on Dental and Oral Surgery Patients.**

Delivering the same proven effective, FDA-cleared tPEMF™ signal as the Assisi LOOP®, the new Assisi DentaLOOP™ device helps reduce pain and inflammation, improve affected tissues, and speed recovery time. In addition, it supports the reduction of opioid use and other pain medications.

**Reduce Pain and Speed Recovery Time in Your Dental Patients with Assisi DentaLOOP.**



Check out the full line of Assisi products at  
[assisianimalhealth.com](http://assisianimalhealth.com) • [calmerk9.com](http://calmerk9.com) • 866-830-7342



# Dental Pain and Inflammation— Acute and Chronic

By Heidi Lobprise, DVM, DAVDC

**T**he role of pain and inflammation in oral and dental disease can be present in many forms, all of which should be addressed. In discussing dental and oral issues and care with pet owners, mentioning pain and infection often elicits empathy and can help them decide to follow your recommendations for optimal care. A pet with a painful mouth may still be eating, but not as well as it could be, and an unkempt cat may be a sign that the mouth is too painful for grooming. Providing the best care that we can is important for our patients, starting with recognizing discomfort.

## Acute Oral and Dental Pain

A patient can have acute pain issues due to tooth trauma, especially if the pulp/nerve complex is open and exposed. Although this can cause significant discomfort initially, once the neurovascular bundle dies and becomes necrotic, the acute pain typically decreases and any underlying chronic infection or inflammation may not seem to cause significant pain, unless an abscess occurs. The owner may not realize there is an issue, but any compromised tooth—open canal or discoloration indicating pulpal death—should be extracted or managed via a root canal procedure (endodontic therapy). Osseous fractures from more severe trauma can cause significant pain until the damage is repaired and healed. Some of the most common causes of acute pain in the oral cavity are surgical extractions and repairs, and even periodontal therapy. A multimodal pain management protocol is optimal to minimize any discomfort for our patients.

A complete perioperative analgesic protocol is critical for every dental surgery patient, no matter how extensive the procedure may be. In fact, even if “just a dental” is anticipated, many surprises often arise once radiographs are taken, so start with preoperative analgesics in every patient. In the presence of significant infection and inflammation or pain, administering oral medications for a few days prior to the

procedure may help decrease the extent of the disease, make the patient more comfortable, and give you healthier tissues to work with. Antibiotics should only be used in the presence of distinct infection and will not be needed in many cases, based on individual situations. Nonsteroidal anti-inflammatory drugs (NSAIDs) can be dispensed for patients with good renal health preoperatively, and in most patients postoperatively. A preanesthetic regimen may consist of a low dose of an opioid for pain, a mild sedative, and even an  $\alpha 2$  antagonist in select patients.

Once the patient is under general anesthesia with appropriate monitoring and support, local or regional blocks should be placed to provide analgesia that will extend into the postoperative period. These will also allow the levels of inhalant anesthesia to be kept to a minimum.

Various techniques exist for regional blocks for regions that include the maxilla (infraorbital or caudal maxillary blocks) and mandible (inferior alveolar or caudal mandibular, and mental blocks). Providing some of these blocks can be technique sensitive, so good training for your veterinary team is suggested. Many local anesthetic drugs are available, and individual preference may be based on their clinical time to onset and duration of action. Lidocaine hydrochloride and bupivacaine hydrochloride are commonly used; however, the longer duration of bupivacaine is an important benefit, especially when the drug is used in conjunction with buprenorphine to potentiate the duration (a 9:1 ratio, bupivacaine:buprenorphine) or in its liposomal-encapsulated form (Nocita; Elanco). Postoperative instructions for patients may include starting or continuing the NSAID, using cool compresses, and avoiding hard diets and chews until healed.

## Chronic Oral and Dental Pain

Dogs and cats can experience chronic pain due to a number of issues, from

untreated periodontal and periapical infections and temporomandibular joint dysfunction (osteoarthritis [OA], ankylosis) to neuropathic pain conditions; they can also have pain after surgical procedures. Ulcerative diseases such as feline stomatitis (or feline chronic gingivostomatitis) and canine chronic ulcerative stomatitis can have varying levels of pain associated with the inflammation and ulceration that is typically due to an overactive host response. Extractions often help these patients extensively, but at times patients can have refractory inflammation and discomfort. Feline oral pain syndrome (FOPS), which is most prevalent in Burmese cats, seems to flare in response to stress and stimuli ranging from erupting permanent teeth to periodontal disease. Traditional medications such as corticosteroids and NSAIDs generally don't help much with FOPS, whereas many patients will respond to phenobarbital, diazepam, or gabapentin.

## Acute and Chronic Oral and Dental Inflammation

By definition, acute inflammation is the local immune response to cellular injury, serving as a mechanism to initiate the elimination of noxious agents and damaged tissue. It can be a complex response, with various cell types and multiple inflammatory mediators involved. As the body's normal response to damaged tissue or the presence of harmful organisms, inflammation typically has a beneficial goal of helping tissues heal, including in the postoperative period. Management of acute inflammation may include the use of corticosteroids or NSAIDs and treating the underlying disease or trauma that was the inciting cause. Short-term use of these pharmaceuticals can be very effective, but there can be adverse effects. When short-term inflammation or pain is not adequately controlled, symptoms and concerns can ramp up.





Chronic pain or inflammation often requires additional levels of a multimodal approach, starting with the appropriate use of medications if the condition is severe, such as in chronic oral pain or OA. Additional therapies may include nutritional intervention, supplements, and antioxidants; applying esterified fatty acids to the gingival tissue for oral issues; and providing specifically targeted nutraceuticals such as glucosamine/chondroitin sulfate for cartilage and connective tissue management for comorbidities. Beyond the oral cavity, excessive adipose tissue affects mobility and places stress on patients with OA; additionally, the impact of excess nutrients and diminished energy expenditure leads to the metabolic issues that form the basis of meta-inflammation, a low-level, chronic inflammation. Untreated oral and dental disease, especially periodontal disease, can also contribute to these levels of chronic inflammation that can have a systemic impact.

### Chronic Inflammation and Aging

Inflammation from chronic oral or dental disease (as well as other causes) can also be a critical influence in the aging process, as has been shown in both humans and dogs. The inflammatory process results in an increase in inflammatory markers, immunosenescence, and oxidative damage, and this can result in pathologic changes linked to the chronic inflammation. With aging, chronic inflammation and cytokine production can result in a slower resolution of inflammation after infection or tissue insult. Although an owner may be concerned about an anesthetic dental procedure in older pets, we can minimize those risk factors with preoperative diagnostics, intervention, and optimal patient support during the procedure. The benefits frequently outweigh those risks, and we often see older patients with an improved quality of life once their dental disease has been controlled.

### Assisting with Acute Pain and Inflammation

In addition to treatment and medications, we can provide adjunctive recommendations such as home dental care and appropriate diet and supplements to address pain and

inflammation. Additionally, removing any environmental stresses can help improve oral discomfort in patients.

In the pre- and postoperative period, and for those patients with chronic inflammation and pain, a therapeutic targeted pulsed electromagnetic field (tPEMF) system, Calmer Canine, can be provided with the Loop for dental care by Assisi Animal Health. A modification of the classic Assisi Loop systems, and delivering the same FDA-cleared tPEMF signal, Calmer Canine is designed to help deliver the EMF to the area of the oral cavity. This technology has been proved to help reduce pain and swelling by increasing endogenous production of eNO (endothelial nitric oxide), a cell signaling molecule that increases production of anti-inflammatory cell mediators and stimulates production of endogenous endorphins and opioids in damaged oral tissue.

This device can be used to help reduce preoperative pain, erythema, and edema in oral inflammatory conditions. Postoperatively, it has been shown to help speed recovery and reduce swelling, pain, and healing time after dental extractions. It also helps reduce the need for opioids and other pain medications.

### Presurgery Protocol

- a. Calmer Canine is activated and applied around the patient's muzzle or held adjacent to the injured, inflamed, or painful area of the mouth twice a day for 15 minutes. It reduces pain and inflammation and improves the condition of the tissues in preparation for a planned dental or orofacial procedure.
- b. *Postsurgery or Post-trauma Protocol*
- c. Apply the device around the patient's muzzle or adjacent to the injured or affected area 2 to 4 times a day for 15 minutes, to reduce edema and pain and hasten healing.

### Assisting with Chronic Pain and Inflammation

Due to the impact that chronic pain and inflammation can have on our patients, who are often suffering in silence, a multimodal approach, again, should be used to help maintain a good quality of life. Many studies and recommendations may start with a basis of providing some relief from chronic maladaptive pain with the use of medications such as gabapentin, amantadine, and even some ketamine protocols. In these patients, the tPEMF therapy of the Assisi Loop for dental care may also provide a benefit. Anecdotal information from dental specialists reports a decrease in inflammation when the Loop is used for patients with feline stomatitis and some refractory inflammation after full mouth extractions. This would not be considered as a monotherapy but used in conjunction with esterified fatty acid application, low dose doxycycline, cyclosporine, and a myriad of other stomatitis protocols. In some cats, increasing the time in between corticosteroid doses may provide a benefit. In fact, many oral medications can be very challenging to administer to a cat with a painful mouth, so the Loop can provide a noninvasive way to help.

### Conclusion

As veterinary professionals, a key part of our patient focus is providing patients with a comfortable quality of life. Oral and dental issues can greatly affect the overall well-being of these patients, and we should work with pet owners to remove or manage any disease we can while continuing to provide options for complete pain management. ■





# Improving your "human skills" with communication

Communication among members of the veterinary team or between the veterinary team and clients can sometimes become tense, but practices can improve the outcomes by understanding key principles of communication and learning to de-escalate a situation.

By Kate Boatright, VMD

**A**lyssa Mages, BS, CVT, and Caitlin Keat, MSM, of Empowering Veterinary Teams, are reframing the conversation around communication, starting with reclassifying it as a "human skill," instead of the more commonly used "soft skill."

During the session they presented at the Fetch *dvm360*® Kansas City conference, they discussed how to improve these essential human skills through key communication.

According to Mages and Keat, to have effective communication, we must first understand the goals of the conversations we are having, whether with clients, team members or others in our lives. Goals of successful conversation can include conveying an understandable and factual message, maintaining a friendly, open, and honest conversation style, and being memorable to create a lasting impression.

Mages and Keat presented 4 types of communication: controlling, promoting, analyzing, and supporting. Understanding and identifying these styles of communication can help you to best engage with those you are talking to:

- Controlling is typically straight to the point and assertive. This type of communication may come across as aggressive, but it is not intended that way in most situations. To best communicate with these individuals, know your facts and stick to the topic at hand.
- Promoting is enthusiastic and engaged and centers on people and experiences. Connecting with this type of communicator can be done through asking and

answering personal questions, but you will probably need to be the one to keep the conversation on track.

- Analyzing involves in-depth conversations and tends to be fact-based and inquisitive. Be ready to answer questions and stay patient while the other person processes the answers and facts.
- Supporting tends to focus on problem solving and connection. This style of communicator tends to be more laid back, excels at conflict resolution, and relies on establishing trust.

It is important to note that in many conversations, multiple styles will be used by both parties. To be good communicators and effectively engage with our audience, we must learn to adapt and use different styles depending on the situation.

## Phone communication

Many interactions in the veterinary hospital start before the client even reaches the doors of our clinic. Our client service representatives (CSRs) and veterinary team members are often communicating with the clients over the phone prior to or after their appointment and can set the tone for the visit.

Having a script to follow can help to guide these conversations, as well as in-person conversations. Scripting does not mean that the same words are used every time in every situation, but it provides a baseline for where to begin.

Mages and Keat want veterinary teams to know that it is important to maintain phone etiquette by

confirming who you are talking to and attempt to make a personal connection. They also recommend the phrase "I'll be right with you," instead of "Would you mind holding?" or "Please hold" as a gentler way to place a person on hold.

When speaking to a client on the phone, and especially when performing teletriage, Mages and Keat suggest remembering the 3 R's: receive, record, and relay. This ensures that no information is missed or lost as it is passed from one member of the veterinary team to another.

## De-escalation

Mages and Keat note that in the current environment, every member of the veterinary team and their clients are under large amounts of stress. When stress levels run high, conversations can go in the wrong direction quickly and anger can ensue. In these situations, it is important that we de-escalate the situation, which requires what Mages and Keat refer to as a "reduction of the intensity of a conflict of a potentially violent situation."

The first step in de-escalating a situation where tempers are flaring, whether it be between client and staff or between staff members, is to recognize that it is happening. Body language and other nonverbal communication can be helpful to notice as they can be early indicators that we are not connecting with the person we are conversing with.

Once we have recognized that a conversation is heading into a heated place, we must pay attention to our own emotions and keep

them in check. Being able to do this is part of emotional intelligence. By understanding and controlling our own emotions, we can alter our communication style, tone, and body language to respond to the situation. Mages and Keat believe that communication is a two-way street and if you can manage your reaction it will help to de-escalate the interaction.

De-escalation can be done in 3 ways, say Mages and Keat: direct, delegate, or defer. Directing a situation involves taking control and telling the other person what the next steps are. Delegating means stepping away and sending someone else into the conversation. Deferring means asking to postpone the conversation (as long as it is a non—life-threatening situation) until a later time when emotions have calmed. Each of these techniques have their place and which option is chosen will depend on the situation and the personalities involved.

## Take-home points

Successful communication requires us to use many different styles of communication depending on whom we are engaging with and the situation we are in. Learning to recognize communication styles, when we are connecting with someone, and when we aren't, will help all members of the veterinary team to better communicate with one another and with their clients. *dvm360*®

*Kate Boatright, VMD, is a 2013 graduate of the University of Pennsylvania, is a practicing veterinarian and freelance speaker and author in western Pennsylvania. She is passionate about mentorship, education, and addressing common sources of stress for veterinary teams and recent graduates. Outside clinical practice, Boatright is active in organized veterinary medicine at the local, state, and national levels.*

## REFERENCE

Udice K. "4 Communication Styles and How They Play out in the Workplace." *Jobs, Company Reviews, Career Advice and Community*. Fairygodboss. April 2, 2019. Accessed October 20, 2021. [fairygodboss.com/career-topics/communication-styles#](https://www.fairygodboss.com/career-topics/communication-styles#).





# Veterinary technicians embrace their roles

National Veterinary Technician Week focused on the professionals who play a vital role in caring for animals in a veterinary practice.

By *dvm360® staff*

**N**ational Veterinary Technician Week in October recognized these professionals' contributions to veterinary medicine. According to the American Veterinary Medical Association (AVMA), they are critical to the function of veterinary practices and play an important role in the welfare and health of animals in their care.<sup>1</sup> Additionally, AVMA says, veterinary technicians drive practice efficiency and well-being, allowing veterinarians to focus on work requiring a more advanced veterinary education.<sup>1</sup>

First observed in 1993, National Veterinary Technician Week is held annually during the third week in October, according to AVMA.<sup>1</sup> In celebration this year, *dvm360®* asked veterinary technicians about their roles and what motivates them most. The responses came by email and through the Veterinary Support Staff Career Group on Facebook. They include the following:

## **Q** What inspired you to become a veterinarian technician?

**Stephanie Adams, LVMT; Family Pet Health, Murfreesboro, Tennessee:** I have always loved medicine, science, and helping [individuals]. I grew up with various pets and combined my interests in animals and medicine to be an LVMT [licensed veterinary medical technician].

**Zoey Smith, LVT; Family Pet Health:** I was inspired to be a veterinary technician because I love how animals touch our lives. There is just something about the human/animal bond that has always moved me. [Although] the pandemic continues to be a challenge for us in the profession, one aspect that has touched me deeply is how important pets have been to so many who needed connection and love this past year and a half.

**Alexia Minschwaner, CVT; Dresher, Pennsylvania:** My love for animals and natural curiosity inspired me to become a veterinary nurse. Animals can be so different from us regarding diet, health, and mannerisms. Becoming a vet nurse has enabled me to learn so much about our pets.

**Bash Halow, BA, CVPM, LVT; Halow Consulting, New York, New York:** My first position in an animal hospital was a kind of veterinary attendant. I was supposed to do whatever anyone else on the staff told me to do. Sounds terrible, but I loved it. Then after enough [individuals] quit, I got to work the front desk. I got [chewed out] by clients, doctors, techs, you name it. I loved that job too. It didn't matter that I got [chewed out]. I just loved it. I loved the multitasking; I loved learning about the medicine; I loved gabbing with my coworkers and the clients.

Still, the real siren song was "the back." If you were a technician who worked in "the back," you got to answer the hard questions, you got to do the cool jobs, and you were directly associated with patient outcomes. I wanted to be a technician. And after enough callouts, enough staff shortages, and enough pleading, I learned some technician skills.

Many years later, New Jersey offered technicians a chance to be "grandfathered in" if you could pass a licensing exam and could get letters from vets vouching for your skills. I studied for weeks to pass that test and pass it I did.

That's how I got to be a licensed tech, but now that I think about it the license is almost an afterthought. The thing that has always turned me on about my position is the learning, the care, and the client education. The knowledge and experience I have had as a tech has made an impact on >>





my own animals' lives and the lives of countless other pets and pet owners I have enjoyed meeting over the years.

**Tasha McNerney, BS, CVT, VTS (anesthesia and analgesia):** The movie *Turner & Hooch*. I wanted to be the veterinarian in that movie. When I realized there was a career [like] being a veterinarian but with more hands-on nursing skills, I went for it.

**Alyssa Mages, BS, CVT; Empowering Veterinary Teams LLC:** To be a voice for the voiceless and to lend my skills and compassion to those who truly need it.

**Kelly Piedrahita, LVT; Bond Vet, New York:** I would say my passion for animals inspired me to become a vet tech. Since a little girl, I was obsessed with animals. When I discovered there was a profession to help and save them, I was sold.

### Q What is your favorite part of being a vet tech?

**Adams:** I love nursing sick pets back to health and reuniting them with their pet parents.

**Smith:** My favorite part of being a technician is the constant opportunity to grow and improve. There is always a new skill or some new knowledge or information that comes up that improves our level of patient care. I strive to be a lifelong learner and I love that there will always be something to learn in the veterinary profession.

**Halow:** I love learning. I love helping clients understand the value of veterinary care and oversight by a veterinary medical team.

**McNerney:** The constant learning, from new techniques to new anesthetic drugs...I love being able to learn new things to make anesthetic events safer for my patients.

**Mages:** Being part of an incredible community that is constantly growing and evolving, all while helping animals and utilizing cutting-edge medicine and technology.

**Athena Ojeda, LVT; Bond Vet:** I love that there is practically no limit to what I can do to help my patients. We as technicians wear so many hats! From basic things like administering vaccines to doing blood transfusions, monitoring anesthesia, performing dental prophylaxis, taking radiographs, caring for wounds, and so much more. I am able to take care of whatever they need to keep them healthy and thriving.

### Q What is something clients would be surprised to know that you do as a vet tech?

**Minschwaner:** Many of us are passionate about training and behavior. I think clients would be surprised to know that we really do take our time and work with our patients and make sure they are not stressed. We want the vet office to be a happy place for every animal and client.

**Smith:** I think clients would be surprised to know that as a licensed technician we do a little of everything. We draw blood and run analyzers, screen blood work and lab results before the doctor sees them, fill prescriptions, answer phones, monitor anesthesia, educate clients, clean up stinky messes and, in the best moments, we get to play with puppies and kittens.

**Halow:** I honest to goodness treat their pet like a thinking, feeling being. I don't work with animals all day; I work with individuals.

**McNerney:** I think clients would be surprised to know the vet tech is usually the one monitoring your pet under anesthesia and is sometimes specialized in anesthesia.

**Mages:** Everything. All joking aside, there is a lack of understanding among the general public of all the things that veterinary technicians and nurses do—anesthesia, phlebotomy, radiology, etc—and we're only limited by how much we push ourselves to learn to accomplish.

**Dianny Felix, LVT; Bond Vet:** I find it humorous that most people don't compare both human medicine and veterinary medicine when they're

actually very similar. Clients are usually surprised knowing that I've performed anesthesia on their pets, pulled blood work, helped doctors come up with a differential diagnosis, and [performed radiographs].

### Q What should veterinarians know about the veterinarian technician role?

**Adams:** LVMTs are the most valuable resource veterinarians have available. Use us to our fullest extent and show gratitude. You want us to be around and to stay around.

**Smith:** I wish all veterinarians and practice owners understood the value of their staff. Treating LVTs and assistants as valuable assets with knowledge, as well as being kind and supportive of them and their mental and physical health, goes a long way to retaining a staff that is loyal and wants your practice to grow and succeed.

**Halow:** Tell me what you need to get done, train me. I'm ready and eager to learn. You and I can make a great team.

**Mages:** We're here, we're skilled, and we're ready to be utilized. Let us do what we are capable of doing so that we can support you to do the amazing work you do.

**Christina Clarke, LVT; Bond Vet:** With all the roles and tasks that [veterinary] nurses have, it is imperative that our voices are heard and respected.

### Q What advice would you give aspiring veterinary professionals?

**Adams:** Surround yourself with kindness and positivity. Be the vet or LVMT that you want your pets to have.

**Minschwaner:** Although this field can be challenging mentally and physically, quality pet care starts with you. Always take care of yourself.

**Smith:** I would advise them to know their worth. Without a support staff, even the best doctor cannot succeed.

Take what you know and use it. This is a hard job but it's incredibly rewarding when you find a practice that values you. Don't dwell on mistakes; own them and learn from them, but then move on.

*“My favorite part of being a technician is the constant opportunity to grow and improve.”*

—Zoey Smith, LVT

**Halow:** Show up. Learn. Be ready to help. The profession is exploding with opportunities. As the world modernizes, there are fewer gatekeepers between you and your goals—but skip the entitlement thing. Be worth it and you will be treated as worthy.

**McNerney:** Go into it with eyes wide open. It's very rewarding, but the field has some drawbacks such as lower pay compared with our human nursing counterparts.

**Mages:** Remember: No one is “just” anything. Own your awesome and advocate for it.

Additional information about veterinary technicians can be found on the AVMA's website and at [dvm360.com](http://dvm360.com).

**Kara Schaffer, LVT; Bond Vet:** The advice I would give to aspiring veterinary professionals is to never forget why you wanted to enter the profession and how you have grown within your role. We work in a profession where you will never stop learning. There will be instrumental people who will help advance your skills regardless of their position title. It is important to always remain open to learning from others and remember to help empower the next generation to thrive as others did for you. [dvm360.com](http://dvm360.com)

#### REFERENCE

National Veterinary Technician Week. American Veterinary Medicine Association. Accessed September 22, 2021. [www.avma.org/national-veterinary-technician-week](http://www.avma.org/national-veterinary-technician-week)





# your calling is calling you

## People.

Our people are as important as the pets we serve. Join the world's largest & most inclusive community of veterinary professionals.

## Pathways.

Your purpose is our purpose. Discover the flexibility and opportunity to find the path that's right for you.

## Progress.

We have a passion for progress. Help forge the future of preventative care and make a better world for pets.

## Banfield's **benefits** unlock healthier living inside and outside of work

### Paid Time Off

For when it's time to get away to refresh, full-time and part-time employees earn paid time off.

### Healthy You

We offer full-time employees medical, dental, vision, out of pockets and coverage for life insurance, short and long term disability.

### Healthy Pets

Happy pets make for happier vet techs. We offer all employees our Optimum Wellness Plans for up to three pets at no cost.

### Keep Growing

A better you makes us better too. We invest up to \$600 annually in your continued education and certification.

### Retirement

We offer full and part time employees a competitive 401k retirement plan. Your future is bright.

### Perks

Among the extras, we offer commuting incentives and discounts from our friends and partners to our employees.

**b**passionate. **b**y you. **b**here.

Now seeking vet techs. [jobs.banfield.com](https://jobs.banfield.com)

[Twitter](#) [Instagram](#) [Facebook](#) [LinkedIn](#) Follow us @[banfieldcareers](#)







## BUTTERFLY IQ VET

### Transportable ultrasound system

This is a first-of-its-kind single probe, whole-body ultrasound system designed for all animal species. It is user-friendly and provides real-time diagnostics within the examination room so owners can view what their pets are experiencing. It features patented Ultrasound-on-Chip technology to leverage the power of a semiconductor chip and pairs this with intuitive software accessible on a compatible mobile device or tablet. The ultrasound system works with the Butterfly iQ app, which includes 12 customized presets and a touch interface to easily scan and improve care.

For more information, visit [vet.butterflynetwork.com](http://vet.butterflynetwork.com)



## KANGAROO BED

### Orthopedic bed for dogs

Touted as the world's first all-season dog bed, the Kangaroo bed features a self-heating mat to retain a pet's body heat in winter and a self-cooling mat to absorb body heat in summer. It features a machine-washable cover and includes a memory foam layer, water-resistant cover, bolster foam, and is resistant to scratches, bites, and skids. The Kangaroo bed is available in small, medium, large, and extra-large.

For more information, visit [kangarobed.com.au](http://kangarobed.com.au)



## CALMER CANINE

### Anxiety treatment device

Calmer Canine is a noninvasive, drug-free method for restoring lasting calm to an anxious dog. It uses a specifically tuned microcurrent signal aimed at the anxiety center in the brain, reaching the core of the problem and stimulating a dog's natural ability to restore emotional balance. Based on technology that is cleared by the United States Food and Drug Administration for human treatment, Calmer Canine is sensation free without adverse effects and does not require a prescription. At-home treatments consist of 15-minute sessions twice daily for 4 to 6 weeks. The device is battery operated and the system comes with a washable, easy-to-apply vest for hands-free operation. The vest is available in extra small, small, medium, and large and the device comes in 2 sizes.

For more information, visit [calmerk9.com](http://calmerk9.com)



## PRACTICEHUB

### Online pharmacy platform

Designed by Chewy Health, Practice Hub enables veterinarians to grow practice revenue by streamlining prescription management and fulfillment for clients. You can create, review, and approve prescriptions through the Prescriptions feature. Plus, clients purchase directly from your clinic through the Marketplace feature, which increases revenue at the practice. Chewy handles inventory, storage, fulfillment, and shipping once the purchase is made. Practice Hub is a free platform that is also available as a mobile app.

For more information, visit [practicehub.chewy.com/app/vmx/practicehub](http://practicehub.chewy.com/app/vmx/practicehub)





## REDBONE NUTRITION CBD PET TREATS

### CBD treats for canine athletes

These organic cannabidiol (CBD) treats contain full-spectrum hemp with naturally occurring CBD to benefit canine athletes' joint health, digestive system, anxiety levels, and brain functions. The treats include all-natural ingredients and are tested by a third-party laboratory. They contain no additives or preservatives and are guaranteed Good Manufacturing Process, organic, and gluten free. Each treat features 13 mg of CBD. They are available in bacon, peanut butter banana, and peanut butter pumpkin flavors.

For more information, visit [redbonenutrition.com/collections/frontpage/products/cbd-treat](https://redbonenutrition.com/collections/frontpage/products/cbd-treat)



## CYCLAVANCE (CYCLOSPORINE ORAL SOLUTION) USP MODIFIED

### Canine atopic dermatitis management

Recommended by the International Committee on Allergic Diseases of Animals for the treatment of canine atopic dermatitis, Cyclavance oral solution is the first United States Food and Drug Administration-approved liquid cyclosporine for dogs. It blocks the release of inflammatory cytokines while providing strong anti-inflammatory and antipruritic effects. The liquid formulation allows precise dosing at 5 mg/kg for all dogs. Simplified dosing enables pet parents to follow instructions and reduces the risk of administering too much or too little. A bottle of Cyclavance contains 100 mg/mL.

For more information, visit [vet-us.virbac.com/Cyclavance](https://vet-us.virbac.com/Cyclavance)



## LAVERDIA-CA1 (VERDINEXOR) Oral canine lymphoma treatment

This first oral tablet to treat canine lymphoma spares healthy cells, targets mutating cells, and immediately works in the nucleus, helping naturally occurring tumor suppressor proteins fight cancer. It can be used with or without the steroid prednisone and works fast to block lymphoma cell reproduction. Laverdia consists of a quick-dissolve shell to deliver the proper amount of medicine rapidly and comes in different colors, so it is easy to administer the correct dose. Available in 3 tablet strengths for precise dosing for dogs of all sizes.

For more information, visit [anive.com/laverdia](https://anive.com/laverdia)



## THE VETIVERSE

### Veterinary blog and online resource

This platform is written by veterinarians because no one else better understands the challenges of practicing veterinary medicine. It joins Practice Life and the IDEXX Learning Center as an additional online resource, offering veterinary education for practitioners and business owners. The Vetiverse features content on topics including diagnostics, technology, skills, and well-being. The site highlights new information each week, serving as a growing database.

For more information, visit [thevetiverse.com/en](https://thevetiverse.com/en)





# MARKETPLACE & PRODUCT SHOWCASE

## MEDICAL SERVICES

### ULTRASONIC REPAIRS

Send your Ultrasonic Scaler for tuning and repair to ENGLER ENGINEERING CORPORATION, the manufacturer of TIPS, STACKS and MARATHON 25K insert, SONUS V, ULTRASON 990, SON-MATE, POLI-X and ADS 1000, SONUS II, SON-MATE II and ADS 2000 (Anesthesia Delivery System/Ventilator). Sole manuf. of spare parts for the ENGLER line of scalers and all the former LITTON units the Sonus II, LT:200, Ultrason 880, Veterinarian II & others. Six month warranty on repairs. In business since 1964.

**NEW** Now Repairing: SHORELINE, Prosonic, OraSonic & AlphaSonic Piezo Electric Ultrasonic Dental Scaler Units  
Check out our NEW SUPPORT WEBSITE [www.engler411.com](http://www.engler411.com) **In Business Since 1964**

 1099 East 47th Street - Hialeah, Florida 33013 USA  Proudly made in the U.S.A.  
**800-445-8581 - FAX 305-685-7671**  
[www.englerusa.com](http://www.englerusa.com) 

## MEDICAL EQUIPMENT

### 6 YEAR WARRANTY



Son-Mate II Scaler / Polisher  
Sale Price \$ 1,825

A.D.S. 2000 Anesthesia Machine / Ventilator  
Sale Price \$ 5,795



Tri-Mate (3 units in 1)  
Scaler / Polisher / Electrosgure  
Sale Price \$2,835

**Engler Scale-Aire**  
High Speed Veterinary Dental Air Unit  
- 360,000 RPM high speed drill  
- 20,000 RPM low speed H.P.  
- Built in 25K ultrasonic scaler  
- Auto-tune circuitry  
- Air water syringe  
- On-Demand Compressor (MF)  
- H-Frame mobile stand  
- Built in water reservoir  
- Switching power supply  
- Automatic handpiece activators  
- Lifetime loaner service  
- Proudly made in the USA

**\$4405**

 **In Business Since 1964**  
QUALITY & EXCELLENCE



 Proudly made in the U.S.A.  
**IN BUSINESS SINCE 1964**  
6 year warranty on Son-Mate II  
1 year warranty on Scale-Aire  
2 year warranty on A.D.S. 2000

1099 East 47th Street - Hialeah, Florida 33013 USA  
**800-445-8581 / FAX 305-685-7671**  
[www.englerusa.com](http://www.englerusa.com) / [www.engler411.com](http://www.engler411.com)

## ANESTHESIA EQUIPMENT

### BLUEPRINT FOR BREATHING

Anesthesia made simple... A.D.S. 2000



#### Revolutionary Veterinary Breakthrough

- Anesthesia Machine (Positive Pressure)
- Electronically microprocessor controlled
- Delivery & Ventilation for small animal use
- Automatically sets breathing parameters
- Very affordable and easy to use
- Just connect to vaporizer & Oxygen
- Two year parts & labor warranty
- Lifetime loaner service



 **In Business Since 1964**  
1099 East 47th Street - Hialeah, Florida 33013 USA  
**800-445-8581 - FAX 305-685-7671**  
[www.englerusa.com](http://www.englerusa.com)

## CONTINUING EDUCATION

### Specializing in Veterinary Architecture



### ARCHITECTS

tcarchitects.com  
430 Grant Street  
Akron, Ohio 44311  
(330) 867-1093

## DENTAL EQUIPMENT

SON-MATE II DENTAL SCALER POLISHER COMBO  
THE ONLY UNIT YOU WILL NEED FOR ALL YOUR DENTAL NEEDS



### 6 YEAR WARRANTY LIFETIME LOANER SERVICE

 Proudly made in the U.S.A. **In Business Since 1964**

**\$1825**



1099 East 47th Street - Hialeah, Florida 33013 USA  
**800-445-8581 - FAX 305-685-7671**  
[www.englerusa.com](http://www.englerusa.com)

## ARCHITECTS/BUILDERS

40+ years of experience in animal care architecture & design  
303.444.4413  
[www.animalarts.com](http://www.animalarts.com)



## ANIMAL ARTS

## MOBILE VETERINARY

### Mobile Veterinary Clinics

Lower stress on your patients by bringing all your services to your clients. With less overhead and more freedom!



Your Mobile Workplace

Compare our products and service before rolling forward and you'll find that Magnum is **By Far The Leader!**

Based in Phoenix, AZ. Delivered Worldwide.

(602) 715-2814 | [MagnumMobilesv.com](http://MagnumMobilesv.com)



[dvm360.com](http://dvm360.com)



Have you checked out our podcast yet? Visit [dvm360.com/podcasts](http://dvm360.com/podcasts)





MOBILE VETERINARY

Helping you prepare for the future.



**La Boit**  
Specialty Vehicles Inc.

[www.laboit.com](http://www.laboit.com)  
800-776-9984

dvm360.com



Have new product news to share? [dvm360products@mjhassoc.com](mailto:dvm360products@mjhassoc.com)



To share an upcoming CE event, [dvm360news@mjhassoc.com](mailto:dvm360news@mjhassoc.com)



Interested in writing for the dvm360® family of publications? [etricarico@mmhgroup.com](mailto:etricarico@mmhgroup.com)

Contact  
**John Hydrusko**  
[JHydrusko@mjlifesciences.com](mailto:JHydrusko@mjlifesciences.com)  
for information about reserving ad space.

PRACTICES FOR SALE OR LEASE

Practice Sales, Valuations, Associate Buy-Ins, Corporate Sales, & Buyer Representation. Practice appraisal completed in just 2 weeks! Contact Rebecca Robinson Davis, CBI, at **912-268-2701** or [Hello@psavet.com](mailto:Hello@psavet.com). See our national listings at [www.practicesalesadvisors.com](http://www.practicesalesadvisors.com).

FL UNDER CONTRACT! ORLANDO Area- Grossing \$1.7M, After-debt income approximately \$670K, Upscale New Residential & Highly Visible Commercial Location. FL NEW! PANHANDLE- Solo Doctor, Experienced Staff, Additional Lot & Tons of Room for Expansion! FL SARASOTA Area- All Pets Clinic, Distress Sale, Posh Commercial Area, Leased Facility. FL PANHANDLE- AAHA Accredited, Grossing \$1.4M, Owner Willing to Stay On. FL MELBOURNE- All Animal & Bird Hospital, Distress Sale, Right off Busy HWY, Room for Immediate Expansion. FL CENTRAL FLORIDA- Fort Meade Animal Clinic, 3,000 SF Facility, Upgrade Cash Allotment Awarded at Closing. GA PERRY Area- Bemby Veterinary Clinic, Grossing Approximately \$900K+, Practice & Real Estate Sales Price Only \$700K. NY NEW! CENTRAL NEW YORK- Real Estate Offered, Owner Willing to Stay On, More Info Coming Soon! SC NEW! BEAUFORT Area- Grossing Approximately \$800K, Steady Annual Growth, Experienced Staff in Place. SC CHARLESTON Area- 2,000SF Facility + 1,500SF Kennel, Bustling Commercial Area, Annual Revenue Up 20%. TN KNOXVILLE Area- Grossing Approximately \$700K, YTD Sales Up 20%, Owner Willing to Stay on. TX NEW! EAST TX- Grossing \$1.1M, Well-Established, Owner Willing to Stay On.

MEDICALWORLDNEWS



With easy viewing access on all our sites, you will be among the first to hear about the following:

- Breaking health care news
- Live updates and opinions on what's happening, with leading experts answering the tough questions
- Cross-specialty feedback for multidisciplinary approaches to treatment and guidelines



[mjhlifesciences.com/medical-world-news](http://mjhlifesciences.com/medical-world-news)







# EZ-BREATH<sup>®</sup>



The EZ-Breath (EZB) was designed to be the simplest anesthesia ventilator available to veterinarians today.

Unlike other ventilators that demand both the space in your operating room and the attention of your technicians, EZB becomes just one more part of your routine surgical procedure. It fits comfortably into any operating room size / protocol and is designed to be permanently attached to your anesthesia machine ready to be used at the push of a button.



Proudly Made in the USA

Easy to use and set up!

Introductory price of \$3150



Engler Engineering Corporation

1099 East 47th Street – Hialeah, Florida 33013 USA  
(800) 445-8581 • (305) 688-8581 • (305) 685-7671  
info@englerusa.com

ez-breathe.com  
englerusa.com  
engler411.com

## Engler Scale-Aire



- 360,000 RPM High Speed Drill
- 20,000 RPM Low Speed H.P.
- Built in Ultrasonic Scaler
- Air Water Syringe
- Auto-tune circuitry
- Maintenance free
- "On-Demand" compressor
- H-Frame mobile stand
- Automatic H.P. activators
- Built in water reservoir
- Switching power supply
- Handsfree operation
- Exclusive Lifetime loaner Service
- Proudly Made in the USA

\$4405



SAVE MONEY \$\$\$ ON YOUR OXYGEN BILLS



NEW \$1120 5 LPM

EverFlo 5 LPM Oxygen Concentrator

Never Pay for Oxygen!! A 5L Concentrator can supply oxygen to 1 anesthesia machine

The Most Affordable High Speed Dental Air Units on the Market

## DRILL-AIRE MINI



NEW \$1295

- 360,000 RPM High Speed Drill
- 3-Way Air Water Syringe
- Easily connects to a Nitrogen tank
- Wall Mount design
- Optional mobile stand
- Speed Control Foot Pedal
- Lifetime loaner service
- Proudly Made in the USA

## DRILL-AIRE MINI PLUS



NEW \$1695

- 360,000 RPM High Speed Drill
- 20,000 RPM Low Speed H.P.
- 3-Way Air Water Syringe
- Easily connects to a Nitrogen tank
- Wall Mount design
- Optional mobile stand
- Speed Control Foot Pedal
- Lifetime loaner service
- Proudly Made in the USA

## ADS 2000 Anesthesia Machine / Ventilator



\$5795

## Son-Mate II Scaler / Polisher Combination Unit



\$1825

## Tri-Mate Scaler / Polisher / Electrosurgery 3 Units in 1



\$2835



Proudly made in the U.S.A.

Web: www.englerusa.com / Email: info@englerusa.com  
www.dynaxusa.com / www.ez-breathe.com / www.25KSeries.com  
for brochures, manuals and "how to" pages please visit:

www.engler411.com

Engler Engineering Corporation  
1099 East 47th Street - Hialeah, Florida 33013 USA  
Tel: (800) 445-8581 / (305) 688-8581 / Fax: (305) 685-7671





Marc Rosenberg, VMD

## THE DILEMMA

# Delivering a needed dose of relief to the veterinary community

A practice weighs its options for the best way to spend surplus income for the betterment of animal lives.

The COVID-19 pandemic has impacted the lives of everyone, and the veterinary profession is no exception. Masking, curbside care, anxiety, and vaccine adherence have wreaked havoc on the profession. One facet of the viral invasion unique to the profession was an increase in pet ownership because of the mandated lifestyle change of a pandemic society. This has resulted in a significant increase in practice incomes.

The Hopson Animal Hospital felt that despite the pandemic restrictions and stress on their practice, some of their monetary good fortune should be used to assist the animals they serve. The clinic administration—with input from the hospital staff—set out to see how they could lighten the economic and emotional fallout of COVID-19 for their clientele.

A clinic staff meeting was convened to address the subject. How could the Hopson animal hospital assist pandemic-impacted pets and clients in need? The hospital director told staff that due to increased client services and government assistance efforts, the clinic was in the position to assist certain clients in need. But what should this assistance look like? It was suggested that help be given to clients that requested aid caused by pandemic hardships. That was countered by the comment that many clients in need may not be comfortable initiating such a request. It was then suggested that the client intake questionnaire include a query asking if the pandemic has significantly affected job status or current income. If the answer was “yes”, a predetermined discount could be applied to those invoices.

Another staff member suggested that nonprofit shelters, adoption agencies, spay and neuter facilities, and pet community outreach organizations could receive a donation from the clinic to assist the animals they are helping. This way, a specific budget could be established to assist these organizations in need. She went on to say that assisting clients that state they need assistance could be overwhelming, and the clinic may not have the funds to meet all of the client needs. This could then end up making things inequitable.

Finally, there was a suggestion by a dissenter in the group. This staff member felt the increased monetary good fortune of the clinic should be used to enhance clinic equipment and resources that could better serve the medical needs of the patients including staff continuing education and facility upgrades. He went on to suggest that it would also be a much-needed morale booster at a difficult time.

The hospital director now had a decision to make. Should efforts be made to assist pandemic-affected indigent clients? Should additional assistance go to local shelters and nonprofits dealing with medical and staff related issues? Or should more of the enhanced budget be directed internally to increase the capabilities of the Hopson Animal Hospital?

After much consideration it was determined that additional resources would be directed to care for animals housed in nonprofit shelters. This aligned most closely with the clinics mission statement to help pets in need through progressive medicine and compassionate care.

I guess this would technically have to be called a champagne dilemma. Nevertheless, after the stress and heartache of this pandemic, charitably helping pets is an important part of the healing process. dvm360®

### Dr Rosenberg's response

The entire staff of the Hopson Animal Hospital participated in the process of designating charitable efforts to pets in need. This effort should not be taken lightly. After masking the entire workday, worrying about family health and school schedules, this feel-good gesture is a godsend. While the profession remains in a pandemic battle, every victory contributes to the health and well-being of our colleagues. This charitable effort by the Hopson Animal Hospital as well as similar efforts from around the country will bring immeasurable relief to pets, clients, and veterinary health care workers.

United States Postal Service

### STATEMENT OF OWNERSHIP, MANAGEMENT, and CIRCULATION

Required by 39 USC 3685

1. Publication Title: dvm360
2. Publication Number: 338590
3. Filing Date: 9-27-21
4. Issue of Frequency: Monthly
5. Number of Issues Published Annually: 12
6. Annual Subscription Price: \$51.50
7. Complete Mailing Address of Known Office of Publication (Not Printer): MULTIMEDIA HEALTHCARE LLC, 2 Clarke Dr, Suite 100, Cranbury, NJ 08512-3619
8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not Printer): MULTIMEDIA HEALTHCARE LLC, 2 Clarke Dr, Suite 100, Cranbury, NJ 08512-3619
9. Full Names and Complete Mailing Addresses of Publisher and Editor – Publisher: John Hydrusko, MULTIMEDIA HEALTHCARE LLC, 2 Clarke Dr, Suite 100, Cranbury, NJ 08512-3619; Editor: Colleen Hall, MULTIMEDIA HEALTHCARE LLC, 2 Clarke Dr, Suite 100, Cranbury, NJ 08512-3619
10. Owner - Full name: MULTIMEDIA HEALTHCARE LLC, 2 Clarke Dr, Suite 100, Cranbury, NJ 08512-3619
11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities: None
13. Publication Title: dvm360
14. Issue Date for Circulation Data Below: September 2021
15. Extent and nature of circulation

	Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
a. Total number of Copies (Net press run)	49,701	50,959
b. Legitimate Paid and/or Requested Distribution		
(1) Outside County Paid/Requested Mail Subscriptions stated on PS Form 3541.	37,431	39,588
(2) In-County Paid/Requested Mail Subscriptions stated on PS Form 3541.	0	0
(3) Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid or Requested Distribution Outside USPS	0	0
(4) Requested Copies Distributed by Other Classes Mailed Through the USPS	12	30
c. Total Paid and/or Requested Circulation [Sum of 15b 1,2,3,&4]	37,443	39,618
d. Nonrequested Distribution (By Mail and Outside the Mail)		
(1) Outside County Nonrequested Copies stated on PS Form 3541	12,224	10,407
(2) In-County Nonrequested Copies stated on PS Form 3541	0	0
(3) Nonrequested Copies Distributed Through the USPS by Other Classes of Mail	0	0
(4) Nonrequested Copies Distributed Outside the Mail	0	0
e. Total Nonrequested Distribution (Sum of 15d (1), (2), and (3))	12,224	10,407
f. Total Distribution (Sum of 15c and 15e)	49,667	50,025
g. Copies not Distributed	34	25
h. Total (Sum of 15f and 15g)	49,701	50,050
i. Percent Paid and/or Requested Circulation	75.39%	79.20%

16. If total circulation includes electronic copies, report that circulation on lines below

a. Requested and Paid Electronic Copies	-	-
b. Total Requested and Paid Print Copies + Requested/Paid Electronic Copies	-	-
c. Total Requested Copy Distribution + Requested/Paid Electronic Copies	-	-
d. Percent Paid and/or Requested Circulation (Both print & Electronic Copies)	-	-

17. Publication of Statement of Ownership – Will be printed in November 2021 issue of this publication.
18. I certify that all information on this form is true and complete. Signature and title of Editor, Publisher, Business Manager, or Owner – Jonathan Severn, Circulation Director, 9-27-21





# Tap the tax, savings potential of cash balance plans

A qualified retirement plan, cash balance plans have seen rapid growth in recent years and are used in many businesses including medical practices.

By Jason M. O'Dell, MS, CWM; and Carole C. Foos, CPA

Cash balance plans (CBPs) are often referred to as today's "modern retirement plans" because their use has grown rapidly in closely held businesses, including medical practices, during recent years. CBPs are a solution for high-income practice owners looking for tools that can provide them with significant short-term tax deductions along with strong long-term economics.

A CBP is a qualified retirement plan (QRP) that can provide dermatologists with a way to increase tax deductions and simultaneously boost retirement savings.

In a CBP, a participating employee will have access to a certain sum upon reaching retirement. Let's use \$100,000 as an example. To get to \$100,000 at retirement, the plan assumes a combination of employer contributions and compound interest over time. When the employee retires, they can take the \$100,000 either as a lump sum or as an annuity that pays a portion of the \$100,000 in periodic payments.

CBPs are like traditional defined benefit plans in terms of the funding and reporting requirements. Minimum funding standards apply; there is a minimum annual employer contribution that is reported on the CBP's tax form 5500. An actuary is required to calculate this contribution amount using a reasonable actuarial funding method and actuarial assumptions specified by the IRS. The employer can decide to contribute an amount between the minimum funding requirement and the maximum permitted deduction but should attempt to fund to the actuary's recommended contribution level to meet the plan's current benefit liability.

On the other hand, CBPs are different from traditional defined benefit plans that promise a specified

monthly benefit amount at retirement (ie, 3% of pay per year of employment, payable at the retirement age of 67). CBPs define benefits in the form of an account balance, rather than a periodic amount. This can be helpful because employees always understand what they are entitled to under the CBP because it is a specific amount. Owners and employees both know what is going into the plan on their behalf and what will come out when they leave.

CBPs and 401(k)s are not mutually exclusive. In fact, a dermatology practice can typically utilize both types of plans simultaneously, "layering" a CBP on top of its existing 401(k).

## Main benefits of CBPs

There are 4 compelling reasons why dermatology practices are interested in CBPs:

### 1 Significantly increased deductions for plan contributions

In 2021, 401(k)s are subject to maximum deductible contribution limits of \$19,500, with profit-sharing plan limits at \$58,000. (The catch-up contribution for those over age 50 is an additional \$6,500 annually.) These limits increase slightly each year. Properly structured CBPs, on the other hand, can allow business owners to make tax-deductible contributions of \$200,000 or more, potentially saving them \$80,000 to more than \$100,000 in income taxes annually.

### 2 Additional costs are much lower than additional tax savings

CBPs usually involve higher annual administration costs and higher employer contribution amounts for employees than 401(k)s and/or profit-sharing plans. Nonetheless,

### TABLE how a cash balance plan can create 2 deductions for the price of 1

Cash balance plans (CBPs) can be used to reduce taxable income enough to qualify for the qualified business income (QBI) deduction even if the taxpayer's business is a specified service trade or business, like a medical practice. That holds true for those whose income puts them above the new tax code's QBI threshold limits. In this way, the CBP can create 1 deduction that leads to a second deduction, as the following example shows.

QBI	Before cash balance plan	After cash balance plan <sup>a</sup>
199A deduction	\$585,822	\$300,000
Total taxable income	\$0	\$60,000
Total taxable income	\$585,822	\$240,000
Federal income taxes <sup>b</sup>	\$154,126	\$45,642
Difference in federal income taxes <sup>c</sup>	-	\$108,484

A: CBP CONTRIBUTION IN YEAR 1 OF \$285,822.

B: BASED ON 2021 TAX RATES FOR A MARRIED FILING JOINTLY TAXPAYER.

C: ADDING A CASH BALANCE PLAN REDUCES FEDERAL TAX BY 70%.

SOURCE: OJM GROUP, CINCINNATI, OHIO

the tax savings typically dwarf these additional expenses, making the CBP extremely attractive.

### 3 Possible second level of tax deduction

For those whose income puts them above the new tax code's qualified business income (QBI) threshold limits, a CBP can be a tool to reduce taxable income enough to qualify for the QBI deduction, creating 1 deduction that leads to a second deduction (Table).

### 4 Greater access to top (+5) asset protection level

As an exempt asset under federal law and most state laws, ERISA-qualified QRPs are protected at the highest (+5) level. Unless a CBP is put in place for only 1 owner, with no other employees, this ERISA protection will usually also apply to the CBP. With larger contribution levels allowed in the CBP, this means more wealth can be protected in the CBP than in most other QRPs. CBPs are powerful planning tools that provide larger contributions than the QRPs most medical practices use today. CBPs can be attractive to practice owners who

are looking for greater tax deductions, asset protection, and superior retirement savings. [dvm360.com](http://dvm360.com)

#### DISCLOSURE

OJM Group, LLC (OJM) is an-SEC registered investment adviser with its principal place of practice in the state of Ohio. SEC registration does not constitute an endorsement of OJM by the SEC nor does it indicate that OJM has attained a particular level of skill or ability. OJM and its representatives are in compliance with the current notice filing and registration requirements imposed upon registered investment advisers by those states in which OJM maintains clients. OJM may only transact practice in those states in which it is registered or qualifies for an exemption or exclusion from registration requirements. For information pertaining to the registration status of OJM, please contact OJM or refer to the Investment Adviser Public Disclosure web site [www.adviserinfo.sec.gov](http://www.adviserinfo.sec.gov). For additional information about OJM, including fees and services, send for our disclosure brochure as set forth on Form ADV using the contact information herein. Please read the disclosure statement carefully before you invest or send money. This article contains general information that is not suitable for everyone. The information contained herein should not be construed as personalized legal or tax advice, or as a recommendation of any particular security or strategy. There is no guarantee that the views and opinions expressed in this article will be appropriate for your particular circumstances. Tax law changes frequently, accordingly information presented herein is subject to change without notice. You should seek professional tax and legal advice before implementing any strategy discussed herein.



# Roll in. Hook up. Start scanning.

Don't have room for high-field MRI?  
Think again. Instillation options available.



Learn more at [info.hallmarq.net/vetted-rollin-mri](http://info.hallmarq.net/vetted-rollin-mri)

**Hallmarq**  
Advanced Veterinary Imaging





**IDEXX Reference Laboratories**

# DISCOVER MORE

- ✓ **Most complete and advanced menu of tests**
- ✓ **Personalized support, guidance, and expertise**
- ✓ **Technology and tools that make your work easier**
- ✓ **IDEXX Preventive Care**
- ✓ **Unrelenting commitment to innovation**

**[idexx.com/DiscoverMore](https://www.idexx.com/DiscoverMore)**

